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DEPARTMENT OF HEALTH AND HUMAN SERVICES 
PUBLIC HEALTH SERVICE 
BOARD OF SCIENTIFIC COUNSELORS (BSC) 
Centers for Disease Control and Prevention (CDC) 
National Center for Injury Prevention and Control (NCIPC) 
 
Eighteenth Meeting: Thursday, January 28, 2016 
 
1600 Clifton Road, N.E. 
Building 19, Auditorium B-3 
Atlanta, GA  30329 
 
Summary Proceedings 
 
The eighteenth meeting of the National Center for Injury Prevention and Control (NCIPC) Board 
of Scientific Counselors (BSC) took place on Thursday, January 28, 2016 at the Tom Harkin 
Global Communications Center on the Clifton Road Campus of the Centers for Disease Control 
and Prevention (CDC) in Atlanta, Georgia.  The BSC met in open session in accordance with 
the Privacy Act and the Federal Advisory Committee Act (FACA).  Dr. Stephen Hargarten 
served as chair. 
 
 
Call to Order / Roll Call / Introductions / Meeting Logistics 
 
Stephen Hargarten, MD, MPH 
Professor and Chair 
Department of Emergency Medicine 
Medical College of Wisconsin 
Chair, National Center for Injury Prevention and Control Board of Scientific Counselors 
 
Dr. Stephen Hargarten called the eighteenth meeting of the NCIPC BSC to order at 9:01 a.m. 
on Thursday, January 28, 2016. 
 
Mrs. Tonia Lindley conducted a roll call of NCIPC BSC members and ex officio members.  She 
asked all members to disclose any conflicts of interest.  The meeting attendance is appended to 
this document as Attachment A.  The following conflicts of interest were disclosed by BSC 
members: 
 
 Dr. Traci Green was previously employed at Inflexxion, a small business that conducts 
Small Business Innovation Research (SBIR) grants and behavioral interventions for pain 
assessments.  She indicated that she would recuse herself from any conversations 
regarding pain assessments.  She provided consultancy to Purdue Pharmaceuticals, a 
privately-held pharmaceutical company, for designing two overdose prevention 
brochures for people who use diverted opioids and who inject opioids.  That salary 
support was approximately $3,000.00, and she indicated that she would recuse herself 
from conversations regarding overdose prevention education materials. 
 Dr. Wilson Compton reported minimal, long-term stock holdings in General Electric; 3M 
Corporation; and Pfizer, Incorporated. 
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Mrs. Lindley confirmed that a quorum was present.  She offered housekeeping notes to the 
meeting participants. 
 
Dr. Hargarten thanked the BSC members and ex officio members for attending the meeting 
and indicated his appreciation for their commitment and thoughtful input.  He also thanked the 
members of the public who were present in person and via teleconference, emphasizing that 
their interest and voice in the topic of opioids abuse is appreciated, and all public comments are 
taken into consideration. 
 
He welcomed Dr. Deborah Gorman-Smith, a previous BSC member who was returning to the 
board.  He also welcomed Captain Kelly Taylor, a new ex officio member from the Indian Health 
Service (IHS) and Mindy Chai, an ex officio member from the National Institute of Mental Health 
(NIMH). 
 
The day’s agenda, the Opioid Guideline Workgroup observations, and two Power Point 
presentations are posted on the NCIPC BSC website so that participants on the telephone could 
more easily follow the presentations.  The website is: www.cdc.gov/injury/BSC and the materials 
are available under the “Meetings” tab.  The meeting’s written and oral comments and other 
materials would be posted on the NCIPC BSC website as the official record of the meeting. 
 
 
 
 
Stephen Hargarten, MD, MPH 
Professor and Chair 
Department of Emergency Medicine 
Medical College of Wisconsin 
Chair, National Center for Injury Prevention and Control Board of Scientific Counselors 
 
Dr. Hargarten reported that the Opioid Guideline Workgroup of the NCIPC BSC was approved 
during the January 7, 2016 BSC teleconference.  Since then, the workgroup has reviewed the 
draft of the CDC Guideline for Prescribing Opioids for Chronic Pain, supplementary documents, 
and public feedback.  The workgroup has met four times and discussed each of the 
recommendations in detail.  Dr. Christina Porucznik served as chair of the group, and Dr. Traci 
Green participated as a member of the workgroup. 
 
He explained that the morning’s presentation would provide an overview of the Guideline, 
including background and rationale for each of the guideline recommendations.  Dr. Porucznik 
would then share the workgroup’s observations.  The day’s agenda includes two discussion 
periods as well as 90 minutes of public comment. 
 
Dr. Hargarten reminded the BSC members and ex officio members to remain for the entirety of 
the meeting in order to maintain quorum.  At the end of the day, BSC members would be asked 
to vote on the workgroup’s observations.  The results of the BSC vote would be forwarded to 
CDC and the US Department of Health and Human Services (HHS).  The authors of the draft 
guideline were available to answer questions during the day. 
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Thomas Frieden, MD 
Director 
Centers for Disease Control and Prevention 
 
Via video, Dr. Tom Frieden apologized for not attending the meeting in person as he was in 
Geneva, Switzerland at the World Health Organization (WHO) where he serves as the US 
representative to the WHO Executive Board. 
 
He emphasized that many people in the US experience chronic pain.  There is an obligation to 
offer safe and effective management of pain and not to increase patients’ risk of addiction, 
overdose, and death.  What was not known 20 years ago that is known now, is just how 
addictive prescription opioids can be.  Every day, 78 Americans lose their lives to an opioid 
overdose.  They leave behind devastated families and communities.  Deaths from opioid abuses 
have been increasing rapidly since 1999, and the rates have never been higher.  Overdose 
deaths from prescription opioids, such as oxycodone, hydrocodone, and methadone quadrupled 
from 1999 to 2013.  Rates of all opioid overdose deaths, including all legally-prescribed opioids 
and illegal drugs such as heroin, increased another 144% from 2013 to 2014 alone. 
 
Addressing the prescription drug overdose epidemic is one of CDC’s top priorities.  Dr. Frieden 
thanked the NCIPC BSC for the time, attention, and commitment that they have devoted to this 
important and urgent issue.  He thanked members of the Opioid Workgroup for their efforts to 
help CDC address the opioid overdose epidemic, and the members of the public who were 
participating in the meeting in person and on the telephone.  CDC has head many voices from 
the public on this important work.  The comments are heard and valued, and they have been a 
critical part of the process.  Prescription drug abuse is an epidemic.  The best science must be 
applied to address it.  Observations from the workgroup and recommendations from the NCIPC 
BSC will enhance CDC’s ability to finalize the guidelines and to take effective action. 
 
Dr. Frieden thanked everyone for the work that they had done and would continue to do, and 
said he looked forward to continuing to work together to protect the public’s health. 
 
 
Guidelines in Public Health 
 
 
Anne Schuchat, MD, RADM, USPHS 
Principal Deputy Director 
Centers for Disease Control and Prevention 
 
Dr. Anne Schuchat welcomed and thanked the NCIPC BSC, the Opioid Workgroup, members 
of the public, and NCIPC staff.  She stressed that this issue is extremely important, and 
guidelines are an important part of CDC’s work.  She remarked on the sense of convergence at 
CDC, as part of the agency is working in the Emergency Operations Center (EOC), focused on 
the Zika virus in the Americas and the urgent need to share information with the public so that 
they can protect themselves.  Her first experience with CDC guidelines was with Group B 
Streptococcus (group B strep, GBS) guidelines.  Group B strep is another infectious disease 
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that can cause severe complications in babies.  Today, this group is deliberating lifesaving 
guidelines to address the best ways to prescribe opiates.  The issues of Zika are in the news.  
Issues of Group B strep are in the past, thanks to the implementation of sound guidelines that 
have prevented more than 90,000 infections.  The Opioid Guideline will have enormous public 
health impact and will make a difference for patients and clinicians who struggle with these 
issues. 
 
Dr. Schuchat has worked on a number of CDC guidelines, particularly in her role as the Director 
of the National Center for Immunization and Respiratory Diseases (NCIRD), which manages the 
Advisory Committee on Immunization Practices (ACIP).  Three times per year, ACIP deliberates 
on immunization recommendations for the American public.  The recommendations have 
significant impact.  The process is helped by following a systematic review of evidence using the 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) system, the 
same system that has guided the Opioid Guidelines.  GRADE helps to coalesce the complex 
evidence and to recognize that values are a factor in decision-making about preferences. 
 
CDC is committed to several principles related to guideline development.  The agency’s pledge 
to the American public is to make the best decisions possible based on the best available 
evidence, openly and objectively reviewed.  The principles of relying on evidence, transparency, 
and understanding the urgency of the problem are critical to their work. 
 
Prescription opioid abuse and overdose is a significant priority for Dr. Frieden and Dr. Schuchat.  
They are frequently briefed by Dr. Houry and NCIPC staff.  They are pleased that the NCIPC 
BSC has assembled to help put the pieces together.  The nation faces an epidemic of addiction 
and overdose that is unrelenting.  Doctors need, and are asking for, additional guidance on 
prescribing these drugs safely.  Patients need and deserve appropriate, effective, and 
compassionate care, especially when they face persistent pain.  NCIPC is listening to all 
perspectives, looking at all of the available evidence, and taking care to get this right. 
 
Dr. Frieden, Dr. Schuchat, and the leadership of HHS are fully engaged and committed to the 
guidelines and to improving the health of all Americans.  The guidelines will support effective, 
safer pain care for all.  She thanked the group for the work that they have done, are doing, and 
will do. 
 
Background: Draft CDC Guideline for Prescribing Opioids for Chronic Pain 
 
 
Debra Houry, MD, MPH 
Director 
National Center for Injury Prevention and Control 
Centers for Disease Control and Prevention 
 
Dr. Debra Houry greeted the group and thanked Drs. Schuchat and Frieden for their remarks.  
Their engagement shows the support that CDC has provided NCIPC during the process of 
creating the draft Opioid Guideline.  She also thanked the BSC and the meeting participants, as 
well as the members of the Opioid Guideline Workgroup and the consultants who joined their 
discussion for their thoughtful evaluation of the evidence reviews that support the guidelines, the 
public comments, and each recommendation in the guideline.  The workgroup conducted the 
Herculean task of a complete and fresh review of all relevant materials to the guideline.  The 
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workgroup convened four meetings to generate a report that would be presented to the NCIPC 
BSC.  She said she looked forward to hearing the report and the BSC’s discussion. 
 
Guidelines sit at the intersection of public health and clinical practice.  Dr. Houry herself is a 
public health researcher and a practicing emergency physician.  At CDC, she sees issues of 
pain, prescription opioid addiction, and overdose on a macro level with systems-level solutions.  
As an emergency physician, she sees the issues “one person at a time.”  From a patient with a 
fractured arm who needs a short course of pain relief, to a patient in chronic pain issues who 
needs comfort and referral to a pain specialist, to a patient after an overdose of a prescription 
opioid or heroin, she has witnessed this epidemic from the front lines.  Patient safety and care 
are her primary concern. 
 
CDC has tracked the rise in opioid overdoses for over a decade.  Approximately 10 years ago, 
CDC epidemiologists noticed a substantial increase in the number of adults dying from 
unintentional poisoning.  Researchers examined the data, and one of CDC’s first landmark 
articles on this emerging issue was a 2006 analysis that studied a dramatic increase in 
poisoning mortality rates and compared it to sales of opioid analgesics nationwide.  The CDC 
authors noted prevention efforts, stating that “the overall goal should be to identify ways to 
reduce deaths from opioid analgesics without diminishing the quality of care for patients.”  Since 
the early days of working on this issue, CDC has sought to prevent prescription opioid 
overdoses while supporting quality care for people with chronic pain.  This goal continues today. 
 
The problem facing the US is significant.  From 2000-2014, nearly half a million people in the 
US died from drug overdose.  By the end of this meeting, 20 people would have died of 
overdose from a prescription or illegal opioid overdose.  Since 1999, the amount of opioids 
prescribed and filled in the US quadrupled, yet there has not been an overall change in the 
amount of pain that Americans report.  Opioid overdoses from prescription and illicit opioids 
killed 78 people a day in 2014.  More than 28,000 lives were lost to opioids in one year.  The 
problem is not getting better, and it is a problem that the US has faced before. 
 
In November 2015, a historian at the University of North Florida published a perspective in the 
New England Journal of Medicine (NEJM) on the history of preventing and treating narcotic 
addiction in the US.  He noted that physicians using morphine injections to treat pain were the 
most important drivers of the addiction epidemic of the 1870s and 1880s.  At that time, 
physicians and pharmacists then “turned the tide” and succeeded through primary prevention.  
The historian noted that history offers grounds for optimism that the prescription opioid epidemic 
in the US can be controlled.  There are similar opportunities today. 
 
The approach being discussed during this meeting, CDC’s Guideline for Prescribing Opioids for 
Chronic Pain, was not a panacea for the opioid or pain problem.  It represented one important 
step toward more cautious prescribing of opioids while ensuring that patients who suffer from 
chronic pain have safer and more effective pain management.  There is a need for more 
research and to build the evidence base on opioid benefits and risks, as well as the 
effectiveness of other pain treatments.  In the meantime, it is important to begin with the 
available evidence regarding effectiveness and safety. 
 
In all of its work, CDC’s strategy is to use the best science to create real-world solutions.  CDC’s 
aim with the proposed guideline is to prevent prescription opioid overdose while ensuring that 
patients have access to safe and effective pain treatment.  The guideline is one part of a 
broader approach. 
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The public comments received throughout the process of creating the guideline indicate that 
there are misconceptions about it.  Hundreds of comments were received from patients with 
chronic pain and their families.  They expressed that opioids reduce their pain, and they worried 
about the legal and clinical implications of the guideline.  For example, there was fear that the 
guideline represents a law that would prohibit providers from prescribing opioid pain medication.  
Because of misconceptions about what guidelines represent, it is important to be clear on these 
issues. 
 
The purpose of the guideline is to help primary care providers offer safer, more effective care for 
patients with chronic pain and to help reduce opioid use disorder and overdose.  The guideline 
is a set of recommendations on the use of opioids for treating chronic pain; that is, pain lasting 
longer than three months or past the time of normal tissue healing.  The guideline will help 
primary care providers determine when to start opioids for chronic pain and provide guidance 
regarding medication selection, dose, and duration.  It will also provide guidance regarding 
when and how to reassess progress and discontinue medication, if needed.  It will help 
providers and patients work together to assess the benefits and risks of opioid use and to 
address potential harms. 
 
The audience of the guideline is primary care providers; however, it is acknowledged that 
providers work within team-based care.  Therefore, the guideline refers to and promotes 
collaborative working relationships with other providers, such as behavioral health providers, 
pharmacists, and pain management specialists. 
 
The guideline does not apply to patients who are in active cancer treatment or who are receiving 
palliative or end-of-life care.  The guideline is not a rule, regulation, or law.  It is not intended to 
deny access to opioid pain medication as an option for pain management, and it is not intended 
to take away physician discretion and decision-making.  Guidelines guide physicians’ practices, 
and Dr. Houry has found them to be helpful in the majority of cases, but not in all cases.  She 
has chosen other options in collaboration with her patients. 
 
The heart of the guideline is an effort to improve communication between providers and patients 
regarding the risks and benefits of prescription opioids.  Pain must be treated effectively and 
safely.  There is an under-recognition of the risks of opioids over the long-term, and limited 
evidence of actual benefits of their long-term use for chronic pain.  There is insufficient evidence 
that long-term opioid therapy reduces chronic pain and improves function, and there is growing 
evidence that non-opioid treatments can be effective with less harm.  Given these uncertain 
benefits in light of substantial risks, the evidence supports, and experts agree, that long-term 
opioid therapy outside of active cancer, palliative, and end-of-life care, should only be used 
when the benefits outweigh the risks, and should be used in combination with other treatments 
to provide greater benefits. 
 
For patients not already taking opioids, opioids should not be first-line or routine therapy for 
chronic pain.  People who have been on opioids long-term and believe that these medications 
are helping them might be understandably anxious about the idea of reducing or discontinuing 
opioids.  Patients deserve the opportunity to learn about new evidence on the risks of opioids, 
particularly at higher dosages; to re-evaluate whether continuing their current treatment is the 
best available option; or to consider changing course if they and their provider together 
determine that it makes sense to do so.  For patients and providers who choose to do so, the 
guideline will have information regarding the safe reduction or discontinuation of opioids. 
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CDC was responsive to concerns regarding the guideline development process, and followed a 
rigorous process using the best and most recent scientific evidence to develop the guideline.  
The guideline and recommendations were drafted after an extensive review of more than 130 of 
the most relevant and recent scientific studies about the effectiveness and risks of opioid and 
other pain treatments.  Many have said that more evidence regarding effective pain treatments 
is needed.  CDC agrees, and the recommendations will be refined when better evidence is 
available.  Guidelines are warranted now, however, with the evidence that is currently available.  
Further, CDC consulted over a dozen of the country’s top experts from many different 
disciplines on the recommendations and evidence.  CDC received more than 1500 comments 
from constituents on the guideline even before the formal public comment period began.  This 
input was helpful in revising the draft guideline.  From the beginning, CDC has valued 
stakeholder and public engagement in a transparent and scientifically rigorous guideline 
development process.  While CDC is dedicated to timely release of the guideline, given the 
urgent public health need, improvement of prescribing and successful control of the epidemic 
will require clinical practice changes.  Support for these changes will benefit from review and 
engagement. 
 
In mid-December 2015, the draft guideline was made available for public comment for 30 days.  
Over 4300 public comments were received, the most of any CDC guideline published on 
www.regulations.gov to date.  Every comment was read.  Dr. Houry was touched by the stories 
of individuals who live with chronic pain and their loved ones who care for them.  Pain was 
described as unrelenting, agonizing, profound, debilitating, and horrific.  Comments were also 
received from individuals struggling with opioid addiction and from individuals who lost loved 
ones to overdose.  In addition to individual comments, letters were submitted from over 160 
organizations, medical professional associations, hospital organizations, pain organizations, 
consumer groups, and state attorneys general.  All feedback on broad themes as well as 
specific statements is carefully considered. 
 
When the Opioid Guideline Workgroup was convened by the BSC in January 2016, public 
comments were heard.  Dr. Houry thanked the individuals who shared their comments in that 
meeting and looked forward to the day’s public comments after the presentation of the Opioid 
Guideline Workgroup.  The workgroup’s thorough review of the guideline and evidence was 
appreciated, as was their comments. 
 
CDC believes that taking action and issuing guidelines now, based on what is known now, is 
warranted.  The amount of drugs prescribed and sold in the US quadrupled since 1999, and the 
opioid overdose rate has risen in lockstep with prescriptions.  Opioids can help manage some 
types of pain, but they also carry serious risks of addiction and overdose.  Patients deserve to 
make informed choices about the benefits and risks of treatment options.  This guideline is a 
balanced approach to achieving the goals of helping physicians manage chronic pain better and 
more safely in partnership with patients. 
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Overview: Draft CDC Guideline in Prescribing Opioids for Chronic Pain 
 
Debbie Dowell, MD, MPH, LCDR, USPHS 
Senior Medical Advisor 
Division of Unintentional Injury Prevention 
National Center for Injury Prevention and Control 
Centers for Disease Control and Prevention 
 
Dr. Debbie Dowell thanked the group for their attention to these critical issues.  She provided 
an overview of the draft CDC Guideline for Prescribing Opioids for Chronic Pain, emphasizing 
that the guideline is needed.  Many Americans, as many as 11% by one estimate, experience 
chronic pain.  Opioids are frequently prescribed for chronic pain.  Approximately 20% of patients 
seen in physician offices with pain receive a prescription for an opioid.  Primary care providers 
account for approximately 50% of opioid pain medications dispensed.  They report concern 
about opioids and insufficient training in opioid prescribing, and in the management of chronic 
pain.  In her experience as an internal medicine physician, Dr. Dowell recognized that although 
pain was among the most common problems affecting patients, the medications offered too 
often failed to address pain adequately.  She started a special clinic to assess and manage the 
most common pain-related conditions, including osteoarthritis, back pain, and musculoskeletal 
pain.  She was quickly overwhelmed by referrals from her colleagues.  Satisfying pain 
management often takes more time than the few minutes that primary care providers have to 
see a patient. 
 
Over the last few decades, opioids have been prescribed more often and other treatments have 
been used less often for chronic pain.  The quadrupling of opioid prescriptions in the US since 
1999 primarily reflects increased use of opioids for the treatment of chronic pain.  National 
guidelines on the prescription of opioids for chronic pain have been published by the US 
Department of Veterans Affairs (VA), the US Department of Defense (DoD), and the American 
Pain Society (APS) with the American Academy of Pain Medicine (AAPM).  However, these 
guidelines were published in 2010 or earlier and do not incorporate new evidence published 
since that time, including several new studies examining the relationship between prescribed 
opioid dosage and overdose risk. 
 
The new CDC guideline is intended to: 
 
 Support informed clinical decision-making 
 Help providers offer safer, more effective care for patients with chronic pain 
 Help reduce misuse, abuse, and overdose from opioids 
 Encourage improved communication between providers and patients about the benefits 
and risks of opioid therapy 
 Improve provider confidence regarding when and how to use opioids in management of 
chronic pain 
 Benefit patient health 
 
The primary audience for the guideline is primary care providers treating patients 18 years of 
age and older with chronic pain (e.g., pain lasting more than three months or past the time of 
normal tissue healing) in outpatient settings outside of active cancer treatment, palliative care, 
and end-of-life care. 
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The guideline development process has reached the point of engagement with the NCIPC BSC.  
The meeting included a presentation on the observations of the BSC Opioid Guideline 
Workgroup.  CDC used the GRADE process to rate the quality of evidence and to determine the 
recommendation categories.  GRADE is a recognized standard for guideline development that 
supports a transparent approach to conducting systematic reviews, rating evidence quality, and 
determining the strength of recommendations.  GRADE is used by more than 100 organizations, 
including CDC.  Within the GRADE framework, recommendations are based on: 
 
 Quality of evidence 
 Balance between benefits and harms 
 Values and preferences 
 Resource allocation, or cost 
 
Evidence is categorized into four types within the GRADE framework: 
 
 Type 1, or high-quality evidence: Randomized controlled trials (RCTs) or overwhelming 
evidence from clinical studies 
 
 Type 2, or moderate-quality evidence: RCTs with important limitations, or exceptionally 
strong evidence from observational studies 
 
 Type 3, or low-quality evidence: Observational studies or RCTs with notable limitations 
 
 Type 4, or very low-quality evidence: Clinical experience and observations, 
observational studies with important limitations, or RCTs with several major limitations 
 
“Low-quality evidence” does not mean that there is no evidence.  Instead, the evidence usually 
consists of observational studies or RCTs that are not well-designed.  Unfortunately, few RCTs 
directly address decisions that clinicians need to make every day. 
 
The recommendations are categorized using GRADE to convey the extent to which there is 
confidence that adherence to the recommendation will do more good than harm: 
 
 Category A: Most patients should receive the recommended course of action. 
 
 Category B: Decisions are made on an individual, case-by-case basis.  Choices vary 
based upon patient values and preferences, as well as specific clinical situations.  This 
category is assigned when the advantages and disadvantages of a clinical action are 
more balanced. 
 
The 12 recommendations of the draft guideline are grouped into three conceptual areas: 
 
 Determining when to initiate or continue opioids for chronic pain 
 Opioid selection, dosage, duration, follow-up, and discontinuation 
 Assessing risk and addressing harms of opioid use 
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Dr. Dowell presented the 12 recommendations and the rationales for each.  Recommendations 
1 through 3 address determining when to initiate or continue opioids for chronic pain.  
Recommendations 4 through 7 address opioid selection, dosage, duration, follow-up, and 
discontinuation.  Recommendations 8 through 12 focus on assessing risk and addressing harms 
of opioid use. 
 
Recommendation One 
Non-pharmacologic therapy and non-opioid pharmacologic therapy are preferred for chronic 
pain.  Providers should only consider adding opioid therapy if expected benefits for both pain 
and function are anticipated to outweigh risks to the patient. 
 
Recommendation Category: A 
Evidence Type: 3 
 
Rationale: 
 
 While there is evidence that opioid therapy can reduce pain in the short term, with most 
trials lasting less than six weeks, there is insufficient evidence to determine whether pain 
relief, function, or quality of life improves with long-term opioid therapy. 
 Long-term opioid use for chronic pain is associated with serious risks, including abuse, 
dependence and overdose. 
 Many non-opioid therapies can improve chronic pain with less risk for harm, including 
exercise therapy, cognitive behavioral therapy, non-opioid pharmacologic therapies, and 
multidisciplinary approaches. 
 When opioids are used, they are more likely to be effective if combined with other 
approaches. 
 
Recommendation Two 
Before starting opioid therapy for chronic pain, providers should establish treatment goals with 
all patients, including realistic goals for pain and function.  Providers should not initiate opioid 
therapy without consideration of how therapy will be discontinued if unsuccessful.  Providers 
should continue opioid therapy only if there is clinically meaningful improvement in pain and 
function that outweighs risks to patient safety. 
 
Recommendation Category: A 
Evidence Type: 4 
 
Rationale: 
 It is difficult for providers and patients to predict whether benefits will outweigh risks of 
long-term opioid therapy.  There is weak evidence that some patients experience pain 
relief long-term, and currently-available risk stratification tools show inconsistent results 
for ability to predict harms. 
 In general, medications should not be continued when harms outweigh benefits. 
 Establishing treatment goals in advance will help providers and patients make decisions 
about continuing or stopping drugs. 
 Pain relief, function, and quality of life are all important. 
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Recommendation Three 
Before starting and periodically during opioid therapy, providers should discuss with patients 
known risks and realistic benefits of opioid therapy and patient and provider responsibilities for 
managing therapy. 
 
Recommendation Category: A 
Evidence Type: 3 
 
Rationale: 
 Providers should involve patients in decisions about whether to start opioid therapy. 
 Many patients lack information about opioids. 
 Essential elements to communicate include: 
 Realistic expected benefits 
 Common and serious harms 
 Expectations for both patients and providers to mitigate risks 
 
Recommendation Four 
When starting opioid therapy for chronic pain, providers should prescribe immediate-release 
opioids instead of extended-release/long-acting (ER/LA) opioids. 
 
Recommendation Category: A 
Evidence Type: 4 
 
Rationale: 
 There is a higher overdose risk among patients initiating treatment with ER/LA opioids 
than among those initiating treatment with immediate-release opioids. 
 The clinical evidence review did not find evidence that continuous, time-scheduled use 
of ER/LA opioids is more effective or safer than intermittent use of immediate-release 
opioids. 
 
Recommendation Five 
When opioids are started, providers should prescribe the lowest effective dosage. 
Providers should use caution when prescribing opioids at any dosage and should implement 
additional precautions when increasing dosage to 50 or more morphine milligram equivalents 
(MME)/day, and should generally avoid increasing dosage to 90 MME/day or more. 
 
Recommendation Category: A 
Evidence Type: 3 
 
Rationale: 
 Risks for serious harms related to long-term opioid therapy increase in a dose-
dependent manner. 
 In a large, national VA sample, the majority of fatal overdose cases had prescribed 
dosages above 50 MME.  Among patients not experiencing overdose, most had 
dosages of 50 MME or less. 
 The benefits of high-dose opioids for chronic pain are not established.  An RCT found no 
difference in pain or function between more liberal dose escalation, with an average 
opioid dosage of 52 MME at the end of the study, and maintenance of current dosage, 
with an average dosage of 40 MME at the end of the study. 
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Recommendation Five is the recommendation for which the most new evidence has 
accumulated in the last five years.  During her medical training in the late 1990s, Dr. Dowell was 
taught that higher opioid dosages did not put patients at higher risk for overdose as long as the 
dose was titrated up slowly enough for patients to develop tolerance.  This teaching was not 
based on controlled studies.  Since 2010, nine well-designed, case-controlled and cohort 
studies have been published demonstrating a strong association between prescribed opioid 
dosage and opioid-related overdose.  Four studies that used similar cut points, and therefore 
could be combined in one chart, are shown here: 
 
 
 
Dosages of 50 to 100 MME per day show an increased opioid-related overdose risk of factors 
from 2 to 5, and dosages of greater than 100 MME per day show an increased opioid-related 
overdose risk of factors of up to 9.  Five additional cohort or case-controlled studies have also 
shown a similar dose-response relationship between opioid dosage and overdose risk. 
 
Recommendation Six 
Long-term opioid use often begins with treatment of acute pain.  When opioids are used for 
acute pain, providers should prescribe the lowest effective dose and should prescribe no greater 
quantity than needed for the expected duration of pain severe enough to require opioids.  Three 
or fewer days will usually be sufficient for most non-traumatic pain not related to major surgery. 
 
Recommendation Category: A 
Evidence Type: 4 
 
Rationale: 
 Opioid use for acute pain is associated with long-term opioid use, and greater amount of 
early opioid exposure is associated with greater risk for long-term use. 
 More than a few days of exposure significantly increases hazards. 
 Fewer days’ supply minimizes the number of pills available for intentional or 
unintentional diversion. 
 In most cases of acute pain, such as acute back pain, not related to major surgery or 
trauma, pain severe enough to require opioids will subside within three days.  If it does 
not, re-evaluation is generally warranted. 
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Recommendation Seven 
Providers should evaluate benefits and harms with patients within one to four weeks of starting 
opioid therapy for chronic pain or of dose escalation.  Providers should evaluate benefits and 
harms of continued therapy with patients every three months, or more frequently.  If benefits do 
not outweigh harms of continued opioid therapy, providers should work with patients to reduce 
opioid dosage and to discontinue opioids. 
 
Recommendation Category: A 
Evidence Type: 4 
 
Rationale: 
 Risks for opioid overdose highest during the first two weeks after initiation for ER/LA 
opioids, within the first three days after initiation for methadone. 
 Patients who do not experience pain relief with opioids at one month are unlikely to 
experience pain relief with opioids at six months. 
 Continuing opioid therapy for three months substantially increases risk for opioid use 
disorder. 
 
There is a strong association between continuing opioid treatment for three months and opioid 
use disorder.  Using data from a large medical claims database, Edlund and colleagues showed 
that patients on more than 90 days of high-dose opioid therapy, defined in the analysis as 
greater than 120 MME, had a 122-fold increase in the likelihood of being diagnosed with an 
opioid use disorder compared with no opioid prescription.  As a comparison, it should be noted 
that the odds ratio for lung cancer in current smokers relative to nonsmokers is estimated at 40, 
and the odds ratio for heart disease in current smokers relative to nonsmokers is estimated at 2.  
Even at relatively lower dosages of 36 MME or lower for more than 90 days, there is a 15-fold 
increase in the likelihood of opioid use disorder. 
 
Recommendation Eight 
Prior to starting and periodically during continuation of opioid therapy, providers should evaluate 
risk factors for opioid-related harms.  Providers should incorporate into the management plan 
strategies to mitigate risk, including considering offering naloxone when factors that increase 
risk for opioid overdose, such as history of overdose, history of substance use disorder, or 
higher opioid dosages (greater than or equal to 50 MME) are present. 
 
Recommendation Category: A 
Evidence Type: 4 
 
Rationale: 
 Opioids can worsen central sleep apnea and increase risk for respiratory depression and 
overdose. 
 Reduced renal or hepatic function can result in a smaller therapeutic window between 
safe dosages and dosages associated with respiratory depression. 
 Patients with mental health co-morbidities and histories of substance use disorder are at 
higher risk for opioid use disorder and overdose. 
 Community-based naloxone distribution has been associated with reduced opioid-
related overdose death. 
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Recommendation Nine 
Providers should review the patient’s history of controlled substance prescriptions using state 
prescription drug monitoring program (PDMP) data to determine whether the patient is receiving 
dangerous combinations that put him or her at high risk for overdose.  Providers should review 
PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy 
for chronic pain, ranging from every prescription to every three months. 
 
Recommendation Category: A 
Evidence Type: 4 
 
Rationale: 
 Most fatal overdoses are associated with high total prescribed daily opioid dosages, 
and/or receipt of opioids from multiple prescribers or pharmacies. 
 Both of these risk factors can be assessed by reviewing PDMP data. 
 
PDMP data can predict overdose risk.  Using data from Vital Statistics in the Tennessee PDMP 
in a matched, case-controlled study, Baumblatt and colleagues found that the risk of death from 
an overdose went up six-fold for patients who received opioids from four or more doctors, or 
from four or more pharmacies.  The risk was 11 times greater for patients on high dosages of 
more than 100 MME. 
 
Patients with one or more risk factors receiving prescriptions from multiple sources and/or total 
dosage, accounted for 55% of all overdose deaths.  They only comprise 6% of patients not 
experiencing fatal overdose.  In other words, information from a PDMP can predict a high 
proportion of patients at risk for overdose death. 
 
Recommendation Ten 
When prescribing opioids for chronic pain, providers should use urine drug testing before 
starting opioid therapy and consider urine drug testing at least annually to assess for prescribed 
medications as well as other controlled prescription drugs and illicit drugs. 
 
Recommendation Category: B 
Evidence Type: 4 
 
Rationale: 
 Urine drug tests can provide useful information about unreported drug use that can 
increase patients’ risk for overdose. 
 Factors influencing category B designation include: 
 These tests are not always covered by insurance, and particularly when more specific 
tests are used can result in significant cost burden for patients. 
 Urine test results are often misinterpreted by providers. 
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Recommendation Eleven 
Providers should avoid prescribing opioid pain medication for patients receiving 
benzodiazepines whenever possible. 
 
Recommendation Category: A 
Evidence Type: 3 
 
Rationale: 
 Concurrent benzodiazepine and opioid prescription are associated with a near 
quadrupling of risk for overdose death, compared with opioid prescription alone in a 
case-cohort study. 
 Concurrent benzodiazepine use has been found in large proportions of opioid-related 
overdose deaths in epidemiologic case series. 
 
Recommendation Twelve 
Providers should offer or arrange evidence-based treatment, usually medication-assisted 
treatment (MAT) with buprenorphine or methadone in combination with behavioral therapies, for 
patients with opioid use disorder. 
 
Recommendation Category: A 
Evidence Type: 3 
 
Rationale: 
 Prevalence of opioid use disorder, previously referred to as opioid dependence or 
addiction, among primary care patients on chronic opioid therapy ranged from 3% to 
26%. 
 Buprenorphine or methadone are effective in preventing relapse among patients with 
opioid use disorder. 
 
NCIPC followed a rigorous process and used GRADE, which provides a transparent framework 
for the translation of evidence into recommendations.  The supporting text in the draft guideline 
provides further information about implementation of the recommendations.  Dr. Dowell thanked 
the group for their time and careful consideration of the draft guideline. 
 
Discussion Points 
 
Dr. Hargarten opened the floor for clarifying questions about the draft guideline.  Regarding the 
background and need for the guideline, he noted that Dr. Dowell reported that 11% of 
Americans experience daily pain.  He asked whether that percentage has changed in the last 
decade or two; that is, is the US as a nation experiencing more chronic pain than ever before, or 
has the situation been fairly steady? 
 
Dr. Dowell replied that it is difficult to tell whether the number of Americans experiencing daily 
pain has changed, as different surveys in different populations ask questions in different ways 
and generate varying ranges.  Some ranges are as high as 40% of adult Americans 
experiencing daily pain, as expressed in the Institute of Medicine (IOM) report, which used the 
definition of “any back pain, arthritis, neck pain, or headache in the last year.”  Other estimates 
are as low as 8%.  It is difficult to track what is happening over time. A study from Daubresse 
and colleagues examined reports of pain in a large database from 2000-2010.  That study 
concluded that the amounts of pain that people reported were relatively constant during that 
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time period.  Interestingly, during that time period, opioid prescribing was increasing as the use 
of other treatments was decreasing. 
 
Dr. Sherry Lynn Hamby asked about the data presented as rationale for Recommendation 
Seven.  She wondered whether the data were presented in comparison with no opioid use and 
whether the cell should not have a zero value, as it is not clear how opioid use disorder would 
be present without opioid use.  She also noted that odds ratios are not equivalent to relative risk 
in many studies and warned that the guideline should take care with that wording.  Relative risk 
could be 122, but that phrasing should not be used to imply an incident rate of over 100%. 
 
Dr. Dowell agreed and clarified that odds ratios are the ratio of one odds to another odds in 
another group, where relative risk is a ratio of proportions.  In terms of the study supporting 
Recommendation Seven, she indicated that opioid use was compared to no opioid prescription.  
The study utilized a claims database to determine opioid use.  People could have been using 
opioids that were not prescribed or that were prescribed outside the managed healthcare 
system. 
18 
 
 
 
Report from Opioid Guideline Workgroup 
 
Christina Porucznik, PhD, MSPH 
NCIPC BSC member 
Chair, Opioid Guideline Workgroup 
 
Dr. Christina Porucznik thanked the group and noted that the Opioid Guideline Workgroup 
included members who represented a range of specialties, experience, and expertise.  The role 
of the workgroup was to provide observations to the BSC about the draft CDC Guideline for 
Prescribing Opioids for Chronic Pain, the clinical evidence review, and the contextual evidence 
review.  The group met four times in 2016 by teleconference on January 8, 13, 15, and 18. 
 
During its January 7, 2016 meeting, the NCIPC BSC suggested that the workgroup engage the 
help of consultants to provide expertise from additional perspectives.  The workgroup engaged 
with consultants from the following additional fields who participated in workgroup discussions 
as the workgroup identified need for additional information in their specialties: 
 
Consultant Area Participation 
Pediatrics & Anesthesiology Ad hoc, not contacted 
Occupational Med & Worker’s Comp Ad hoc, not contacted 
Obstetrics & Gynecology Participated 1/15 
GRADE methods & cost effectiveness Participated 1/8, 1/13, & 1/15 
Medical Ethics Ad hoc, not contacted 
Addiction Psychiatry Participated 1/15 
Physical Medicine & Rehabilitation Participated 1/13 
Addiction Psychiatry Participated 1/15 
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The group made overall observations about the guideline.  These observations apply either to 
more than one of the recommendation statements or to the guidelines as a whole rather than to 
a single statement. 
 
 Workgroup members support efforts reflected in the guideline to encourage integrated care 
for people with chronic pain.  As defined in the draft National Pain Strategy, integrated care 
is the systematic coordination of medical, psychological, and social aspects of healthcare.  It 
includes primary care, mental health care, and specialist services when needed. 
 
 Workgroup members suggest continued monitoring of Guideline implementation for 
evidence of their impact and of unintended consequences, and modification of the guideline 
when warranted by evidence. 
 
 Several workgroup members suggest that pediatric and adolescent populations should be 
considered for future updates of opioid prescribing guidelines.  The current draft guideline is 
intended for adults over age 18 being managed in primary care for chronic pain. 
 
 Risks and benefits of opioid therapy and chronic pain, and the epidemiology of prescription 
drug misuse and abuse, are areas of active research.  The workgroup suggests that the 
contextual evidence review may need to be updated more frequently than the clinical 
evidence review.  The workgroup encourages CDC to work with partners to support 
additional research in this field. 
 
 Workgroup members expressed strong preference for Guideline Recommendations that are 
framed with positive rather than negative language. 
 
 Several workgroup members observed that they were asked to consider cost feasibility for 
the recommendations.  In general, the group feels that such data are lacking and are subject 
to great variability.  More research is required in this domain in order to have evidence 
related to cost feasibility that could be evaluated. 
 
 Concerns about access to care, cost, and insurance coverage were raised by several 
workgroup members in discussion of Guideline Recommendations One, Six, Seven, Eight, 
Nine, Ten, and Twelve. 
 
 Systematic changes in payment policies will likely be required to support implementation of 
the guideline.  Workgroup members encourage CDC to work with federal partners to support 
payment policies that are congruent with the guideline. 
 
 Discussions about safe medication storage and disposal are mentioned in several sections 
of supporting text that accompany the guideline.  Workgroup members observed that these 
discussions are relevant throughout the course of opioid therapy for chronic pain and 
encourage providers to include patient education on safe storage and disposal of 
medications as a routine part of therapy along with discussions of risks, benefits, treatment 
goals, mental health, pain, and function. 
 
 Workgroup members observed that primary care providers may require additional education 
on approaches integral to implementation of the Guidelines, including education on: 
 Non-pharmacologic and integrated care 
 Offering naloxone to patients with chronic pain 
 Medication-assisted treatment for opioid use disorder 
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 Workgroup members encourage CDC to work with partners to support and/or provide 
appropriate education to primary care providers. 
 
The workgroup also offered the following observations about each of the recommendations in 
the draft guideline: 
 
Recommendation One 
 All members of the workgroup agreed with the type and category of evidence for 
Guideline Recommendation One. 
 Workgroup members commend the ordering of statements and agree that the topic of 
this recommendation should be first. 
 Clear wording that opioids are not routine therapy for adults in chronic pain managed in 
primary care, as well as mention that both pain and function are important, are good 
messages to present first in the guideline. 
 Several workgroup members expressed significant concerns about access to care, 
particularly for non-pharmacologic therapies mentioned in this recommendation.  It was 
suggested that there should be clear preference for integrated care for chronic pain 
expressed in Recommendation One and throughout the guideline and supporting text. 
 
Recommendation Two 
 All members of the workgroup agreed with the type and category of evidence for 
Guideline Recommendation Two. 
 Workgroup members particularly commend this recommendation for its focus on patient-
centered goals for improvement of pain and/or function. 
 There was some concern that some providers would interpret the phrasing of “pain and 
function” to mean that improvements are required in both pain and physical function in 
order to justify continuation of opioid therapy.  Such meaning could be clarified in the 
supporting text.  Spinal cord injury patients, for example, may never walk again; 
however, continued opioid therapy may be appropriate if it helps manage their pain and 
improves social or psychological function. 
 Many people with chronic pain also experience mental health concerns, such as 
depression and/or anxiety.  There is evidence that treating these co-existing conditions 
can improve pain outcomes as well.  Several workgroup members encouraged the 
addition of language in the supporting text for Recommendation Two to include 
evaluation of mood in addition to pain and function. 
 
Recommendation Three 
 All members of the workgroup agreed with the type and category of evidence for 
Guideline Recommendation Three. 
 Several members observed that suggesting a safety discussion in response to 
unexpected findings in the PDMP data or urine drug screen results in the supporting text 
for this recommendation may suggest to providers that safety discussions are for 
extreme events, rather than conversations that should occur at initiation of opioid 
therapy and should continue as a routine matter throughout the duration of therapy. 
 Disposal of medications is a complicated situation.  Information about safe disposal of 
medication should be included in the tools accompanying the guideline. 
 Several workgroup members suggest that consideration of possible risk to household 
members from accidental ingestion or diversion of opioids should be included in the 
discussion of risks and benefits with the patient who will be receiving the opioids. 
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Recommendation Four 
 All members of the workgroup agreed with the type and category of evidence for 
Guideline Recommendation Four. 
 This recommendation is evidence type 4, which includes observational studies and 
clinical experience.  The subject matter experts (SMEs) in the workgroup agreed that 
this recommendation is consistent with best practices and well-deserves a Category A 
designation. 
 
Recommendation Five 
 This recommendation generated significant discussion about content in addition to the 
discussion about the recommendation category and evidence type: 
 Six of the nine workgroup members agreed with the category A and evidence type 3 
designation. 
 Three workgroup members felt that the evidence type 3 was appropriate, except for 
the last paragraph of supporting text.  If the discussion of tapering in the supporting 
text was removed, then Category A and evidence type 3 designation was 
appropriate. 
 Two workgroup members suggested revisions to the statement. 
 Most members felt that the evidence for the last paragraph of supporting text, which 
involves tapering, was type 4 evidence, but would support type 3 evidence for the 
remaining paragraphs of supporting text. 
 One specific observation was that the last paragraph of the supporting text for this 
recommendation, regarding patients already taking opioids, does not directly support 
Recommendation Five itself, which is about initiation of opioid therapy. 
 In comparison to contextual evidence for risk and harm for opioid therapy, there are 
virtually no studies of long-term benefits or improvement in pain and function with opioid 
therapy.  Workgroup members encourage future studies to populate this data gap. 
 One member of the workgroup strongly opposes Recommendation Five as it is written.  
This member stated repeatedly that the current recommendation clearly suggesting dose 
limits is not supported by any data showing a decrease in benefit-to-risk ratio at the 
arbitrary number stated in the recommendation.  This member expresses concern that 
the current wording of Recommendation Five will undermine support for the entire 
guideline from providers and professional organizations. 
 The focus on patient pain and function included in the text of Recommendation Two is 
not similarly included with Recommendation Five.  Improvement or decrement of pain 
and/or function should be the impetus for any change in dose, either increasing or 
decreasing.  Workgroup members observed that this message should be repeated here. 
 
Recommendation Six 
 All members of the workgroup agreed with the evidence type for Recommendation Six. 
 There was considerable discussion about the category for this recommendation: 
 One member recommended that this recommendation should be Category B. 
 Many members are able to support the Category A designation only if the statement 
is reworded to include a range for the duration of therapy. 
 The duration of therapy was the focus of animated discussion: 
 Many members felt that three days was too limited and preferred a range of values, 
none of which exceeded seven days. 
 Seven days or fewer: four members 
 Three to seven days: two members 
 Five to seven days: one member 
 Three to five days: one member 
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 One member was strongly opposed to seven days as too long. 
 A specific wording suggestion for this recommendation is, “Avoid prescribing more than 
three days’ supply, unless circumstances clearly warrant additional opioid therapy.” 
 The supporting text for this recommendation should also include information and tools 
about safe medication storage and disposal. 
 
Recommendation Seven 
 All members of the Workgroup agreed with the type and category of evidence for 
Recommendation Seven. 
 This recommendation should apply to all patients.  Several workgroup members 
expressed concern that the wording of this recommendation applies only to opioid naïve 
patients. 
 Individual workgroup members suggested specific edits to this recommendation, 
particularly to the final sentence.  There was concern that it implies that all patients 
should be at a dose of zero opioids and fails to suggest what else providers should do 
regarding other therapies besides eliminating the opioid medication. 
 
Recommendation Eight 
 All members of the Workgroup agreed with the type and category of evidence for 
Recommendation Eight. 
 Two members suggest that the recommendation would be stronger with the inclusion of 
concomitant use of central nervous system (CNS) depressants or sedatives among the 
listed risk factors in the statement. 
 
Recommendation Nine 
 All members of the Workgroup agreed with the type and category of evidence for 
Recommendation Nine. 
 The bulleted information in the supporting text for this recommendation should also 
apply to patients on high dosages of medications and dangerous combinations, not just 
patients receiving medications from multiple providers. 
 Workgroup members observe that access to PDMP data and the utility of that data vary 
among states.  Issues of data sharing can limit PDMP utility in border areas.  CDC and 
its federal partners are encouraged to support PDMP development and operation across 
the country and to help to work toward efficient data access and interfaces for all 
providers of controlled substances. 
 
Recommendation Ten 
 All members of the workgroup agreed with the evidence type for Recommendation Ten. 
 The majority of workgroup members felt that this recommendation should be a Category 
A recommendation, rather than Category B. 
 The universal recommendation from Category A is perceived to be both more focused 
on patient safety and less likely to result in urine drug testing being applied selectively 
among already-stigmatized or stereotyped patients. 
 Supporting text for this recommendation should encourage providers to use the simplest 
urine drug testing appropriate for each patients in order to reduce cost and improve the 
feasibility of the recommendation. 
 Workgroup members emphasized the need for providers to be educated about 
interpretation of the results of the urine drug testing implemented in their practice 
settings. 
 Research on risks and benefits of urine drug testing is limited, and more such research 
is encouraged. 
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Recommendation Eleven 
 All members of the workgroup agreed with the type and category of evidence for 
Recommendation Eleven. 
 Risk mitigation in the presence of co-prescription of opioids and benzodiazepines was 
universally supported by the workgroup. 
 Members of the workgroup observed and supported that the intention of this 
recommendation is to discourage concurrent prescribing of opioids and benzodiazepine 
medications; however, several members felt that the current language presumes that the 
benzodiazepine is appropriate and fails to encourage patient-centered decision-making 
about risks and benefits for each medication. 
 Supporting text for this recommendation could include language regarding the 
importance of the pharmacist in co-prescribing situations and the role for the use of 
PDMP data to identify concurrent medication use. 
 Workgroup members noted that the wording of Recommendation Eleven has changed 
significantly during the comment and review process. 
 Several workgroup members preferred the original wording. 
 Some workgroup members preferred that this statement be modified to state that 
“providers should use caution when” prescribing opioids, rather than “providers 
should avoid” prescribing opioids. 
 Several workgroup members supported the “avoid” wording, and two members 
strongly preferred the “avoid” wording. 
 Discussion about this recommendation surrounded concerns about inter-professional 
communication; that is, between psychiatrists, who frequently prescribe the 
benzodiazepine and the primary care providers, who prescribe opioids.  The discussion 
included challenges and the need for providers and patients to jointly discuss the 
patient’s needs, prioritize patient goals, and weigh risk of concurrent benzodiazepine 
and opioid exposure before deciding upon initiating, continuing to prescribe, or tapering 
either medication. 
 
Recommendation Twelve 
 There was disagreement among the workgroup members regarding the evidence 
category for this recommendation.  One member strongly supported a Category B 
designation, while the remaining members were comfortable with Category A. 
 Workgroup members agreed that the evidence for MAT for opioid use disorder is strong 
and recommended that the evidence type for this recommendation be upgraded from 
Type 3 to Type 2. 
 Workgroup members commended the wording of this recommendation, particularly the 
“providers should offer or arrange” clause.  The workgroup members felt that this 
wording will help encourage primary care providers to be proactive about treatment for 
opioid use disorder and perhaps encourage more providers to acquire training and 
licensure for buprenorphine prescribing. 
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The workgroup also reviewed and generated observations on supplemental materials to the 
draft guideline, including the Clinical Evidence Review, the Contextual Evidence Review, and 
Comments from Stakeholders, Peer Reviewers, and the Public. 
 
 The Clinical Evidence Review was thorough and well-done for the specific clinical 
questions. 
 Workgroup members recommend continued support for future clinical and contextual 
research on benefits and risks of opioid therapy for chronic pain. 
 Future updates of the Contextual Evidence Review should seek out more information 
about specific non-pharmacologic therapies for chronic pain, such as exercise therapies, 
interventional therapies, integrated medicine, and behavioral therapies. 
 Evidence in the Contextual Evidence Review supports that mental health disorders 
frequently co-occur among people with chronic pain.  The supporting text for 
Recommendations Two and Five, which describe evaluating pain and function, should 
be modified to include evaluation of patient mood as well. 
 Comments from constituents demonstrated the breadth and variety of positions on the 
issue of opioid therapy for chronic pain among adults managed in primary care.  
However, there seemed to be general agreement that guidelines are urgently needed, 
even if this set of guidelines is only the first step. 
 Comments from patients and family members in particular expressed the desire that 
patient-centered care is enhanced, rather than reduced, by this guideline.  Members of 
the workgroup felt that the guideline could be implemented in a manner consistent with 
patient-centered care. 
 
Discussion Points 
 
Dr. Shelly Timmons asked about the extent to which the workgroup took into account the 
larger context of chronic pain, its diagnosis, separation of pathophysiologies, and the 
determination of appropriate treatments of chronic pain other than opioids.  She noted that Dr. 
Houry had mentioned that this guideline is part of a larger effort on chronic pain.  The guideline 
has a limited scope for a reason and is only addressing the use of opioid therapies; however, 
she wondered about the context of the workgroup’s formulation of language, particularly in the 
contextual section.  There is some paucity of language in that section that could expand on the 
problem of diagnosis and pathophysiology, and the selection of appropriate treatments. 
 
Dr. Porucznik replied that the workgroup extensively discussed the difficulty of patient access 
to non-pharmacologic therapy for chronic pain.  Members of the group agreed that it is a great 
idea for patients to manage chronic pain through means other than opioids, and that opioids 
should not be a first step of treatment.  Members were also in agreement that it is difficult in 
practice for patients to access other therapies and for providers to get patients into care that 
does not have a prescription.  There was a great deal of concern that because this document 
focuses on opioids, it may give the impression that opioids are normal and that other therapies 
are alternative when in reality, the characterizations should be reversed.  Opioids should be 
reserved for cases in which they are the only approach that works.  The workgroup realized that 
this guideline is for the prescription of opioids in primary care. 
 
Dr. Traci Green added that the focus of the guideline was on what to do after an assigned 
diagnosis of an acute or chronic pain condition, not on what do to before the diagnosis. 
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Dr. Timmons expressed concern that only alternative therapies that are not medical were being 
considered.  The first step is to decide whether opioid medication is even appropriate for the 
type of chronic pain that a patient is experiencing.  There are surgical therapies and other 
medications and classifications that could be more appropriate.  Headache and back pain, for 
instance, have multiple etiologies and it is important to work through the range of appropriate 
and possible approaches.  The emphasis on that decision-making process is in a brief 
paragraph in the draft guideline, but the process may have been given short shrift.  More 
clarifying language on may be needed, if possible. 
 
Dr. Porucznik responded that the workgroup had discussed this issue.  There is limited 
evidence comparing opioids to other therapies.  Encompassing the spectrum of evidence is 
challenging. 
 
Regarding the workgroup response to Recommendation Five and the statement on dosage 
limits, Dr. Deborah Gorman-Smith noted that one workgroup member strongly opposed 
including specific limits.  She assumed that the other workgroup members were not concerned 
about the dose levels stated in the guideline and asked for more detail about the group’s 
conversation. 
 
Dr. Porucznik said that there was a great deal of workgroup discussion on this point.  Other 
workgroup members did not have as strong a response to the limits as the member with the 
strong response.  There was concern that nearly any specified level chosen could be described 
as “arbitrary.”  The available evidence is primarily from large claims databases and related 
sources.  Opioid dosing is not discrete.  It is in “chunks of pills.”  Therefore, it is not possible to 
look at a uniform distribution and find an inflection point.  The other workgroup members were 
comfortable with the levels presented in the draft guideline. 
 
Dr. Greenspan reminded the participants on the telephone that they could access the 
workgroup observations document at www.cdc.gov/injury/BSC, under the tab “Meetings.” 
 
Dr. Hargarten thanked Dr. Porucznik and the workgroup and congratulated them on a 
thoughtfully organized summary of their observations. 
 
 
Lunch Break / Call to Order / Roll Call 
 
Dr. Greenspan dismissed the group for a lunch break at 10:40 a.m.  The meeting resumed at 
11:30 a.m.  Mrs. Tonia Lindley conducted a roll call of the BSC members and ex officio 
members and established that a quorum was present. 
  
25 
 
 
Draft Meeting Minutes NCIPC Board of Scientific Counselors January 28, 2016 
 
 
Discussion of Workgroup Report 
 
Stephen Hargarten, MD, MPH 
Professor and Chair 
Department of Emergency Medicine 
Medical College of Wisconsin 
Chair, National Center for Injury Prevention and Control Board of Scientific Counselors 
 
Dr. Hargarten thanked Dr. Porucznik for her leadership of the Opioid Guideline Workgroup, and 
Dr. Green and the other workgroup members for the time and effort that they dedicated to 
reviewing the draft CDC Guideline for Prescribing Opioids for Chronic Pain and its supporting 
documentation.  He reminded the participants that the materials were available online.  During 
this session, he opened the floor for questions and comments regarding the content of the 
Opioid Guideline Workgroup observations and requested that BSC members provide input 
regarding their priority areas of concern or clarification. 
 
Discussion Points 
 
Dr. Angela Mickalide requested a more engaged discussion regarding safe storage of 
medications, particularly with the pediatric population, as well as further discussion regarding 
the lack of Type One and Type Two evidence within GRADE and whether this type of evidence 
will ever be available moving forward. 
 
Dr. John Allegrante suggested that they discuss professional education and the potential 
partnerships that will need to be formed for provider education regarding the guideline and 
regarding the problem of opioid abuse in general.  This guideline will be an organic, living 
document, but he said he hoped to discuss further provider education and the implementation of 
the guideline. 
 
Dr. Joan Duwve asked for additional conversation regarding urine drug monitoring, especially 
the availability of specific urine drug tests that are appropriate for office-based use and that are 
powerful enough to discern the types of information that providers may need to make informed 
decisions.  There may need to be more robust language in the guideline regarding urine drug 
monitoring.  She also hoped for a discussion regarding the workgroup’s suggestion that this 
recommendation should be Category A rather than Category B. 
 
Dr. Samuel Forjuoh observed that there are already too many recommendations and 
wondered if they could be combined.  There may be a way to simplify them, especially given 
that primary care physicians are already overwhelmed and may be burdened by several 
recommendations on opioids. 
 
Dr. Wilson Compton asked for discussion regarding evaluating the outcomes of implementing 
the guideline and assessing its impact both on pain patients, the larger drug abusing community 
and on overdose rates, which is the main goal of the guideline.  There are potential positive 
impacts, such as reducing opioid misuse, abuse, and overdose.  There are also potential 
benefits and complications for patients that seek pain treatment. 
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Dr. Hamby suggested that the group discuss the review of state policies and how they figured 
into the development of the guideline.  She encouraged that they consider using the rich data 
that are available from a number of states that have implemented different guidelines with 
different features in order to determine which approaches have the biggest impact on overdose.  
There is an opportunity to advance evidence-based practice.  Further, there should be 
consideration of inclusion of other outcomes and possible adverse effects, such as patients who 
have had less-successful pain management due to more restricted access to opioids.  National 
guidelines that were released in 2010 apparently had little impact on prescribing practices, 
which have increased considerably. 
 
Dr. Duwve expressed confusion with respect to Recommendations Eight and Eleven, 
particularly regarding the workgroup recommendation to include depressants and sedatives in 
Recommendation Eight.  Recommendation Eleven speaks to this point when it refers to the co-
prescribing of benzodiazepines.  Perhaps the CNS depressants could be added to 
Recommendation Eleven so that Recommendation Eight remains focused on multiple 
prescribers for opioids specifically. 
 
Dr. Gerald Gioia asked to hear more discussion regarding non-pharmacologic therapies and 
the guidance that can be provided to primary care providers to prepare them to inform their 
patients about those options if they are not actively pursued. 
 
Dr. Timmons emphasized that in addition, surgical therapies may be considered, as well as 
other, non-opioid pharmacological therapies.  The BSC might consider recommending 
increased language regarding the context.  The guideline refers to integrated care for chronic 
pain, which is a combination of multiple diagnoses.  It is important to integrate that conversation 
at least into the guideline’s background materials and to educate primary care providers on 
choosing therapies appropriately. 
 
Dr. Hargarten noted that some of the BSC’s responses addressed the workgroup observations, 
and others focused on content within the guideline. 
 
Dr. Porucznik addressed Dr. Duwve’s observations on Recommendations Eight and Eleven.  
Recommendation Eight lists different risk factors and times when people should take more 
caution, including before starting and periodically during continuation of opioid therapy.  The 
workgroup felt that CNS depressants and sedatives represent a real risk factor at this point and 
should not be left out of this recommendation.  The recommendation chiefly refers to 
benzodiazepines, and it is important for another recommendation to focus on benzodiazepines.  
The workgroup did not specify benzodiazepines in Recommendation Eight because they did not 
want to be too specific and possibly imply that other depressants or sedatives are free from risk.  
There has been a great deal of work on the combined harms of opioids and benzodiazepines, 
partly because they both appear in PDMP data and it is relatively easy to evaluate them. 
 
Dr. Duwve agreed about the risks of co-prescribing.  In Indiana, she hears of people taking the 
“holy trinity” of a muscle relaxant, benzodiazepines, and opioids to potentiate the effects of the 
opioids.  She had been confused regarding why there were two recommendations, but she 
agreed that there is sufficient risk to warrant mentioning them twice. 
 
Dr. Porucznik turned to Recommendation Ten and the availability of office-based urine drug 
testing and the assignation of Category A versus Category B.  The workgroup felt that assigning 
Category B to the recommendation was tantamount to having no recommendation at all.  
Presently, urine drug testing is used by some providers.  It is probably more often used for 
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patients who are members of more stigmatized populations or in a stereotypical testing.  The 
workgroup felt that assigning Category A to the recommendation for urine testing would 
strengthen it, systematize it, make testing more part of routine care, and not relegate the testing 
to an approach that providers use to “fire patients.”  Regarding the availability for office-based 
use, there is a wide variety of technologies being used for urine drug testing.  The larger 
concern of the workgroup was that providers may not be aware of the testing that occurs when 
they call for urine drug screening.  There is a corollary of providers who buy expensive 
machines and conduct office-based testing as a means of generating income.  Neither scenario 
is appropriate.  Therefore, the workgroup suggested using language that refers to the “simplest 
appropriate test.”  This recommendation incorporates not testing for something that will not 
change the management, and considering testing in a qualitative rather than a quantitative 
fashion.  Providers should observe the prescribed medications to check for diversion and should 
ensure that there are no other opioids present.  Many primary care providers will need 
education regarding the appropriate types of testing so that the testing is cost-efficient for 
patients and useful in practice. 
 
Dr. Duwve agreed that it is difficult for providers to tease out who needs to be tested and who 
does not.  This concept was confirmed in Indiana when a family practice doctor tested all 
patients in his practice in a small rural community.  The results were surprising.  Patients who 
had never violated any of the contractual provisions had no evidence of drug in their urine when 
tested.  Providers can be poor judges about who needs to be tested.  There has been a great 
deal of discussion in Indiana regarding language that is applied to testing.  There are many 
options, and it can be challenging for a busy primary care provider to navigate them.  She 
recommended that the guideline include detailed directions for when to use a test, what its 
results mean, and more.  Indiana uses language that states that “a prescribing physician shall 
perform or order a drug monitoring test that must include a confirmatory test using a method 
selective enough to differentiate individual drugs within a drug class.”  Reducing cost and 
improving feasibility are worthy goals, but if the test is meaningless, then the approach is not 
cost-effective. 
 
Dr. Porucznik said that the implementation choices are likely to occur at system levels rather 
than in individual private offices.  CDC can provide tools in the supporting text to the guideline to 
help the decisions get made. 
 
Dr. Hargarten asked about follow-up plans for education, such as their specificity, instructions, 
and emphasis. 
 
Dr. Dowell added that the key to the success of the guideline will be provider education and 
implementation.  CDC is not at that stage yet, but there has been a great deal of thinking about 
the best way to ensure that the guideline is understood and used.  Fact sheets and a checklist 
will be created for providers.  In particular, a fact sheet is planned on non-opioid treatments, 
including non-pharmacologic treatments as well as non-opioid pharmacologic treatments.  It will 
take longer to develop, but it will be important to provide fact sheets on urine drug testing, 
dosage, and understanding MME.  Fact sheets are also planned on PDMP checks and what 
they mean and do not mean, as well as suggestions to help patients.  A mobile app is also 
planned.  In the future, CDC hopes to engage with medical professional societies and clinical 
decision support mechanisms to help providers follow guidelines, when appropriate, with their 
patients.  Quality improvement (QI) measures may present another avenue, and it may be 
possible to work with academic institutions that can partner with health systems to develop a QI 
technical package.  Other ideas are welcomed. 
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Dr. Allegrante said that medical societies are logical partners, given continuing medical 
education (CME).  He suggested partnering with the pharmaceutical industry.  It may be 
controversial, but given the impact that the industry has on prescribing behavior among 
clinicians, it may be worth consideration. 
 
Dr. Dowell replied that CDC had not yet thought about the pharmaceutical industry, but there is 
an extensive risk evaluation and mitigation strategy (REMS) program for extended release and 
long-acting opioids, which is funded by pharmaceutical companies. 
 
Dr. Timmons asked about plans for developing a research agenda for comparative 
effectiveness research or other types of research on this subject. 
 
Dr. Dowell answered that research is very important and critically needed.  This research will 
also be expensive to do well.  There have been discussions with potential funding partners 
regarding how to prioritize the research. 
 
Dr. Timmons said that one of the benefits of developing guidelines is the light that they shed on 
where evidence is lacking and to develop and publish a research agenda, even if it is not funded 
through CDC. 
 
Regarding the co-occurring use of benzodiazepines and other medication, Dr. Hamby said she 
understood that the majority of overdoses are among people who are on multiple medications.  
It would be worth considering emphasizing this point more in terms of identifying the most at-risk 
patients.  Regarding language, she noted that Indiana uses the phrasing “shall” in reference to 
certain urine testing, and the workgroup debated whether this point should be Category A or B 
in the guideline.  These questions are empirical and data are already available to address them.  
Data are available because there is variability in the language used in state prescribing policies.  
It is possible to examine the differences in rates in urine testing and the more important final 
outcome of overdose.  The best available scientific evidence should be used to craft policy, and 
this state information is not currently being used to inform the guideline. 
 
Dr. Hargarten noted that the recommendation was to classify selective urine testing as 
Category A, as opposed to Category B.  This change would be consistent with the current 
understanding of the best approach. 
 
Dr. Hamby pointed out that the workgroup’s conclusion represented a consensus judgment.  
Actual data could support the classification and allow the language to be strengthened.  State 
data are probably available on increasing the percent of patients are being urine tested and on 
the type of testing that is offered.  With these data, many ideas that are presented as 
professional judgment calls could be treated as empirical questions with current available data. 
 
Dr. Robert Johnson noted that while evidence is available regarding how frequently people are 
tested, there is no evidence regarding how urine drug testing impacts outcomes.  There is the 
potential for harm, which was considered by the workgroup, because urine drug tests can be 
difficult to interpret and many primary care providers are not skilled in interpreting them.  The 
cost issue is complex.  Confirmatory tests add $50 to $100 each, and patients may be billed for 
them.  Confirmatory tests may not be needed in all situations, such as when the detected drug 
was expected.  These issues need to be addressed within laboratories and clinic systems.  If a 
confirmatory test is mandated, it may not be based on strong data and the cost-effectiveness is 
not clear.  Some people may be found through this testing who would not be expected; 
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however, a low-risk person with 10 urine drug tests with expected results may not need to 
continue being tested.  Many questions are not addressed well and supported with evidence. 
 
Dr. Hamby concurred regarding cost issues, which could be incorporated into the products that 
accompany the guideline.  Information is available regarding evidence of the impact on the 
outcome of overdose, but has not been analyzed.  The state policies could be coded for their 
strength of recommendation, the type of testing, whether it is required or optional, and other 
factors.  Good state-level data are available on overdose rates.  It would be a simple matter to 
code state policies for key issues within the recommendations and determine whether states 
with stronger wording show fewer overdoses, for instance, or whether the policy does not affect 
outcome.  This point is an example of the states as “laboratories,” as a wide range of policies 
have been implemented.  The variability and CDC surveillance could be used to craft guidelines 
based on the factors that are most correlated with reductions in overdose. 
 
Dr. Johnson pointed out that the data analysis requires resources and time.  A larger problem 
is the number of confounding factors.  Most of the states that implement urine drug testing 
policies are implementing a number of other opioid-related policies.  It would be highly 
challenging to separate the causative factors with any reliability. 
 
Dr. Porucznik replied that this issue relates to the questions of evaluating outcomes and 
implementation.  Her state tried to conduct a project to determine the impact of the guidelines 
that were promulgated some years ago.  Many of the guideline statements were difficult to 
assess in practice.  It was difficult to measure the degree to which the recommendations had 
been implemented at a statewide, health systems, or practice level and therefore to determine 
whether there had been changes in practice.  Urine drug screening is a discrete practice that 
could be assessed by billing data, for example, to determine how frequently certain practices 
and providers order the tests.  The same billing data cannot be used to learn what the providers 
do about the results of the tests, or how they decided to make a request for testing for one 
patient and not another.  She agreed that evaluating implementation and associated outcomes 
is important, but the work will not be straightforward and it will require a great deal of 
cooperation not only among state PDMPs, but also among health systems to access medical 
record data that will include diagnoses, laboratory requests, billing, and other elements.  
Systems will need to work together in a manner that they presently do not in order to move 
forward with this implementation. 
 
Dr. Hamby stressed that complete information is almost never available about mediators or 
mechanisms.  Many of these factors could be relatively “low-hanging fruit” for determining 
indicators of mechanisms.  Data have been presented, for example, from Washington State on 
the year that the guidelines changed and the subsequent overdose rates.  A small step beyond 
this work is to guide the state guidelines and re-run the analyses.  Details on implementation, 
mediators, and mechanisms would be welcomed.  However those details are not necessary for 
global associations that could add a higher degree of confidence in the conclusions in the 
guideline. 
 
Dr. Porucznik said the question of the availability of Type One and Type Two evidence is 
worthwhile.  She noted that the draft guideline recommendations are based on Type Three and 
Four evidence, which rely on observational studies, the epidemiological literature, and the 
contextual evidence review rather than on clinical trials.  Clinical trials in this area are highly 
unlikely.  For instance, a long-term clinical trial on more than a year of opioid therapy versus 
surgery is not likely to occur.  Therefore, it is important and valuable that the guideline 
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incorporates not only a clinical evidence review, but also information from the literature review 
and contextual evidence review to support its statements. 
 
Dr. Green added that comparative effectiveness work could contribute to the understanding of 
GRADE Types One and Two. 
 
Dr. Timmons thought that this area needed additional emphasis on the pathophysiology of pain 
mechanisms.  Interventions cannot be compared and providers need context regarding the type 
of pain that is being treated.  This guideline focuses on patients who already have been deemed 
to have a pain problem or some other problem that is amenable to main.  Therefore, it should 
put these mechanisms into context. 
 
Dr. Porucznik addressed the question of attempting to measure, document, and consider both 
pain and function.  These issues should be based not only on a pain score, but also on 
consideration of how they are doing and whether the current therapy is helping them live a 
better life.  That discussion should take place between patients and providers regarding the 
course of action that will get patients to their best point. 
 
Dr. Timmons agreed and supported the guideline’s emphasis that function is not only physical.  
Other factors affect how people function in their daily lives.  One therapy versus another will be 
different for each individual, and these questions should be central to every discussion between 
a patient and provider. 
 
Dr. Porucznik agreed and added that it can be easy to latch on to something like a pain score 
or a functional assessment, which is easier to record.  If providers only focus on aspects of a 
patient that are easy to record in simple categories, then important parts of the discussion are 
missed.  CDC hopes to encourage patients to think with their providers about other benefits, 
such as their ability to play with their children, which are not easy to fill in on a form. 
 
Dr. Gioia pointed out that these issues relate to the bio-psycho-social aspect of pain, which is 
that mood and mindset should be assessed with function.  Mood can be a transient, situation-
specific effect or an existing mood or anxiety disorder that now frames the pain experience and 
potentially the effect of the biological agent that is prescribed to modify the pain response.  The 
close integration of the psychological component is important. 
 
Dr. Porucznik turned to the subject of safe storage, especially as it pertains to the protection of 
children from accidental ingestion.  The workgroup discussed this issue at length, as it is related 
to safe and reasonable disposal practices so that unused medication is not available for 
diversion or accidental ingestion.  CDC plans to make information about safe storage and 
disposal available as part of the accompanying tools to the guideline document. 
 
Regarding non-pharmacologic therapies and providing guidance to primary care providers, Dr. 
Porucznik said that partnerships for professional education will be important to help primary 
care providers implement the recommendations in their practices. 
 
Dr. Gioia commented on discussion in the psychological and psychiatric sciences regarding 
how to screen patients for a variety of medical disorders related to mood and anxiety, knowing 
that these disorders can be mediators and moderators of response and even of outcome.  To 
that extent, he wondered about the workgroup’s discussion regarding elevating or reinforcing 
the integrative model and particularly the need to emphasize the assessment of mood and its 
relationship to the opioid prescription. 
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Dr. Porucznik said that the workgroup discussions about non-opioid and non-pharmacologic 
returned to the same perceived barrier of patient access, primarily for insurance coverage for 
such therapies.  The US is a large country with diverse regions, and a comprehensive pain 
center is not within the reach of everyone.  The workgroup was somewhat at a loss with this 
point, as there was agreement that therapies other than opioids are important to help people 
manage chronic pain, but there was great concern regarding how people can access those 
therapies.  The workgroup fervently hopes that inclusion of these other therapies within the 
guideline recommendations may help serve as a “bully pulpit” to encourage payment changes 
so that patients can potentially access other therapies.  Further, the inclusion within the 
guideline could help providers think about discussing other therapies with their patients.  
Including information in the tools that accompany the guideline regarding how to have these 
conversations and about the other potential therapies will be helpful; however, the resources will 
be different in every individual practice and health system.  Therefore, it is not possible to 
encourage a “one size fits all” strategy.  It is not possible to change the curricula of medical 
schools or to force practitioners to take CMEs in this area, but the guideline can help start the 
conversation and provide a means for academic and medical partners to address the issue. 
 
Dr. Gioia thanked the workgroup for not allowing the barriers to interfere with making the right 
decision to include this recommendation.  Access will not be advanced until these questions are 
asked and these problems are defined.  It is important to include these issues. 
 
Dr. Porucznik noted that the workgroup had many conversations regarding whether the 
guideline should reflect the world as it is, or the world that they would like to live in. 
 
Dr. Timmons said that most change in areas such as these comes from patients themselves as 
they ask questions and advocate for themselves and their family members.  She asked about 
plans for patient education materials on types of pain, types of alternative therapies, and related 
issues. 
 
Dr. Dowell said that CDC plans patient educational materials. 
 
Dr. Porucznik commented that this issue relates to the idea of a research agenda related to 
guidelines and the types of professional education opportunities that might make the most 
difference in providers changing their practices.  The effort may not focus on educating 
individual practitioners, but about educating administrators of health systems. 
 
Regarding the comment that there are “too many recommendations,” Dr. Porucznik also 
participated on the Core Expert Group that participated in the initial development of the 
guideline.  At one point, there were approximately 26 recommendations.  There has been 
significant reduction since then.  In order to reach practicing physicians effectively, she 
wondered if the recommendations should be reordered so that the top three that are most likely 
to be retained are of highest priority.  Many of the recommendations will be operationalized at a 
system level more than in an individual provider’s head.  For instance, recommendations such 
as not beginning therapy with a long-acting prescription in a patient who has not had such a 
prescription could be incorporated into the electronic medical record (EMR). 
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Dr. Forjuoh said he understood the points, but reiterated that there are too many 
recommendations.  He works with primary care providers who are overwhelmed with 
recommendations, so he always thinks about how to make their work easier.  He suggested that 
Recommendations Four and Five, which both refer to prescribing the lowest effective dosage, 
could be combined. 
 
Dr. Porucznik said that the use of checklists could be helpful in provider offices.  This issue 
speaks to the research agenda that will be possible, as well as to the evaluation and 
implementation phase.  It will be important to learn how different health systems operationalize 
the recommendations and to make comparisons to determine which models are best so that 
they can be disseminated throughout the country. 
 
Dr. Green commented that the recommendations fall into three conceptual areas:  1) beginning 
opioid therapy, 2) continuing opioid therapy, and 3) assessing risk.  The different areas apply to 
different types of patients along the care trajectory. 
 
Dr. Porucznik revisited the idea of evaluating outcomes.  It is important to think about the kinds 
of outcomes that might be available for evaluation.  They all want to “move the needle” on 
overdose fatality, but outcomes that are closer on the causal chain should be considered, such 
as prescription dispensing, studying a reduction in the duration of days of supply or reductions 
observed in PDMP data of patients having concurrent prescriptions from different providers.  
She asked the BSC for other suggestions that can help inform the research agenda. 
 
Dr. Hamby suggested measuring unintended consequences, not just reduction in overdose.  
Reduction in overdose is a desirable outcome, but it is important to meet the needs of the 
heterogeneous group people with chronic pain.  Adverse outcomes could include increased cost 
and difficulty in accessing pain treatments.  There are counties in her region that do not have a 
physician, much less a massage therapist or acupuncturist.  These services are far more 
expensive and difficult to access.  Patients should not be “fired” by their doctors as the providers 
are under pressure regarding prescribing.  Some providers may opt not to treat people with 
chronic pain.  These unintended consequences, or side effects and complications, should be 
considered.  Is healing delayed from the service utilization point-of-view if a three-day 
prescription is provided rather than a seven-day prescription?  In this case, it may be necessary 
for a practice to accommodate twice as many medical visits for pain patients, and the burden to 
the practice as well as the cost borne by insurance companies is important.  It would be helpful 
if the guideline shared thinking on these issues, as many people have raised concerns about 
them. 
 
Dr. Porucznik agreed that measuring unintended consequences will be important.  These 
points cannot be derived from an administrative database.  She said she hoped that 
collaborations could be engaged with qualitative researchers that do not rely on extracting 
information from medical records in order to measure these impacts.  The impacts should be 
incorporated into the evaluation of the guideline and into future iterations of the guideline.  
Patients should not die, but they also should not suffer. 
 
Dr. Duwve said that physicians are uncomfortable prescribing opioids because they see the 
overdoses that present to hospitals and they see the mortality that results from overdose.  
Several physicians have related that they are more comfortable prescribing within a set of 
guidelines, as they are more secure knowing that they are prescribing appropriately and safely. 
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Dr. Tamara Haegerich described some of the proposed translation materials.  A Quality 
Improvement (QI) technical package for health systems could outline specific education for 
providers, quality metrics for monitoring treatment, and pulling quality metrics from the EHR to 
monitor average daily dose, whether urine drug screens are conducted, and PDMP checks.  
Patient outcomes can be included in the EHR to gather this information.  The “plan, do, study, 
act” cycle can be implemented: plan the education and the necessary practice changes to 
implement the guidelines, measure, reflect and determine whether changes are needed, and 
engage in the cycle again.  CDC envisions creating a package that health plans can adopt and 
utilize as well as forming groups of health systems that work together in a QI collaborative to 
share best practices, changes, and adverse and beneficial outcomes.  Evaluation at the smaller 
health systems level is less concerned with confounding factors and can isolate practices. 
 
Dr. Allegrante said that this approach is the operational answer to the pushback on the notion 
of moving to RCT-type designs too quickly.  A focus on implementation and measures related to 
implementation may be more feasible and perhaps more important as the first part of the 
research agenda.  Regarding outcomes over time, these issues are complex behavioral 
changes on the part of patients, providers, industries, and insurance companies.  There will be 
so many confounding factors that it will not be possible to point to the guideline’s internal validity 
with any integrity.  He supported an investigative approach to evaluation that will draw on 
historical documentation and anthropologic methods, and the kinds of qualitative methods that 
may yield a great deal of information about the behavior of this guideline in the hands of various 
stakeholder groups.  The approach proposed by NCIPC is ideal. 
 
Dr. Green observed that there is tremendous opportunity with Recommendation Twelve, 
especially in the treatment of opioid use disorder.  Systems-level change and incorporating MAT 
into the conversation at the systems-wide level will be important.  There has been constrained 
access to treatment and medications in rural areas.  Moreover, payer-based systems have 
placed many prior authorizations and other challenges to accessing treatment.  Discussing non-
opioid therapies and non-pharmacological treatment can incorporate ideas regarding access to 
effective and evidence-based opioid use disorder treatments. 
 
Dr. Timmons supported the idea of incorporating more of the workgroup’s thought process into 
the document, which will have a wide audience of thoughtful, intelligent, and educated people 
who can help solve the problems.  For the document to be received by the audience with 
credibility, it may be helpful to describe the lines of thinking, such as a discussion of the 
limitations associated with using an administrative or billing database for drawing conclusions, 
as they are fraught with problems.  If the document outlines the thinking behind the 
recommendations, the available data or data gaps, and the suggested ways forward, then the 
living document can help guide and shape future research. 
 
Dr. Porucznik agreed and noted that “science happens in bits” and it is important to start 
somewhere.  When this guideline is put forward, it will start many conversations and spark many 
scientific questions.  They should be glad that the process will lead to more evidence and help 
to save lives. 
 
Dr. Timmons stressed that the workgroup put a great deal of work and time into conducting 
thoughtful analyses, and the extent to which this work can be reflected in more detail will be 
beneficial. 
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Dr. Hargarten said that the workgroup observations can be advanced by the BSC to inform the 
guideline.  The discussion thus far had highlighted much of the workgroup’s deliberations.  
Evaluation is important and was touched on by the workgroup.  The intended consequence of 
the guideline is, of course, fewer deaths.  The unintended consequences that have been 
discussed are important.  It is complicated to implement a federal guideline when many state-
based guidelines are being implemented and evaluated. 
 
Dr. Porucznik emphasized that the guideline is a guideline, not legislation.  There will be 
situations in which a health system already has practices in place that are more restrictive than 
the guideline suggests.  Situations such as these should be measured as implementation 
progresses.  The BSC is not putting forward the guideline; rather, the BSC’s function is to make 
a recommendation to CDC regarding moving forward with the guideline, taking the observations 
from the workgroup and the public into account as the guideline is finalized. 
 
Dr. Holly Hedegaard commented on the layout and presentation of the document, which will 
have an impact on its acceptance.  The documents shared thus far were dense and wordy, with 
a layout that was not conducive to readers’ full understanding.  Each recommendation in the 
guideline could include a section on the clinical analysis and a section on the discussion points 
that have arisen.  The recommendations would be stronger if they were accompanied by not 
only the scientific thinking behind them, but also the additional factors that were considered in 
generating them, the additional research that is needed, and potential prioritization. 
 
Dr. Hargarten agreed that the materials should be clear.  This guideline is patient-centered and 
is informed by the best available science to equip providers to make the best decisions for their 
patients.  He noted that Recommendation Five in the guideline spurred a great deal of 
discussion in the workgroup and asked for the BSC’s thoughts. 
 
Dr. Hamby appreciated the work of the workgroup and the opportunity for robust discussion 
among people of varying opinions.  She commented on the range of consensus among the 
workgroup members and noted that not all of the recommendations had the same level of 
endorsement or consensus.  NCIPC would do well to take the differences into consideration as 
the guideline is finalized, particularly regarding Recommendations Five and Six.  The 
recommendations may be helped if text is included to describe the thinking behind the 
establishment of specific dosage ranges and opioid treatment duration.  She did not feel that the 
evidence supported a specific recommendation and that the three-day duration specified in 
Recommendation Six was somewhat arbitrary.  If there were strong feelings about that duration, 
then the argument should be described clearly.  Almost any of the ranges better reflect the 
quality of the evidence.  She appreciated that the workgroup highlighted these issues.  
 
Dr. Porucznik said that the workgroup discussions had a planned agenda, and different 
recommendations were discussed in different meetings.  Some recommendations were 
expected to be more controversial than others, so they were not discussed on the same day in 
order to ensure that appropriate time was allotted to discuss all of the issues.  Their meetings 
were via telephone, and some workgroup members spoke up more than others.  Before the 
discussion was closed on each recommendation, a roll call was conducted of all workgroup 
members to ensure that everyone had a specific time and opportunity to weigh in.  This 
approach enhanced the discussion and captured perspectives from all of the specialties and 
backgrounds represented in the group.  When there was disagreement, it was not the 
workgroup’s role to establish consensus.  The workgroup’s role was not to edit or change the 
document.  The different observations were captured so that they could be shared with the BSC 
and CDC. 
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Regarding Recommendation Six, Dr. Duwve appreciated the variety of opinions expressed and 
the different ranges.  There did not appear to be consensus regarding a number of days.  The 
language in the recommendation and the supporting text stated that the prescription should be 
for no greater quantity than needed for the expected duration of pain severe enough for opioids.  
The text then stated that three or fewer days will “usually be sufficient.”  The use of the word 
“usually” left the number of days to the discretion of the provider.  Further, the text stated that 
providers should consider a default of less than or equal to three days and adjust the duration 
based on circumstances of the pain syndrome.  Therefore, the document gives flexibility to 
providers to use clinical judgment.  The larger message is that 30 days with three refills are not 
needed.  Short durations are appropriate because there is risk beyond a certain amount of time, 
but the prescription is at the provider’s discretion. 
 
Dr. Gorman-Smith addressed Recommendation Five and dosage limits.  She asked about the 
workgroup discussion regarding suggested language, as well as the two recommendations and 
two levels of evidence regarding tapering that are reflected. 
 
Dr. Porucznik replied that this recommendation was a point of great contention among the 
group, because workgroup members felt that the last paragraph of supporting text, which 
focuses on patients who are already on opioid therapy, is important but may not belong where it 
is placed in the document.  The conversation was difficult, because the workgroup did not want 
to recommend creating an additional recommendation to address tapering for patients who are 
already on opioid therapy. 
 
Dr. Dowell said that the draft of Recommendation Five reflected earlier discussions during the 
guideline development process, with numerous levels of feedback, comment, and review.  
There were concerns regarding this recommendation being applied to both patients starting 
opioid therapy and patients who are already on high dosages.  The initial intent of the 
recommendation was to address initiation and not reaching high dosages in the first place.  The 
paragraph in question in the supplemental text was added to give providers and patients more 
flexibility and to acknowledge that the issues are different for patients who are already on high 
dosages.  The text acknowledges that the possibility of dosage reduction could be anxiety-
provoking for patients who have been on high dosages for years, and that the risk-benefit 
equation is different for them.  However, these patients should be given the opportunity to 
reevaluate their continued use of opioids in light of recent evidence.  She understood the 
questions regarding whether this point belonged in Recommendation Five and whether the 
evidence type was the same as the rest of the recommendation. 
 
Dr. Porucznik said that the workgroup agreed that the conversation is important to have and 
that the information is important to share, but they concluded that the evidence type was not the 
same for that paragraph of information.  Including that paragraph calls into question the 
evidence type for all of Recommendation Five.  The workgroup observed that keeping 
Recommendation Five about initiation and finding another place in the document to discuss 
information about patients who have been on long-term, high dosages would be cleaner and 
more consistent. 
 
Dr. Compton understood that the 90 MME limit applied to longer durations and not to initiation 
of opioid therapy.  The evidence is for chronic care, not just for initiation.  The recommendation 
mixed initiation and long-term, given its focus on MMEs for initiation and for longer terms of 
therapy. 
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Dr. Porucznik replied that views of the length of the initiation process may differ.  If a patient is 
starting therapy and receiving dose escalations, then a provider could still perceive that the 
patient is in the initiation phase as the dose is escalating, as opposed to a patient the provider 
“inherited” who is already on opioid therapy. 
 
Dr. Hamby noted that the workgroup’s discussion also related to specificity and the provision of 
a single point of duration.  If the research states that three or fewer days is usually sufficient for 
most non-traumatic pain that is not related to major surgery, it implies that there is evidence that 
two days is not enough, four days is too many, and seven days is definitely too many.  The 
evidence review does not have that level of specificity regarding the impacts of different 
dosages.  The same point applies to 90 MMEs versus 80 MMEs, as there are not hard scientific 
data to support the specific dose recommendations.  It may be preferable to follow the 
recommendations of the workgroup and acknowledge that the evidence base does not have 
that level of specificity and to offer a range, or to word the recommendation so that it does not 
make a strongly affirmative statement in the absence of specific data.  These data are needed 
in the research agenda, but the guideline may need to be more cautious, given the current state 
of scientific knowledge. 
 
Dr. Porucznik said that particularly regarding Recommendation Six, the workgroup agreed that 
“knee-jerk” prescriptions for 30 days should not be written.  The workgroup felt that three days 
was too short but could support ranges.  If one fixed number is offered, then there may be a 
perception that there is something “magical” about it.  Offering a range, even if it includes or is 
centered upon a fixed number, gives a better perception of the uncertainty related to the 
number. 
 
Dr. Dowell pointed out that even though Recommendation Five was assigned evidence Type 3, 
this area has had the most new research since the latest guidelines were released.  A 
systematic review of opioid prescribing guidelines published before 2012 considered doses 
greater than 200 MME confer higher risk.  The cut points were arbitrary in order to put patients 
in categories of dosages.  Other studies have showed similar results.  A study by Bohnert, et al 
used a national VA sample to match patient prescriptions with death certificate data.  The 
average dose among overdose decedents was 98.1, and among patients not dying of overdose 
was 47.7.  These findings contribute to the notion that a dosage of 100 is too high.  This paper 
tried to drill down specifically.  The median prescribed dosage among patients dying of 
overdose was 60, with an interquartile range (IQR) of 30-120.  Among controls, the median 
prescribed dosage was 25, with an IQR of 15-45.  Initially, the thinking was that stopping and 
reevaluating at a dosage of 50 made sense.  Most patients are under that dosage, although 
there may be reasons to be on higher dosages.  Some of the data suggest that 100 may be too 
high for safety in most cases.  There is not a single cutoff below which opioids are safe and 
above which they are unsafe, but there is building evidence that risk increases in parallel with 
dose.  There is no robust evidence to suggest that increasing dosages results in greater control 
of pain. 
 
Dr. Hamby noted that Recommendations Five and Six will apply to a higher percentage of 
cases, as the recommendations focus on sufficient doses and length of treatment duration for 
adequate pain control.  It is not disputed that the longer a patient is on opioids, and the higher 
the doses that the patient receives, that the risk of overdose increases.  However, that 
conclusion does not provide direct evidence to support a specific statement such as “three or 
fewer days is usually sufficient for non-traumatic pain.”  It is important to describe other 
outcomes and goals to ensure that pain management is adequate.  Millions of people receive 
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treatment for the management of pain, and a smaller number are at risk for overdose.  These 
distinctions should be made, and the science should be presented carefully. 
 
 
 
 
Stephen Hargarten, MD, MPH 
Professor and Chair 
Department of Emergency Medicine 
Medical College of Wisconsin 
Chair, National Center for Injury Prevention and Control Board of Scientific Counselors 
 
Leslie Dorigo 
National Center for Injury Prevention and Control 
Centers for Disease Control and Prevention 
 
During this session, Dr. Hargarten opened the meeting for the public comment period.  He 
thanked the members of the public who were participating in the meeting in-person and via 
teleconference.  As described in the Federal Register notice announcing the meeting, the public 
was asked to pre-register in order to provide comments.  Comments were to be provided on a 
first-come, first-served basis.  The comment period was scheduled to be open from 1:00 p.m. 
until 2:30 p.m. 
 
Ms. Dorigo added her welcome and explained the public comment period format.  She thanked 
the individuals and organizations who had pre-registered to make comment, indicating that the 
commenters would be called in the order in which they pre-registered.  The in-person 
commenters were instructed to speak at the microphone, and those in attendance via telephone 
were informed that the telephone operator would un-mute their respective lines when it was 
their turn to speak.  Ms. Dorigo indicated that remarks were to be limited to two minutes, and 
that reminders would be provided when approximately 30 seconds remained in the allotted time.  
If commenters were not available when their name was called, their name would be called again 
at the end of the queue.  All public comments will be included in the official record of the 
meeting and posted on the CDC website with the complete meeting minutes at 
www.cdc.gov/MASO.  She indicated that the public comment period would not include questions 
and answers, but assured participants that any questions posed during the period would be 
considered by the BSC and CDC. 
 
The teleconference operator provided the commenters on the telephone with instructions for 
making their comments. 
 
Gary Mendell 
Shatterproof 
 
Mr. Gary Mendell introduced himself and explained that he is a father who has experienced the 
anguish of burying his first-born son, who was addicted to opiates.  He is also the founder of 
Shatterproof, a national organization committed to identifying and implementing solutions to the 
tragic epidemic of overdose death in the US.  Shatterproof is sensitive to the many Americans 
who suffer chronic pain; however, the draft CDC guideline makes it clear in the first sentence 
that the guideline is not intended for patients who are undergoing active cancer treatment, 
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palliative care, or end-of-life care.  To reverse this horrific epidemic, the medical community is 
urgently in need of guidance from CDC.  The previous day, the US Senate Judiciary Committee 
held a hearing that documented unanimous support for the CDC guideline from the 
administration and bipartisan Senators who advocated with unanimity that over-prescribing of 
opioids is a root cause of this epidemic, and that better provider education and guidelines are 
necessary, quickly. 
 
Mr. Mandell has seen first-hand countless wonderful people who have become addicted to 
prescription painkillers, many of whom have died and left their families torn apart and 
“shattered” as his was.  Those who have died cannot be present to testify.  CDC can wait for 
years for further research, but if it does, tens of thousands of people will die, and tens of 
thousands of families will be torn apart beyond imagination—not to mention the millions of 
Americans who lead subpar lives with their families, parents, sons and daughters, as they wait 
for the phone call that no one wants to receive.  In this regard, he urged CDC to disregard all 
comments made by individuals with financial conflicts of interest and to issue as quickly as 
humanly possible the guideline that has been prepared for months.  As a father of four other 
children, he and families across America are depending on CDC. 
 
Susan Peschin 
Alliance for Aging Research 
 
Ms. Peschin serves as President and CEO of the Alliance for Aging Research.  She thanked 
CDC for the opportunity respectfully to request changes to the draft CDC Guideline for 
Prescribing Opioids for Chronic Pain.  In Recommendation One, the guideline should 
acknowledge the real-world issues of non-pharmacologic therapy and non-opioid pharmacologic 
therapy as first-line treatments for chronic pain.  While acupuncture, massage, and other types 
of treatment demonstrate short-term benefits, the primary focus of this guideline is the long-term 
management of chronic pain.  Further evidence is needed before they can be suggested as 
alternatives to opioids.  Most of these treatments are not reimbursed by public and private 
insurers, so providers should be directed to consider their patients’ coverage status before 
prescribing an unaffordable intervention. 
 
Additionally, the Alliance for Aging Research is concerned about the overuse of over-the-
counter (OTC) pain relievers by providers attempting to avoid an opioid prescription, particularly 
for older persons with multiple chronic conditions.  Nonsteroidal anti-inflammatory drugs 
(NSAIDs) are contraindicated for several diseases that seniors experience concurrently with 
pain.  Acetaminophen also has a maximum daily limit that easily can be exceeded in the pursuit 
of chronic pain management. 
 
In Recommendation Five, the dosage thresholds are in direct conflict with the US Food and 
Drug Administration’s (FDA) approved product labeling, which deliberately excluded dosage 
thresholds based on evidence review.  A June 2015 piece in the journal Pain Medicine found 
that “dosage levels are not informed by high-quality evidence are arbitrary and may amount to 
experimentation with increased risk to patients.”  Recommendation Five is not supported by 
evidence, and the Alliance for Aging Research urges that it should be removed from the 
guideline. 
 
Recommendation Six imposes a three-day limit for the prescription of opioids to treat acute 
pain.  The clinical evidence for this recommendation focused on the emergency setting, not on 
acute pain post-surgery.  This recommendation disproportionately impact seniors, since they 
are 2.6 times more likely to have surgery than younger adults.  Ms. Peschin requested that CDC 
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remove a time or specific pill limit for acute pain treatment.  The emphasis of this 
recommendation should be on prescribing the lowest dose of a short-acting opioid in a number 
and duration that the provider determines to be clinically necessary. 
 
Opioids may not be the panacea, but they have helped reduce pain and improve function for 
millions of people.  This effort should focus on the need to ensure access while preventing 
harm. 
 
Gary M. Franklin, MD, MPH 
Washington Department of Labor and Industries 
Co-chair, Washington State Agency Medical Director’s Group (WA AMDG) 
 
Dr. Franklin stated that the over-prescribing opioid epidemic represents the worst man-made 
epidemic in modem medical history, with over 175,000 deaths from unintentional overdose, 
many more hundreds of thousands of emergency department and hospital admissions from 
overdoses, and millions with potential addiction. 
 
The recent paper by Case and Deaton in the Proceedings of the National Academy of Sciences 
(PNAS) pointed out the shocking increase in mortality among middle-aged, lower-educated 
whites.  A large proportion of this increase in mortality in this very susceptible group of 
Americans is related to unintentional overdose of prescribed opioids.  Dr. Franklin reported the 
first deaths in the US from unintentional overdose of prescribed opioids in a peer-reviewed 
journal in 2005.  These unintentional overdose deaths primarily occurred among injured workers 
who had entered the workers compensation system due to a mild musculoskeletal injury.  This 
was the saddest thing he had seen in many years as Medical Director. 
 
By 2006, the public programs in the State of Washington already had over 10,000 citizens on 
doses of opioids greater than 100 MMEs.  By 2008, this translated into 508 deaths from 
prescribed opioids.  More than half of these deaths were in the Medicaid program.  In response, 
the WA AMDG, in full collaboration with a large group of the state’s well-respected academic 
and clinical pain experts, developed the nation’s first opioid dosing guideline.  WA AMDG has 
subsequently developed two more guidelines, the most recent in 2015.  The result has been a 
40% decline in unintentional overdose deaths in Washington state. 
 
WA AMDG strongly supports the CDC guideline, which is consistent with the WA AMDG 
guidelines. 
 
Don Flattery 
Citizen Advocate / Impacted Parent 
 
Mr. Don Flattery lives in Alexandria, Virginia.  He is a grieving parent who has suffered the loss 
of his 26-year-old only son to an opioid overdose sixteen months ago.  His talented, highly 
educated, and loving son became addicted to OxyContin® as a working adult.  Like thousands 
of others, including members of the medical community, he did not fully comprehend the 
addictive power of opioid drugs, and that misunderstanding led to his demise. 
 
Mr. Flattery strongly believes that the draft CDC guideline is a rational first step in returning to 
more cautious prescribing of opioids in the US.  Moreover, the guideline is urgently needed and 
cannot wait for more research, more debate, and more deliberation.  The imperative to act is 
now. 
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Recommendations One, Two, Three, and Seven are much-needed, common sense statements 
of caution for physicians to consider as they establish long-term treatment goals while also 
improving communication between doctors and patients regarding the immutable addiction risks 
associated with opioid therapy, something clearly lacking in today’s practice. 
 
Mr. Flattery said he appreciated the focus of several recommendations, especially 
Recommendation Eight, to the continual evaluation of risk factors, particularly in select 
populations such as pregnant women, the elderly, patients with existing substance use disorder, 
and those co-prescribed benzodiazepines.  He believes that his son’s adolescent exposure to 
opioids related to a sports injury possibly inculcated him and created a physiological response, 
making him more susceptible to future opioid addiction.  While the guidelines are not aimed at 
those under the age of 18, prior adolescent use of medically-prescribed opioids should be 
factored into physician assessments of patient vulnerability to addiction.  Such patients are 
potentially at risk as opioid-prescribed adults. 
 
Mr. Flattery implored CDC to maintain the recommendations that specify dosage and duration.  
To remove such limits and numerical recommendations would render the guideline 
meaningless, a potential goal of some outside groups with business or financial interests to 
protect.  Further evidence and future studies could address slight modifications that could be 
accomplished through future guidance or supplemental documents. 
 
Mr. Flattery encouraged CDC to issue the prescribing guideline as expeditiously as possible.  
He applauded the creation of a valuable tool that does not impede physician decision-making, 
but improves patient care and protects public health. 
 
Michael Britt Doyle 
Widower of a Wife With Opioid Addiction 
 
Mr. Michael Britt Doyle lives in the San Francisco Bay area and is the father of four.  He urged 
CDC to implement the opioid prescribing guideline.  Last year, his wife passed away after a 15-
year battle with opioid addiction, starting with her third Caesarian section.  In 2000, they did not 
realize the dangers that opioids presented as they do now.  When addiction took hold of his 
wife, she went to various pharmacies and different doctors all over the area.  He heard her say 
many times, “I’m just following doctor’s orders.”  The response was convenient, but it was also 
true.  She eventually ran out of doctors and pharmacies, but she was taking nearly 50 pills per 
day and experienced horrible withdrawal for several months.  She received prescriptions for 
other medications, such as Klonopin, Valium, and other benzodiazepines.  When she could no 
longer get those drugs, which she took at a rate of 20-30 pills per day, she turned to alcohol.  
When she would drink so much that she would be taken to the hospital in an ambulance, the 
protocol was the same: a 72-hour hold followed by a 28-day substance abuse program.  CDC 
has the possibility to save lives. 
 
Dr. Hargarten noted that the line had dropped and the last of Mr. Doyle’s comments were not 
heard, but his written comments had been submitted for the official meeting record. 
  
41 
 
Draft Meeting Minutes NCIPC Board of Scientific Counselors January 28, 2016 
 
Kerilyn Whitehead 
Sister of a Brother Who Overdosed 
 
Ms. Kerilyn Whitehead expressed thanks for the opportunity to speak.  Many people are not 
aware of the growing epidemic of addiction.  There is a stigma surrounding society that 
addiction is something that one can control.  One can decide whether or not he or she wants to 
be an addict.  People are taught to look at addicts as criminals and deadbeats who deserve the 
life they have built for themselves.  This could not be further from the truth behind addiction. 
 
Further education needs to be given not only to children, adolescents, and teenagers in schools, 
but to families and medical professionals as well.  Addiction is a disease just like diabetes, 
cancer, Alzheimer’s, and Lyme Disease.  Addiction affects not only the addict, but also the 
addict’s family, friends, and anyone in the addict’s close circle. 
 
April 1, 2015, is a day that Ms. Whitehead will never forget.  At about 3:30 in the morning, she 
awoke to her parents’ frightened screams.   They were screaming her brother’s name from his 
room in hopes that he would respond.  Her 19-year-old brother was lying in his bed, 
unresponsive.  Strange noises came from his mouth and nose.  She got out of bed to see what 
was going on his room and immediately called 911.  Her brother had overdosed on opioids and 
was nearly dead from taking OxyContin®. 
 
Hospitals are not given the proper tools or education they need to treat addicts and addiction or 
overdoses.  Many hospitals do not even want addicts brought into the emergency room; 
however, they have no other choice.  Stamford Hospital did not treat her drug addicted brother 
properly; however, she was not sure if they actually knew how. 
 
With more than two million Americans age 12 or older abusing or dependent on opioids, all 
hospitals, doctors, and nurses should know how or what to do with this epidemic.  Drug 
overdose deaths have more than doubled since 2000, with a record of 45,000 deaths in 2014.  
Six in ten of those deaths involved opioids, such as prescription pain relievers like isocodone 
and OxyContin®.  Getting prescriptions has never been easier.  More education, policies, and 
awareness need to be brought to this growing epidemic, and it needs to happen now. 
 
Dr. Harold Laski 
Southside Medical Center 
Jacksonville, Florida 
 
Dr. Harold Laski addressed the problem that lies in the unintended consequences that will 
occur.  The guideline states that it is voluntary, but past history shows that state medical boards 
and others will view these as standards of care. 
 
Recommendation Five states a total daily dose ceiling of opioid, and the addition of the word 
“generally” does not add to the clarity of the phrase and does not alleviate patients’ fear.  
Physicians will not prescribe higher doses, even when appropriate.  It is the CDC’s obligation to 
create a guideline that helps resolve all of the unintended consequences of its action.  This task 
is hard, but if not, chronic pain sufferers will look for other, more dangerous avenues to obtain 
relief.  If just 10% of the 100 million Americans with chronic pain seek treatment, there would be 
a necessity of 10 million doctor visits a month just for chronic pain.  Generalists need to treat the 
vast majority of chronic pain patients.  
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The guideline must be created so that only those who merit receiving the controlled medications 
are able to get them.  Mark Twain once said, “There are three kinds of lies: lies, damned lies, 
and statistics.”  The statistics that show that controlled substances are often involved in medical 
cases of morbidity and mortality are misleading.  If all cases were removed in which the 
presence of opioid was inappropriate, such as persons who obtained the drugs illegally and 
patients who were inappropriately prescribed the medications, only the patients who were 
appropriately prescribed the correct medication and dose would be left.  This group of users 
statistically shows a very low number of cases of morbidity and mortality. 
 
It is important not to “put our heads in the sand” and ignore chronic pain sufferers.  The solution 
must be part of the guideline and not something that waits for future solutions.  Educational 
requirements for physicians who prescribe, as well as for patients who use controlled 
substances, should be part of the guideline.  Incentives must be given to drug researchers so 
that every opioid is available only in forms that cannot be abused—not just the branded, long-
acting opioids, but all opioids. 
 
The guideline should recommend a national drug database, not just state, to eliminate doctor-
shopping and pharmacy-hopping.  Physicians and pharmacists have access to full drug 
information that at this point is not accessible, such as for Methadone clinics in government 
institutions such as the VA.  It is important to do something that helps everyone and does not 
create unintended consequences. 
 
Barron Joseph Clepp 
Father of a Son Who Died of an Overdose 
Retired Human Resource Director 
 
Mr. Barron Joseph is a father from Texas with first-hand knowledge of the need for better 
management of opioid prescribing patterns.  Before he retired in 2013, he was Director of 
Human Resources for a local branch of a large national organization.   He supported 
approximately 1200 working people, mostly between the ages of 19 and 25.  In this position, he 
had complete visibility of terminations, drug testing, medical leave, and performance 
evaluations.  The use of painkillers was a large factor in terminations, medical problems, and 
poor job performance evaluations. 
 
One worker was a 24-year-old male who was a prescription drug user.  He was terminated.  He 
went home and told his mother, who was caring for him, that he was getting a glass of water 
from the kitchen.  He went to the kitchen, took an overdose of painkillers, and killed himself.  
The Human Resources system could not do anything for these young people.  In 2013, over two 
millions Americans abused or were addicted to opioid painkillers.  What could they do?  The 
Human Resources system placed their behavior in their permanent record and forced them to 
seek another job. 
 
In 2014, 28,000 people in the US died from prescription opioid painkillers and heroin overdoses. 
Those 28,000 people were real people.  Mr. Clepp’s son David was addicted to painkillers and 
alcohol.  He fought a long, difficult fight against addiction.  He died of a heroin overdose on 
August 2, 2011 in San Antonio, Texas.  He was 27 years old. 
 
“For the public record, I love you, David.  Thank you.” 
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Lexi Reed Holtum 
Steve Rummler Hope Foundation 
 
Ms. Lexi Reed Holtum stressed that with the 14% increase in opioid overdose deaths in 2014, 
the highest rate on record with a total of 28,467 opioid overdose deaths, it is clear that active 
steps must be taken to support prescribers and to change prescribing practices.  Ms. Holtum 
supported the CDC draft guideline. 
 
It is especially frustrating to those who have studied how this problem came about that there 
was never any scientific evidence that these medicines were safe and effective in the long-term.  
Further, the data over the last 15 years have seen no proven benefit to those taking these 
opioid medicines, such as decreased rates of disability for musculoskeletal pain or reduced 
need for surgery, such as spinal fusion.  The incidence of both continues to increase to new 
heights, with over 11 million recipients of Social Security Disability Insurance (SSDI) in 2014 
compared to four million in 1992.  In short, there is no evidence of benefit and ample evidence 
of harm. 
 
Many prescribers have received only limited education on how to treat pain or addiction.  How 
could they be expected to intuitively know how to assess for the dangers in prescribing opioids?  
The proposed guideline offers a simple and modest formula for prescribers to follow to more 
safely manage patients’ pain.  The proposed guideline is not mandatory.  It is simply a guideline 
and does not restrict prescribers’ ability to assess individual situations, case-by-case, in order to 
determine the best outcome.  The guideline also supports pain patients by using better care and 
providing the opportunity to understand the risks of prescribing. 
 
Dee DeLuca-Mattos 
Mother of a Son in Recovery From Opioid Addiction 
 
Ms. Dee DeLuca-Mattos introduced herself and said that on January 28, 2012, she and her 
husband, frightened beyond words, drove their son to the airport so that he could travel to begin 
treatment for opioid addiction. 
 
In 2013, almost two million Americans aged 12 or older either abused or were dependent on 
opiates.  Her family is part of that number.  She supports greater caution in prescribing opioids 
as a mother of a son in recovery from opioids.  His addiction did not start from buying drugs on 
the streets or from a drug dealer on the wrong side of the tracks, as everyone perceives.  His 
addiction began as a result of an accident after which he was prescribed 60 OxyContin® to go 
home with, with two refills thereafter. 
 
He was in his last year of college with a bright future when his addiction started spiraling out of 
control.  The family struggled to save him not only from his addiction, but also from the medical 
professionals who were so recklessly prescribing the opioids to him not for pain, but because he 
asked for them.  Ms. Deluca-Mattos is one of the lucky ones, because today her son is in 
recovery.  But he will have to fight every moment of every day, work a program, and commit 
himself to sobriety because his addiction will never go away. 
 
Each night Ms. Deluca-Mattos chats with a group of women who have been brought together 
not by tea or tennis, but who found each other in the darkest of moments—all of their children 
are addicted to opioids.  Most of the women are not as fortunate as she.  So for them and for 
the children whom they have lost, she pledges not only to help in the fight against illegal drugs, 
but also to stand as a beacon of hope and change.  This change needs to happen, because 
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who needs 60 OxyContin®?  Ms. Deluca-Mattos implored CDC to implement change and 
education so that this epidemic can be eradicated. 
 
Sarah Svoboda  
National Safety Council 
 
Ms. Sarah Svoboda said that the National Safety Council (NSC) would like to thank CDC, 
NCIPC, and the BSC for their work to address the Nation’s opioid epidemic and to develop the 
draft guidelines.  NSC is a 100-year-old, Congressionally-chartered nonprofit safety organization 
with the mission of saving lives by preventing injuries and deaths at work, in homes and 
communities, and in transportation through leadership, research, education, and advocacy. 
 
After a thorough review of the evidence assembled and the draft recommendations, NSC 
strongly supports the draft guideline.  There is little evidence that chronic opioid therapy (COT) 
offers effective relief from chronic pain; however, there is abundant evidence about the harms of 
COT.  These recommendations, which provide clear, evidence-based guidance for clinical 
decision-making, could have saved Bill, a 33-year-old machinist, who died of an unintentional 
overdose of methadone in July 2006.  He had been taking hydrocodone for severe lower back 
pain relief but developed a tolerance to it.  On a Friday phone call, Bill’s doctor prescribed 
methadone, a long-acting opioid.  The methadone dose Bill took that weekend led to his death.  
He left behind a wife and two sons.  Recommendation Four specifically cautions that 
“methadone should not be the first choice for an ER/LA opioid” as methadone’s unusual 
characteristics make the safe prescribing for pain especially challenging. 
 
A number of these recommendations (numbers Seven, Eight, Nine, and Twelve) cite the 
increased risk of opioid-use disorders when encouraging physicians to re-evaluate COT after 
three months.  Michael, a 20-year old patient with Crohn’s disease, became addicted to the 
opioid painkillers prescribed for this condition.  He took his own life while on a waiting list for 
substance abuse treatment.  Recommendation Twelve speaks directly to the life-saving role of 
physicians and how collaboration with their patients and substance abuse treatment providers 
can prevent senseless outcomes such as Michael’s. 
 
Betts, a chronic pain patient on COT, had concerns about the safety of her high dose and the 
quality of life.  When she asked her physician if she could be addicted, the doctor did not 
address those concerns, so she found a different physician.  Working together to set realistic 
treatment goals and expectations, her physician helped her taper off of opioid pain medications, 
obtain counseling for her addiction, and use a variety of non-opioid therapies to better and  
more effectively manage her pain.  The patient-centered principles Betts’s physician employed 
are echoed in the draft guideline. 
 
Lawrence Little 
Hunterdon County, New Jersey 
 
Mr. Lawrence Little lives in Hunterdon County, New Jersey, which is the highest-income 
county in the state, and the fourth-highest-income county in the nation.  What is less known is 
that the county has dark statistics of which it is less proud.  Hunterdon County law enforcement 
reported that overdose cases increased 33% from 2014 to 2015.  In 2015, 88% of the overdose 
cases were due to heroin or opiates, which represented a five-time increase over 2014.  In 
2015, overdose fatalities increased by 50%, even with the increased use of Narcan™ in the 
county. 
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The statistics are not just numbers to Mr. Little, who has witnessed the impact of opioid abuse in 
his own family.  He watched his niece struggle just days after her birth with the opiate 
withdrawal she inherited from her mother during pregnancy.  A local athlete has received 
prescriptions for opiates for months at a time for sports injuries, with the result of addiction.  His 
life and his family are spiraling out of control. 
 
Mr. Little’s wife recently underwent gallbladder surgery.  After surgery, the hospital staff insisted 
that she take Percocet® prior to being released.  She explained that she reacts poorly to opioids 
and did not want to take them.  She felt that ibuprofen would be fine.  This preference led to a 
“full-court press,” so she relented and took one Percocet®.  She regretted this immediately, as it 
made her nauseated.  The hospital insisted that she take a prescription for Percocet®, even 
when she insisted that she would not fill it.  The next day, the hospital followed up with his wife 
and was incredulous that she had not filled the prescription and was shocked that she was 
doing fine on ibuprofen alone.  Mr. Little and his wife were horrified that the prescription was for 
a 30-day supply of Percocet® which, for someone less scrupulous, would have been worth 
considerable money on the street. 
 
The CDC must approve opioid prescription guidelines without delay, and without watering them 
down.  Every day of waiting results in more people becoming addicted or dying. 
 
G. Caleb Alexander, MD, FACP 
Johns Hopkins Bloomberg School of Public Health 
 
Dr. Caleb Alexander is a practicing General Internist and Pharmacoepidemiologist.  He co-
directs the Center for Drug Safety and Effectiveness at the Johns Hopkins Bloomberg School of 
Public Health.  He noted that the draft CDC guideline focuses on a critical area where clinicians 
need more guidance.  Contrary to what some have claimed, the recommendations provide 
sufficient scientific support to justify their strength and the derivation of “strong” 
recommendations is entirely consistent with best practices in guideline development.  A big part 
of the problem is that manufacturers have generated much of the “evidence” used to promote 
opioids, and almost none of it is relevant to chronic opioid use, as has been discussed.  Despite 
how frequently some argue that guidelines like these may hurt patients’ access to effective 
treatments, he is not aware of any high-quality evidence to support these assertions. 
 
Much of the opposition to the guideline has been based on a faulty premise; namely, that the 
recommendations will somehow jeopardize the care of those living with pain.  This is a false 
dilemma that presupposes that there are only two options: reducing opioid use or maintaining 
patients’ access to beneficial treatments.  There are multiple options for doing both.  High-
quality care for those in pain is not jeopardized by guidelines such as these; in fact, it requires 
them. 
 
The Bloomberg School of Public Health recently released a comprehensive set of 
recommendations entitled “The Prescription Opioid Epidemic: An Evidence-Based Approach.”  
The document was submitted to the docket.  In addition to supporting prescribing guidelines 
such as those proposed in the CDC draft guideline, the Bloomberg School of Public Health also 
recommends targeting other points along the spectrum of prescription drug production, 
distribution, prescribing, dispensing, and use.  Comprehensive and coordinated approaches to 
opioid-related injury, addiction, and death offer the greatest promise for reducing the incredible 
morbidity and mortality from these products.  Dr. Alexander expressed his gratitude for the 
consideration of these matters. 
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Joan Peters-Gilmartin, PA-C, MHP 
Mother of a Son Who Died from a Heroin Overdose 
Nauset Family Practice, Orleans, MA 
The Open Door of Cape Cod, North Eastham, MA 
 
Dr. Joan Peters-Gilmartin is not only a primary care provider in family medicine, but also she 
represents a family of loss, having lost her son to heroin overdose in 2014.  His opioid abuse 
disorder began with prescription pills. 
 
Most of the general public have no idea about the history of pain management that was 
promulgated to health care providers over the last 20 years and how we got to where we are 
today with a widespread, full-blown epidemic of opioid overdose deaths across all ages and 
demographics.  Healthcare providers are just as poorly trained in assessing pain as they are in 
treating it, and there have never been evidence-based guidelines for using long-term opioids for 
chronic pain until recently.  New neuro-biological research indicates, in fact, that we have been 
doing it wrong for decades, unwittingly following the pressures of big Pharma and medical board 
warnings that pain was being under-treated.  In fact, we have often made chronic pain worse 
with long-term opioid use, driving the patient request for increased doses by creating the 
condition of hyperalgesia. 
 
Given that the USA is the largest consumer of opioid prescriptions, it also is time to look at this 
issue and ask why that is the case.  In part, prescribers were driven this way because insurance 
companies refused to cover, or limited access to coverage for, other modalities for chronic pain 
management that can be efficacious and that other countries use first-line, such as 
acupuncture, myotherapy / massage, chiropractic or osteopathic manipulation, biofeedback, 
yoga, et cetera.  Or, they limit access.  Additionally, insurance has limited access to mental 
health to deal with the psychodynamic alterations that accompany chronic pain and are known 
to exacerbate it or alter the perception of pain.  People living with chronic pain need to have a 
treatment plan that includes teaching them how to live with some level of pain and not to have 
that pain define their existence, which Dr. Peters-Gilmartin sees so often in clinical practice.  
Primary care practitioners need to receive better training in the use of opioids and the 
management of chronic pain syndromes, as it often takes weeks or months in regional areas to 
get a patient referral to a Chronic Pain Management Specialist.  Practitioners need to be 
mandated to use a PDMP, but first that program needs to be uniform, nationalized, and 
simplified.  The ability to renew a US Drug Enforcement Administration (DEA) license to 
prescribe controlled substances should be tied to demonstrated use of the PDMP in the future in 
addition to proof of continuing education hours devoted to not only Pain Assessment and  
Management, but Addiction Management as well. 
 
No one is saying never to use opioids for chronic pain, and nowhere is it suggested never to 
treat post-surgical, malignant, or end-of-life pain and suffering.  The new proposed guideline 
from CDC is very sensible and practical.  Now that we recognize the breadth and depth of the 
wrong that we as a medical community have been part of, we have a moral and ethical 
responsibility to fix it.  Because we have done something wrong for so long is no reason to 
continue to do so.  As a medical provider, a parent of loss, and an addiction recovery advocate, 
Dr. Peters-Gilmartin supports the urgent passage of the draft CDC guideline. 
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Dr. David Juurlink 
University of Toronto and American College of Medical Toxicology 
 
Dr. David Juurlink commended CDC for taking action to address the prescription opioid crisis. 
He also expressed concern that focusing on the problems of mortality, addiction, heroin, and 
other harms associated with prescription opioids will lead to an overlooking of the other harms 
that opioids cause, particularly over the long-term. 
 
How many falls, fractures, and head injuries are caused by these drugs, particularly in patients 
on high doses of them?  The answer is not known.  How many cases of delirium result from 
these drugs each year, and how many patients suffer and die from opioid-induced constipation?  
No one knows.  There is a cascade of effects of opioid-induced disruptions of sleep architecture, 
particularly when a doctor wanting to help prescribes a sedative.  How many cases of 
depression are caused by these drugs?  How many patients suffer from testosterone 
depression or from opioid-induced hyperalgesia, with patients worsened by the drugs?  How 
many people are harmed or are killed by opioid-related car accidents? 
 
No one knows the answers to these questions, but clearly millions have been harmed by these 
phenomena, which are dose-related and offer strong support for CDC’s proposed dose 
thresholds.  The harms of opioids should be weighed against the benefits, and while there can 
be increased quality of life from low-dose opioids, it must be acknowledged that the evidence 
base is terrible, and the determination of effectiveness is based solely on anecdote.  This point 
is important, as physical dependence is a near-universal consequence of COT.  When doses 
are reduced or missed, symptoms of withdrawal ensue, and patients realize quickly that all it 
takes to feel better is to resume the drug.  Understandably, this effect is perceived as an 
ongoing need for opioids. 
 
As CDC reviews feedback from patients regarding pain, Dr. Juurlink urged that the phenomenon 
of physical dependence, which is another form of harm, be considered.  The drugs are easy to 
continue and difficult to stop, even when there are analgesic effects. 
 
Dr. Rebecca Cunningham 
Emergency Physician & Injury Researcher 
University of Michigan 
 
Dr. Rebecca Cunningham emphasized that the enormous impact of the current epidemic and 
the need for public health response simply cannot be overstated, and CDC is to be commended 
for taking the large action that can impact the nation’s public health.  In her 20 years of practice 
in emergency medicine, she was first trained that opioids were dangerous medications to be 
used with great care.  Then the pendulum swung to widespread opioid prescribing for many 
patients.  With that swing, she has watched first-hand the river of patients brought into hospitals 
who have overdosed, and the anguishing and increasing calls by 911 providers seeking medical 
guidance who are unable to revive teens and young adults often who are overdosing in the 
community and are too late for help.  There is urgent need for public health action. 
 
As a clinician-educator of student doctors, Dr. Cunningham sees great need for guidance on 
best practices given the complete current vacuum of such guidance and wide disparity in daily 
and individual practices.  Clinicians are currently working almost blindly on how to care best for 
their patients’ pain.  They are confused at the best action and do not want to see their patients 
in pain, but without clear guidance such as being proposed by CDC, they cannot make safer 
Draft Meeting Minutes NCIPC Board of Scientific Counselors January 28, 2016 
 
49 
 
prescribing decisions.  Physicians need immediate guidance on how best to align care with 
safer prescribing.  Only then can physicians begin to have difficult conversations with patients 
and to aid the next generation of doctors in safer prescribing.  There is a widespread lack of 
understanding of the benefits and potential harms of the typical options, and there is 
tremendous physician variability.  Every day that medicine is practiced with this much variability 
and not guided by current science is another day the next generation of student doctors is 
taught potentially harmful practices, and patients are failed by the lack of provision of safer 
options to ameliorate their pain. 
 
The state of the science around opiate use is fairly extensive, and it is very convincing regarding 
harms and the need for action relative to other practice guidelines.  Although GRADE 1 
evidence is the gold standard, this is not level of evidence that drives most change in practice. 
Many such practice guidelines are typically based on observational data such as used in this 
guideline, as the science of rigorous RCTs is often fundamentally cost-prohibitive and, more 
importantly, not ethical when studying outcomes that include death from overdose.  Finally, the 
time lag to obtain the highest ideal of ideal evidence is arguably not ethical, given the national 
epidemic of overdose.  There are many times in medicine that doing nothing is not ethical.  In 
this case, waiting for the gold standard, RCT, longitudinal study while there is evidence that 
current practice is harmful is not ethical.  In addition, the grade of evidence provided in the draft 
CDC guideline is well in-keeping with other evidence-based changes suggested across medical 
care.  The grade of evidence provided in this guideline is more than sufficient.  Specifically, the 
dosage guidelines should not be altered. 
 
Ms. Ada Guidice-Tompson 
Mother of a Son Who Died from an Opioid Overdose 
 
Ms. Ada Guidice-Tompson said that if the draft CDC guideline had been in effect in 2002, her 
son Michael would still be alive today.  His pain would have been consciously treated without 
addictive opioids, and he would not have been given a prescription for a month’s supply.  
Michael is a clear example of how the medical use of opioids for acute pain quickly leads to their 
prolonged and chronic use, and over-prescribing. 
 
Ms. Guidice-Tompson’s son died within two years of his first opioid prescription, while under the 
care of one doctor.  Many prescribers and patients believe opioids are helping relieve pain and 
fail to link the drug’s impact on overall mood and pain in the long-term.  Tolerance, dependence, 
opioid-induced hyperalgesia, withdrawal, and substance use disorder are inter-related and 
common among medical and non-medical users.  Pain is often a surrogate for addiction, and 
the two are not mutually exclusive. 
 
Informing patients that opioids are pharmaceutical-grade heroin would make it clear that these 
drugs do not have to be misused or abused in order to cause harm and would educate patients 
who might then be less likely to accept even a three-day prescription for a short-term opioid.  
Looking at the increase in babies born with neonatal abstinence syndrome (NAS) to mothers 
prescribed opioids for pain should have made us stop and take notice.  Prescribers cannot 
change the inherent properties of opioids, and using opioids as prescribed for pain does not 
protect patients.  Relying on REMS and other external measures to mitigate harm is important; 
however, the natural physiological reaction within a human body cannot be stopped or 
prevented when an individual ingests an opioid, even an abuse-deterrent one. 
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Pharma marketing, misinformation, conflict of interest, and weak regulatory controls have 
manipulated science and downplayed the inherent risks of opioids within a legally sanctioned 
system.  Both patients and clinicians have been operating under impaired choices.  Patients 
need pain relief that is safe, does not reduce their quality of life, and does not cut their lives 
short.  Patients who are already on opioids should not be abandoned.  The CDC guideline is 
urgently needed to end the epidemic caused by inappropriate and over-prescribing of opioids.  
To save lives and protect people, this guideline and its resulting impact must be independent of 
opioid manufacturers and their lobby groups. 
 
Dr. Mark Roberts 
American College of Occupational and Environmental Medicine 
 
Dr. Mark Roberts expressed his gratitude for the opportunity to speak.  He is the President of 
the American College of Occupational and Environmental Medicine (ACOEM), which focuses on 
the protection of workers and their families.  ACOEM supports the CDC’s proposed 
recommendations for the safer and more effective use of opioids for chronic, non-cancer pain. 
 
The rationales supporting the recommendations are well-reasoned and supported by the best 
available evidence and expert consensus.  Guidance from an unbiased, authoritative source 
such as the CDC is especially important in light of the continued absence of quality evidence of 
effectiveness of opioids for chronic, non-cancer pain treatment.  The proposed CDC 
recommendations are consistent with ACOEM’s 2014 update of its guidelines for opioid use, 
based on an extensive systematic review of published material. 
 
Physicians seek accurate and unbiased guidance for the treatment of chronic, non-cancer pain, 
according to more than 40 surveys of US, United Kingdom (UK), and Canadian physician 
organizations.  In these surveys, physicians noted minimal education in pain management at all 
levels.  They felt that many patients’ perceptions of pain were confounded by untreated or 
inadequately treated psychiatric disorders or emotional distress.  Physicians were concerned 
about addiction, dependence, diversion, and side effects associated with opioid use.  Many 
physicians felt uncomfortable prescribing opioids for chronic, non-cancer pain in the absence of 
objective findings or specific diagnoses.  In most cases, the specific pathophysiological aspects 
of chronic, non-cancer pain are not known, so the target of treatment must be unknown.  
Chronic, non-cancer pain does not fit the pathophysiological model that is used in modern 
medicine. 
 
Prescriptions without quality evidence represent a return to eminence-based medicine.  
Reliance on clinical judgment alone results in the variation of care.  Wide variations in the rates 
of prescription of opioids and overdose and deaths have been demonstrated.  Clinical judgment 
must be guided by the best available evidence to achieve improvements in the appropriate use 
of opioids.  Public education and physician education are needed due to the general poor health 
knowledge about the benefits and risks of opioids.  Many people believe that opioids are safe if 
they are prescribed by a physician.  People often view opioids as a first choice for chronic pain, 
rather than more effective and less dangerous alternatives such as exercise, cognitive-
behavioral therapy, and other modalities.  Physicians have stated that they need and will use 
guidelines to create boundaries for patients demanding opioids.  This situation is a classic public 
health problem, when hazards in the community are associated with increased adverse effects. 
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Howard Techau 
Individual 
 
Mr. Howard Techau expressed his gratitude for the opportunity to speak and expressed 
condolences to those who have lost loved ones due to overdoses.  Many chronic pain patients 
are suffering more now due to the restrictions that are already in place.  Some are seen as 
drug-seekers, but only approximately 5% of chronic pain patients are addicts.  There need to be 
limits on prescription opioids for people who have sustained sports or work-related injuries.  But 
for those who are in chronic pain, such as fibromyalgia patients, opioids have a great effect. 
 
Many opioid overdoses are due to fentanyl, which is cheaper than heroin.  Another aspect of 
this issue is that many chronic pain patients are depressed and may commit suicide by 
overdosing on prescription or illicit drugs.  One study examined people who were thought to 
have died due to heroin; however, many of them died due to suicide. 
 
Mr. Techau recommended the creation of a federal database similar to the mechanism that is in 
place for Sudafed.  He expressed the hope to take the pressure off of doctors who prescribe 
opioids responsibly, and the pharmacies that fill the prescriptions.  If the CDC guideline is not 
law, then why are pharmacies denying patients opioids that they have been prescribed, saying 
that they are over the limit?  He agreed with the need for a database to stop doctor-shopping 
and pharmacy-shopping.  He said he hoped that chronic pain patients are not overlooked when 
this guideline is implemented. 
 
David Laws 
Father of a Daughter Who Died from An Accidental Overdose 
Georgia Overdose Prevention 
 
Mr. David Laws asked the group to indicate, by a show of hands, how many know someone 
who is either affected by or lost a life to opioids.  Mr. Laws is a father of three.  He urged CDC to 
remain steadfast in taking action for safer opioid prescribing and managing practices.  His first 
child, daughter Laura Hope, was prescribed opioid-based medication at age 14 after she broke 
her jaw in a soccer game.  She was a freshman in high school, and she never made it to her 
senior year.  He received the call that her senior photographs were ready to be picked up in the 
limousine on the way to her memorial service. 
 
Opioid addiction took over, and the Laws family lost Laura to an accidental overdose on 
November 27, 2013 at the age of 17 ½.  As a result of her death, Mr. Laws joined club that he 
would never want to be a member of—a lonely, growing club of grieving parents whose children 
have been lost to opioid addiction. 
 
CDC made recommendations with the right balance between over-prescription of opioids that 
can be highly addictive, while allowing pain management to continue for deserving patients.  
Balance is needed, as shown by recent government successes in cracking down on “pill mills.”  
It is time now to take action on the well-thought-out, balanced guidelines presented by CDC.  
Delay means that more lives will be lost needlessly.  Every day that the CDC delays issuing the 
guidelines as recommended, there is a chance that another young person might unintentionally 
get on a road that is difficult to get off of.  As a result, there can be lifelong struggles, or as with 
Laura, a life that is much too short. 
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Mr. Laws applauded CDC for listening to real stories of real people and families that have been 
forever affected by irresponsible opioid prescribing practices.  He urged CDC to be strong, fair, 
and fearless in issuing guidelines that are as strong as the recommendations of last year.  If we 
can change a heart, we can change a mind; if we can change a mind, we can change a life.  His 
life has been changed forever. 
 
Pete William Jackson 
Father of a Daughter Who Died From One OxyContin® Pill 
Advocates for Reform of Prescription Opioids (ARPO) 
 
Mr. Pete William Jackson, President of Advocates for the Reform of Prescription Opioids 
(ARPO), conveyed on behalf of ARPO strong support of the CDC Opioid Prescribing 
Guidelines.  ARPO represents many people who have been harmed by opioid medications, a 
majority of whom are, or were, pain patients who became involved with opioids through a 
legitimate prescription for pain, only to become addicted after prolonged use. 
 
Mr. Jackson became involved in advocating for more reasonable prescribing practices after 
losing his 18-year-old daughter, Emily, to one OxyContin® pill.  She was three days from her first 
day in college.  Her tragedy underscores how terribly potent these opioid medications are.  How 
can somebody die from consuming one pill? 
 
With the recent news from CDC that opioids were involved in over 28,000 deaths in 2014, the 
proposed guideline could not come at a more critical time.  People know about opioids being 
restricted, but Americans continue to consume more opioids, not fewer.  Yet, there are forces 
within the opioid industry and their paid lobbyists and pain organizations pushing back mightily, 
for a variety of reasons, which collectively threaten to undermine the public health benefits of 
these reasonable, long-overdue guidelines.  ARPO urges the CDC not to allow the profit-driven 
pressure from the opioid industry to delay further the adoption of this important guideline. 
 
Mr. Jackson emphasized that we are all pain patients at one time or another.  It is accepted that 
these medications have an important role in healthcare.  No one, especially pain patients, is 
well-served by the overly aggressive prescribing practices that have been well-documented by 
the CDC.  The CDC guideline will save many lives and will also result in better healthcare for 
people who suffer from pain.  Doctors need to prescribe more cautiously.  The bottom line is 
this: everyone benefits from sound, evidence-based prescribing guidelines, including pain 
patients.  Please adopt this guideline as soon as possible so that more people can live and 
enjoy better healthcare.  Thank you for protecting American lives! 
 
Ms. Carolyn Noel 
Chronic Pain Sufferer 
Pain Action Alliance to Implement a National Strategy (PAINS) 
 
Ms. Carolyn Noel introduced herself and said that she has lived with chronic pain for 13 years.  
She was present to speak on behalf of Pain Action Alliance to Implement a National Strategy 
(PAINS), a national alliance of professional societies, patient advocacy groups, and ethics and 
policy organizations.  PAINS is a program of the Center for Practical Bioethics in Kansas City, 
Missouri.  PAINS was organized for the purpose of promoting cultural transformation in the way 
that pain is perceived, judged, and treated as called for in the IOM report entitled, “Revealing 
Pain in America.” 
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PAINS strongly encourages this community to align its efforts with recommendations made in 
the IOM report and recommendations that are in the forthcoming National Pain Strategy Report, 
developed for the implementation of those recommendations.  Those reports move away from a 
biomedical pain care model, to a bio-psycho-social approach.  Clearly, the intent of the 
proposed guideline is to reduce the abuse of opioids.  PAINS supports that intent and is 
committed to working with CDC and with others focused on this issue. 
 
However, it must be acknowledged that the guideline will also have tremendous impact on those 
who struggle to live with chronic pain.  Pain is individualized, and formulaic approaches will not 
work or are likely to harm patients.  Today, PAINS asks CDC to answer three questions before 
publishing the opioid prescribing guideline: 
 
 Will they improve function and quality of life for those who live with this dreadful 
disease? 
 Will they allow physicians to fulfill their ethical duties and obligations to chronic pain 
patients? 
 Can they be justified with evidence that exists today? 
 
Carol Thornton 
Safe States Alliance 
 
On behalf of the Safe States Alliance, Ms. Carol Thornton offered the group’s support to CDC 
for its leadership in the development of Guidelines for Prescribing Opioids for Chronic Pain.  
Safe States Alliance is a national nonprofit 501c(3) organization and professional association 
with the mission of strengthening the practice of injury and violence prevention.  Among its 
diverse membership are state health departments and injury and violence prevention programs.  
These programs are vital partners in CDC’s Prescription Drug Overdose Boost for State 
Prevention, which provides financial resources and scientific and technical assistance to support 
state prevention efforts to maximize PDMPs, improve public insurance mechanisms to protect 
patients, and evaluate policies to identify prevention that works.  Many of these state programs 
are actively involved in the development, dissemination, and evaluation of state-level 
prescribing guidelines. 
 
Safe States Alliance is strongly supportive of providing physicians with tools that can be used, 
along with their personal clinical judgment, to assess and develop a plan to appropriately 
address acute and chronic pain for patients in the most appropriate and safe way possible.  The 
scientific review conducted by the expert panel provides the best available evidence.  The 
guideline will be an incredibly useful resource for states in the development, review, and 
updating of state-specific guidelines.  
 
Safe States Alliance thanks CDC for its leadership in providing strong scientific analyses and 
guides to support states and communities in addressing this public health crisis. 
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Dr. Jane Ballantyne 
Anesthesia Pain Specialist 
President of Physicians for Responsible Opioid Prescribing 
University of Washington 
 
Dr. Jane Ballantyne has been an anesthesia pain specialist since 1990.  She is the President 
of Physicians for Responsible Opioid Prescribing.  When she began practicing, opioids were 
rarely used for chronic pain because they were thought to be ineffective or unsafe.  In the 
following 20 years, opioid prescribing increased four-fold in the US and is still rising.  Many 
factors produced this increasing, but most important is the new teaching that came largely from 
palliative care and industry.  This teaching aimed to establish the right of chronic pain patients to 
receive opioids; change the belief that chronic opioids were neither effective nor safe; and 
encourage open-ended dosing according to the stated pain level.  The result of this shift was 
that both the number of people receiving opioids and the doses they were receiving increased 
exponentially, and a whole culture changed. 
 
By the end of the 1990s, Dr. Ballantyne and her colleagues began to question the basis of the 
teaching they had received, and their own practice.  Patients receiving high doses of opioids 
typically reported high pain levels and rarely showed the expected improvements in function and 
quality of life.  Dr. Ballantyne and her colleagues searched the literature and found no evidence 
to support their practice.  They published their findings and began teaching more rational 
approaches, but nothing seemed to stem the tide of increased and unsafe prescribing.  There is 
now growing evidence that opioid prescribing for pain has harmed both society and pain 
patients and has not relieved the nation's burden of chronic pain, yet there is a reluctance to act 
on the basis that more scientific research is needed—research that will take years to complete, 
if it ever gets done at all. 
 
The CDC guideline is urgently needed.  The guideline was created using the best available 
evidence, expert review, and input from a broad and balanced group of stakeholders.  It 
recommends precautions that very few people would argue.  The suggested duration limitations 
for new patients are suggested on the basis that lower doses have been shown to be more 
effective and safer.  The guideline does not suggest taking opioids away from people who have 
already become dependent, does not suggest taking opioids away from people have already 
become dependent, nor anything that would compromise pain relief. 
 
Dr. Ballantyne expressed hope that the BSC would appreciate the urgent need for action, the 
reality of the limited state of the evidence, and the care with which the guideline was crafted. 
 
Andrew Kolodny, MD 
Chief Medical Officer 
Phoenix House Foundation  
 
Dr. Andrew Kolodny is the Chief Medical Officer of Phoenix House.  He commended CDC for 
the work to address the opioid addiction epidemic, and he voiced strong support for issuing 
guidance to the medical community on opioid prescribing.  Primary care has contributed to an 
epidemic of overdose deaths and addiction by over-prescribing opioids.  Over-prescribing was 
not done out of malicious intent, but because of a desire to treat pain more compassionately.  
To bring this public health crisis under control, doctors must prescribe much more cautiously. 
  
54 
 
Draft Meeting Minutes NCIPC Board of Scientific Counselors January 28, 2016 
 
The increase in opioid prescribing was not in response to new evidence, but in response to an 
industry-funded campaign that minimized the risk of addiction and other adverse effects and 
exaggerated the benefits of using opioids in the long-term for chronic pain.  The medical 
community was misinformed. 
 
Primary care needs guidance on opioid prescribing that is free of industry bias.  The CDC 
guideline accomplishes this.  Evidence shows that the widespread use of opioids for chronic 
pain is harming more people than it is helping.  Many patients on long-term opioids continue to 
suffer from significant pain and dysfunction.  The field has also come to realize that addiction 
and other serious side effects are common.  CDC has demonstrated a strong association 
between increased opioid sales and overdose deaths and other adverse public health effects.  
Aggressive prescribing is harmful to everyone, including people with chronic pain.  Dr. Kolodny 
urged CDC to accept and release the guideline as quickly as possible.  Appropriate pain care is 
not jeopardized by the guideline: it demands it. 
 
Judy Rummler 
Mother of a Son Who Died of An Opioid Overdose 
FED UP! Coalition 
Steve Rummler Hope Foundation 
 
Ms. Judy Rummler expressed her thanks for the opportunity to present comments on this 
important issue.  She is chair of the FED UP! Coalition, a grassroots movement of individuals 
and organizations from across the country.  The group holds rallies and advocates for change in 
public policy that will help pain patients and those suffering with the disease of addiction.  The 
group is fed up with the failure of the FDA to take action that could end the over-prescribing of 
opioids and save thousands of lives.  FED UP! applauds CDC for creating this draft guideline 
which will lead to more cautious opioid prescribing and reverse the trend of ever-increasing 
overdose deaths.  Many of FED UP!’s members and partners have friends and family members 
who have died from opioid overdoses.  The voices of these lost loved ones have been silenced, 
but their stories need to be told. 
 
Ms. Rummler’s story, similar to thousands of others, is about the loss of her son Steve 
Rummler.  If Steve had had the opportunity to present to the BSC five years ago, he would  
have said that he had intractable chronic pain due to his back injury.  He would have said that 
he needed his opioids in order to any have any quality of life.  He had become addicted to the 
opioid painkillers that were being prescribed to him for his chronic pain, and he would have 
been terrified at the thought of losing access to his pills.  Steve died of an accidental overdose 
on July 1, 2011.  Among his belongings was a note referring to his prescription that said, “At first 
it was a lifeline.  Now it is a noose around my neck.” 
 
As the mother of a son who suffered with chronic pain and the founder of the Steve Rummler 
Hope Foundation, Ms. Rummler has compassion for pain patients.  Their voices are being 
heard in this discussion and they have posted many comments.  But there are more than 
200,000 Americans who have tragically died from the opioid epidemic, and these mothers, 
fathers, sons, and daughters are unable to post comments or otherwise participate in this 
discussion.  These are people who had faith in their doctor’s knowledge of the risks associated 
with opioids and who were not expecting that something bad would happen to them. 
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She urged the CDC and the BSC to consider these silenced voices when evaluating the need to 
release the guideline.  What would they say about a guideline that could have saved their lives?  
This proposed guideline, including guidance on dosage, duration, and increased access to 
integrative care, is long overdue as a way to prevent pain patients from getting started on a 
cycle of opioid use that can lead to more pain, the disease of addiction, and overdose death. 
 
Dr. Asokumar Buvanendran 
Pain Medicine Specialist, Rush University Medical Center 
Vice-Chair, American Society of Anesthesiologists (ASA) 
 
Dr. Asokumar Buvanendran is a Pain Medicine Specialist at Rush University Medical Center.  
He is also the current Vice-Chair of the American Society of Anesthesiologists (ASA) Committee 
on Pain Medicine.  ASA supports the federal government’s efforts to reduce opioid overdose 
deaths and supports the majority of recommendations in the CDC Guideline.  ASA has two 
primary concerns with the recommendations in the draft guideline. 
 
ASA is concerned that the draft guideline inaccurately portrays the effectiveness and risks of 
interventional procedures, which is particularly concerning since interventional pain procedures 
are a key non-opioid therapy to treat chronic pain.  When performed by a pain medicine 
physician, there are an extremely small number of complications associated with interventional 
therapies, such as epidural injections, radiofrequency denervation, and spinal cord stimulation, 
and the complication rate is far lower than the complication rate for chronic opioid therapy for 
chronic pain.  To make the available non-opioid options clear to the prescribing physician, ASA 
proposes that CDC revise Recommendation One to include examples of non-pharmacological 
and non-opioid pharmacological therapies, which should include interventional pain procedures. 
 
ASA is concerned that the guideline would curtail the ability of perioperative physicians, 
including physician anesthesiologists, surgeons, and co-managing internists or hospitalists, to 
treat patients’ acute pain after surgery.  Any recommendations made by CDC need to balance 
the over-prescription of opioids for acute pain with perioperative physicians’ imperative to treat 
post-surgical pain.  In Recommendation Six, the ASA recommends that CDC revise the 
statement: 
 
“When opioids are used for acute pain, providers should prescribe the lowest effective 
dose of short-acting opioids and should prescribe no greater quantity than needed for 
the expected duration of pain severe enough to require opioids.  Three or fewer days will 
usually be sufficient for non-traumatic pain not related to surgery.” 
 
Emily Brunner, MD 
Hazelden Betty Ford Foundation 
 
Dr. Brenner expressed her thanks for addressing this important topic.  She is a physician at the 
Hazelden Betty Ford Foundation, where she treats patients affected by opioid addiction on a 
daily basis.  She voiced strong support for the proposed draft recommendations and the CDC 
Guideline for Prescribing Opioids for Chronic Pain. 
 
The Hazelden Betty Ford Foundation has seen a pronounced increase in the number of patients 
with opioid use disorders.  Opioid dependence among residential treatment admissions in the 
youth program, for example, increased from 15% in 2001 to 42% in 2014.  The foundation 
works with countless families who have been devastated by opioid addiction, and far too many 
have lost loved ones to the disease. 
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This is a crisis that demands attention and commitment, and at the center of this problem is 
over-prescribing.  To be sure, doctors did not start over-prescribing opioids out of malicious 
intent, but out of a desire to relieve pain more compassionately.  However, years of 
misinformation and, frankly, a lack of education on addiction led doctors to underestimate the 
risks of these medications. 
 
It does not help that the number-one reason people visit a physician is pain, or that physician 
visits are increasingly shorter.  Pressure to make decisions and provide quick solutions adds to 
the doctor’s dilemma.  Reimbursement tied to patient satisfaction surveys also intensifies the 
pressure to prescribe opioid painkillers in hospital emergency departments.  Often it is easier for 
a physician to write a prescription to maintain the status quo than to ask the difficult question, 
“Should I change how I am treating this patient?” 
 
Physicians need to limit opioid medication to the treatment of moderate to severe acute pain, 
and rarely use them for chronic pain.  Mistakes made with these drugs can be lethal.  As a 
result, there is a responsibility to be as cautious as possible in prescribing them. 
 
The proposed guideline would encourage more and better physician-patient conversations and 
help both parties by encouraging alternative interventions and treatment strategies when 
appropriate.  The national crisis around opioid addiction and overdoses deserves the attention 
CDC is providing and requires a substantial response not only from the federal government, but 
also from all of medicine as well.  Every day that meaningful action is delayed, more people’s 
lives and families are endangered. 
 
This is not about taking needed medications away from those who need them; instead, it is 
about changing the culture around prescribing opioids so the next generation of pain patients 
receives the best and least risky treatments possible.  Contrary to the claims of opponents, CDC 
has put forth a rather modest proposal.  It is not a mandate.  It includes no black-and-white 
requirements, and it does not apply to active cancer treatment, palliative care for other serious 
illnesses, or end-of-life care.  The proposal is more likely to bring about a balanced approach 
than to swing the pendulum too drastically.  Dr. Brunner and the Hazelden Betty Ford 
Foundation thank CDC for its leadership and backs the agency’s efforts. 
 
Faye Roscoe 
Mother of a Son Prescribed Vicodin® Against Her Request 
 
Ms. Faye Roscoe expressed her gratitude for the opportunity to provide comments on the 
guideline.  She supports the original proposal.  Twelve years ago, Ms. Roscoe’s son, then age 
23, had knee surgery.  At the time of release from the hospital, the physician prescribed 
Vicodin® against her request to prescribe a non-narcotic drug due to his existing drug issues.  
Had stricter guidelines been in place, such as discussing other alternatives for pain medication, 
she believes that Vicodin® would not have been prescribed. 
 
The goal of the guideline is not to ban opioid medications, but to enact stricter guidelines for 
healthcare providers who provide people with medication.  While pain medication is necessary 
for many, opioid medication, by default, is not.  The lack of concern to best prescribe the correct 
pain medication has fueled a drug addiction epidemic and skyrocketed overdoses and deaths. 
CDC has data indicating that 259 million prescriptions were written in 2012 for opioid pain 
medications.  Why are these prescriptions being written for children as young as 12, when 2 
million Americans either abused or were dependent on these pain relievers in 2013?  It is 
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imperative that CDC acts immediately.  Lives are lost daily to prescription opioid abuse.  It could 
be anyone’s family member. 
 
Dr. Daniel Carr 
Professor of Public Health & of Anesthesia and Medicine, Tufts University 
President-Elect, American Academy of Pain Medicine (AAPM) 
 
Dr. Daniel Carr is the President-Elect of AAPM and is a Professor of Public Health as well as 
Anesthesia and Medicine at Tufts University, where he directs the program in Pain Research, 
Education and Policy.  AAPM has participated in educational programs on the safe and effective 
use of opioids.  The group’s upcoming annual meeting will feature education for primary care 
providers.  AAPM is devoted to patients with pain and offers comments on the stigmatization of 
patients with pain in several aspects of the draft guideline.  AAPM agreed with and supports 
many of the recommendations that have been put forth.  In particular, many comments have 
indicated that there is no evidence that opioids are effective in the long-term for chronic, non-
cancer pain.  The review of the literature was of the “best available evidence.”  On the other 
hand, to say that there is “no evidence” is a misstatement.  The same methodologic group who 
performed the literature review for the draft guideline already performed prior reviews in 2009, in 
part supported by AAPM with the APS, and also in the Cochrane library, which has a review to 
this point in Issue One of 2016.  Therefore, the statement that there is no evidence to support 
the chronic use of opioids is a misstatement and does not reflect a “best available evidence” 
approach. 
 
The evidence must be made transparent, which does not weaken the compelling account of 
tragedy of people who have misused, abused, or otherwise overdosed on opioids.  It is 
important to increase the evidence from clinical trials.  This work can be conducted by a 
sensitivity analysis, which will assess the effects upon the conclusions of the literature review by 
including studies of various durations.  Dr. Carr and his colleagues have conducted this 
analysis, using the roster of studies that were excluded from the CDC’s literature review 
because of their duration.  They analyzed these studies and found a considerable amount of 
evidence. 
 
In a recent issue of NEJM, there is a balanced editorial by a specialist in pain aggregation in 
Boston.  The bottom line is to recognize that there is evidence, and the evidence extends to 
individual variability in the response to opioids, which weakens the logic for setting firm dosage 
thresholds as the basis for policy.  It is known that very often, the nuances of recommendations 
are lost by insurers and other regulators.  AAPM is concerned that the patients who are already 
stigmatized because of their chronic pain will be further stigmatized. 
 
Jonathan Fielding, MD, MPH, MBA 
Professor, Fielding School of Public Health  
University of California, Los Angeles School Public Health 
 
Dr. Jonathan Fielding thanked the group for this important opportunity for CDC and for the 
nation.  He is a Professor at the Fielding School of Public Health, a former Health Officer for Los 
Angeles County, and the Director of Public Health for Massachusetts.  He chairs the US 
Preventive Services Task Force (USPSTF), an independent, nonfederal, unpaid panel of public 
health and prevention experts that provides evidence-based findings. 
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Certainly, opioids offer pain relief to many suffering patients and are an important treatment 
option, when medically indicated; however, it is clear from prescribing data and related addiction 
treatment admission and overdose death that the medical community has over-relied on opioids 
to treat pain.  Prescription opioid sales in the US have increased by over 300% since 1999, 
while opioid-related overdose deaths nearly quadrupled.  To reverse this horrific epidemic of 
opioid drug overdose deaths and to prevent opioid-related morbidity, the medical community is 
urgently in need of guidance from CDC, because aggressive opioid prescribing is harming pain 
patients and fueling an unprecedented epidemic of addiction and overdose deaths. 
  
Dr. Fielding applauded the CDC scientific committee and the rigorous process they undertook to 
develop this guideline to improve the dialogue between primary care physicians and patients 
surrounding the benefits and the risks associated with these medications for the treatment of 
chronic, non-malignant, and non-terminal pain.  This guideline will improve the way opioids are 
prescribed and can ensure that patients have access to safer, more effective chronic pain 
treatments while reducing the number of people who misuse, abuse, or overdose from these 
powerful medications. 
 
The CDC guideline is based upon an unbiased, exhaustive analysis of the best available 
research.  Critics have suggested that there is not definitive evidence to support the guideline 
related to levels of dosage and duration of use recommendations; however, Dr. Fielding 
believes that the CDC guideline has sufficient evidence to provide clinical guidance to 
physicians and that further delays will cause more American lives to be lost unnecessarily, not 
to mention the millions of Americans who will lead subpar lives.  Dr. Fielding has read the draft 
guideline and strongly urged CDC to release the guideline without revision as quickly as 
possible. 
 
Dr. Hargarten thanked all participants for providing input and commentary in person and via 
telephone, and reiterated that the commentaries would become a part of the official record. 
  
 
Discussion and BSC Recommendations 
 
 
Stephen Hargarten, MD, MPH 
Professor and Chair 
Department of Emergency Medicine 
Medical College of Wisconsin 
Chair, National Center for Injury Prevention and Control Board of Scientific Counselors 
 
Dr. Hargarten observed that the day had been extraordinary, with extraordinary discussion and 
input from a variety of perspectives, including the BSC and the public.  They had held 
constructive and thoughtful discussion on the workgroup’s observations and recommendations.  
The next step is to further advance the workgroup’s recommendations.  He opened the floor for 
discussion and BSC recommendations. 
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Discussion Points 
 
Dr. Duwve thanked the commenters for the wisdom, stories, and insight that they provided.  
She recommended that CDC consider the observations made by the workgroup.  There was 
strong support in the day’s testimony for integrated care and pediatric and adolescent 
populations to be considered in future updates to the guideline.  She moved that the CDC adopt 
the workgroup recommendations that had unanimous support or were supported by the majority 
of workgroup members, and that the CDC continue to consider the variety of recommendations 
made by the workgroup when there was not consensus. 
 
Dr. Hargarten called for discussion of the three parts of Dr. Duwve’s motion to adopt the 
workgroup’s observations. 
 
Ms. Amy Peeples specified that the workgroup was not tasked with making recommendations, 
only observations and considerations.  That role informed the way the report was structured and 
written. 
 
Dr. Hargarten clarified that the motion was to support the observations made by the workgroup; 
to support the workgroup observations on the recommendations that had unanimous and 
majority support; and to support the additional suggestions and observations made by the 
workgroup that will further inform CDC’s efforts to formulate and structure the guideline. 
 
Dr. Duwve and Dr. Forjuoh agreed with the description. 
 
Dr. Hamby felt that the motion was appropriate, but asked for Dr. Porucznik’s comments if her 
role permitted her to do so. 
 
Commenting as a BSC member, Dr. Porucznik noted that she was the chair of the workgroup 
because the chair had to be a member of the BSC.  The workgroup executed its charge to 
review the evidence and guideline recommendation statements, and to provide observations 
that were presented to BSC.  With this motion, the BSC would be approving the report as the 
completion and fulfillment of the workgroup charge and moving that CDC take the observations 
into consideration as the final version of the guideline is created.  The motion was consistent 
with what the BSC requested in its January 7, 2016 meeting.  The BSC was not creating the 
guideline, but was BSC recommending to CDC that the final version of the guideline should take 
the workgroup observations into account. 
 
Motion / Vote 
 
Dr. Duwve formally stated her motion:  1) CDC should support the observations made by the 
workgroup; 2) CDC adopts the workgroup observations that were unanimous or where there 
was a majority consensus; and 3) CDC further considers the variety of observations made by 
the workgroup when there was not consensus.  Dr. Forjuoh seconded the motion.  The motion 
passed unanimously with no abstentions. 
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Conclusion and Adjourn 
 
 
Stephen Hargarten, MD, MPH 
Professor and Chair 
Department of Emergency Medicine 
Medical College of Wisconsin 
Chair, National Center for Injury Prevention and Control Board of Scientific Counselors 
 
Dr. Hargarten expressed his gratitude for an extraordinary day and a process that was 
conducted in a professional, science-driven, thoughtful manner.  He said he was honored to be 
part of the work. 
 
Dr. Greenspan expressed her appreciation to the BSC and to Dr. Porucznik and Dr. Green for 
spending so much time to meet and develop the workgroup report.  She thanked Dr. Hargarten 
for chairing the meeting and the BSC members and ex officio members for their participation, 
and expressed her appreciation for the dedication of all participants in the meeting.  She 
proposed that the next BSC meeting be convened on June 15-16, 2016 in order to coincide with 
the secondary review process. 
 
With no additional discussion, Dr. Hargarten officially adjourned the meeting at 2:44 p.m. 
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Acronym Expansion 
AAPM American Academy of Pain Medicine 
ACIP Advisory Committee on Immunization Practices 
ACOEM American College of Occupational and Environmental Medicine 
APS American Pain Society 
ARPO Advocates for Reform of Prescription Opioids 
ASA American Society of Anesthesiologists 
BSC Board of Scientific Counselors 
CDC Centers for Disease Control and Prevention 
CEO Chief Executive Officer 
CME Continuing Medical Education 
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COT Chronic Opioid Therapy 
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DOD (United States) Department of Defense 
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 Opioid Guideline Workgroup 
 
Observations presented to the National Center for Injury Prevention and Control’s  
Board of Scientific Counselors 
 
Preparatory material for Board of Scientific Counselors meeting on 
January 28, 2016 
 
Submitted by: 
Christina Porucznik, PhD, MSPH, Workgroup Chair 
 
Workgroup Members: 
Anne Burns, RPh 
Penney Cowan 
Chinazo Cunningham, MD, MS 
Katherine Galluzzi, DO 
Traci Green, PhD, MSc 
Mitchell Katz, MD 
Erin Krebs, MD MPH 
Gregory Terman, MD, PhD 
Mark Wallace, MD 
 
 
Designated Federal Official: 
Amy B. Peeples, MPA 
  
In addition to the identified members of the Workgroup additional consultation was arranged for 
specific content areas.  
Consultant Area Participation 
Pediatrics & Anesthesiology Ad hoc, available for questions, not contacted 
Occupational Medicine & Worker’s 
Compensation 
Ad hoc, available for questions, not contacted 
Obstetrics & Gynecology Participated in meeting on 1/15/16  
GRADE methodology & cost effectiveness Participated in meetings on 1/8, 1/13, and 1/15 
Medical Ethics Ad hoc, available for questions, not contacted 
Addiction Psychiatry Participated in meeting on 1/15/16 
Physical Medicine & Rehabilitation Participated in meeting on 1/13/16 
Family member affected by loss of a loved one to 
opioid overdose 
Participated in meeting on 1/13/16 
 
Overall Observations 
• Workgroup members support efforts reflected in the Guidelines — specifically in the supporting 
text and statements of Guideline Recommendations # 1, 9, 11, and 12 — to encourage 
integrated care for people with chronic pain. As defined in the Draft National Pain Strategy, 
“Integrated care is the systematic coordination of medical, psychological and social aspects 
of health care and includes primary care, mental health care, and, when needed, specialist 
services.” (http://iprcc.nih.gov/docs/DraftHHSNationalPainStrategy.pdf, p.9) 
• Workgroup members suggest monitoring of Guideline implementation for evidence of 
impact and unintended consequences and modification of Guidelines when warranted by 
evidence. 
• Several workgroup members suggest that pediatric and adolescent populations should be 
considered for future updates of opioid prescribing guidelines. 
• Risks and benefits of opioid therapy in chronic pain and the epidemiology of prescription drug 
misuse and abuse are areas of active research, so the Workgroup suggested that the contextual 
evidence review may need to be updated more frequently than the clinical evidence review. We 
encourage CDC to work with partners to support additional research in this field. 
• Workgroup members express strong preference for Guideline Recommendations that are 
framed with positive rather than negative language.  
• Several workgroup members observed that we were asked to consider cost feasibility for the 
recommendations and in general feel that such data are lacking and subject to great variability. 
More research is required in this domain in order to have evidence relating to cost feasibility 
that could be evaluated.  
• Concerns about access, cost, and insurance coverage were raised by several workgroup 
members in discussion about Guideline Recommendations #1, #6, #7, #8, #9, #10, and #12. 
Systematic changes in payment policies will likely be required to support implementation of the 
Guidelines. Workgroup members encourage CDC to work with federal partners to support 
payment policies congruent with the Guidelines.  
• Discussions about safe storage and disposal are mentioned in several sections of supporting 
text. Workgroup members observe that these discussions are relevant throughout the course of 
opioid therapy for chronic pain and encourage providers to include patient education on safe 
storage and disposal of medications as a routine part of therapy along with discussion of risks, 
benefits, treatment goals, mental health, pain, and function. 
• Workgroup members observe that primary care providers may require additional education on 
approaches integral to implementation of the Guidelines, including education on non-
pharmacologic and integrated care, offering naloxone to patients with chronic pain, and 
medication assisted treatment for opioid use disorder.  Workgroup members encourage CDC to 
work with partners to support and/or provide appropriate education. 
Observations Specific to Guideline Recommendation Statements  
The observations presented here follow the ordering of the Guidelines. 
GUIDELINE RECOMMENDATION #1: Non-pharmacologic therapy and non-opioid pharmacologic therapy 
are preferred for chronic pain. Providers should only consider adding opioid therapy if expected 
benefits for both pain and function are anticipated to outweigh risks to the patient. 
(Recommendation category: A; Evidence type: 3) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #1. 
• Workgroup members commend the ordering of statements and agree that the topic of 
Guideline Recommendation #1 is first. Clear wording that opioids are not routine therapy for 
adults in chronic pain managed in primary care as well as mention of both pain and function are 
good messages. 
• Several workgroup members expressed significant concerns about access to care, particularly 
for non-pharmacologic therapies mentioned in Guideline Recommendation #1 and suggestion 
that there should be clear preference for integrated care for chronic pain expressed in Guideline 
Recommendation #1 and throughout the Guidelines. 
GUIDELINE RECOMMENDATION #2: Before starting opioid therapy for chronic pain, providers should establish 
treatment goals with all patients, including realistic goals for pain and function. Providers should not initiate 
opioid therapy without consideration of how therapy will be discontinued if unsuccessful. Providers should 
continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs 
risks to patient safety. (Recommendation category: A; Evidence type: 4) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #2. 
• Workgroup members commend Guideline Recommendation #2 in particular for its focus on 
patient-centered goals for improvement of pain and/or function. There was some concern that 
some providers would interpret the phrasing of “pain and function” to mean that improvements 
were required in both pain and physical function in order to justify continuation of opioid 
therapy.  Such meaning could be clarified in the supporting text.  Spinal cord injury patients, for 
example, may never walk again, but continued opioid therapy may be appropriate if it helps 
manage their pain and improves social or psychological function.  
• Many people with chronic pain also experience mental health concerns such as depression 
and/or anxiety, and there is evidence that treating these co-existing conditions can improve pain 
outcomes as well. Several workgroup members encourage addition of language in the 
supporting text to include evaluation of mood in addition to pain and function. 
GUIDELINE RECOMMENDATION #3: Before starting and periodically during opioid therapy, providers should 
discuss with patients known risks and realistic benefits of opioid therapy and patient and provider 
responsibilities for managing therapy. (Recommendation category: A; Evidence type: 3) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #3. 
• Several members observed that suggesting a safety discussion in response to unexpected 
findings in the PDMP or urine drug screen in the supporting text for Guideline Recommendation 
#3 may suggest to providers that safety discussions are for extreme events rather than 
conversations that should occur at initiation of opioid therapy and continue as a routine matter 
throughout the duration of therapy. 
• Some members suggested that the supporting text for Guideline Recommendation #3 could be 
strengthened by moving information about consideration of risk to household members from 
opioid exposure or improper storage in the home (e.g. pediatric poisoning events) from the last 
bullet to higher in the text. 
• Disposal of medications is a complicated situation. Information about safe disposal of 
medication should be included in the tools accompanying the Guidelines.  
• Several members suggest that consideration of possible risk to household members from 
accidental ingestion or diversion of opioids be included in the discussion of risks and benefits 
with the patient. 
GUIDELINE RECOMMENDATION #4: When starting opioid therapy for chronic pain, providers should prescribe 
immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids. (Recommendation 
category: A; Evidence type: 4) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #4. 
• Guideline Recommendation #4 is evidence type 4. This recommendation is consistent with best 
practices and well-deserves Category A designation. 
GUIDELINE RECOMMENDATION #5: When opioids are started, providers should prescribe the lowest effective 
dosage. Providers should use caution when prescribing opioids at any dosage, should implement additional 
precautions when increasing dosage to 50 or more morphine milligram equivalents (MME)/day, and should 
generally avoid increasing dosage to 90 or more MME/day. (Recommendation category: A; Evidence type: 3) 
This statement generated significant discussion about content in addition to the discussion about 
recommendation category and type of evidence.   
• Six of the nine Workgroup members agreed with the category A and evidence type 3 
designation. Three members felt that the evidence type 3 was appropriate except for the last 
paragraph of supporting text and if the discussion of tapering in the supporting text was 
removed then the category A and evidence type 3 designation was appropriate. Two Workgroup 
members suggested revisions to the statement. 
• One specific observation was that the last paragraph of the supporting text for Guideline 
Recommendation #5, regarding patients already taking opioids, does not directly support 
Guideline Recommendation #5 which is about initiation of opioid therapy.  
• In comparison to contextual evidence for risk and harm from opioid therapy there are virtually 
no studies of long-term benefits or improvement in pain and function with opioid therapy.  
Workgroup members encourage future studies to populate this data gap. 
• One member of the Workgroup strongly opposes Guideline Recommendation #5 as it is written. 
This member stated repeatedly that the current recommendation clearly suggesting dose limits 
is not supported by any data showing a decrease in benefit/risk ratio at the arbitrary numbers 
stated in the recommendation. This member expresses concern that the current wording of 
Guideline Recommendation #5 will undermine support for the entire Guidelines from providers 
and professional organizations. 
• The focus on patient pain and function included in the text of Guideline Statement #2 was not 
similarly included with Guideline Statement #5. Improvement or decrement of pain and/or 
function should be the impetus for any change in dose, either increasing or decreasing, and 
members observed that it should be repeated here. 
• There was not agreement about the evidence type for this statement, in part because of the 
inclusion of the last paragraph of supporting text.  Most members felt that the evidence for the 
last paragraph of supporting text was type 4 but supported type 3 evidence for the remaining 
paragraphs of supporting text.  
• Individual Workgroup members suggested specific edits to the text which are included here for 
information. The reworded statements alleviated more general concerns about perceptions of 
limit setting, implications of safe dosing below those limits, and observation that all of the 
evidence presented is about risk and harm rather than potential benefits or risk/benefit ratios 
associated any with dosing levels.  
o “When opioids are started, providers should prescribe the lowest effective dosage.  
Prescribers should be aware that risk of opioid-associated harm is greater with 
higher dose opioid therapy and should, therefore, carefully justify a decision to 
titrate opioids beyond 90 MME/day.  In this regard, providers should use caution 
when prescribing opioids at any dosage but should implement additional 
precautions when increasing dosage to > 50 MME/day.” 
o “When opioids are started, providers should prescribe the lowest effective dosage. 
There is no safe dosage of opioids, but risks of serious harms rise with increasing 
dosages. Providers should use caution when prescribing opioids at any dosage, 
should carefully reassess evidence of individual benefits and potential harms when 
considering increasing dosage to ≥50 MME/day, and should generally avoid 
increasing dosage to ≥90 MME/ day.” 
GUIDELINE RECOMMENDATION #6: Long-term opioid use often begins with treatment of acute pain. When 
opioids are used for acute pain, providers should prescribe the lowest effective dose of immediate-release 
opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough 
to require opioids. Three or fewer days usually will be sufficient for most non-traumatic pain not related to 
major surgery. (Recommendation category: A; Evidence type: 4) 
All members of the Workgroup agreed with the evidence type for Guideline Recommendation #6. 
There was considerable discussion about the Category rating for Guideline Recommendation #6. One 
member recommends that Guideline Recommendation #6 be Category B. Many members are able to 
support the Category A designation only if the statement is re-worded (see suggestions below).   
• The duration of therapy was focus for animated discussion.  Many members felt that three days 
was too limited and preferred a range of values, none of which exceeded seven days.  Four 
members preferred seven days or fewer. Two members preferred a range of 3–7 days. One 
preferred a range of 5–7 days. One preferred a range of 3–5 days. One member was strongly 
opposed to seven days as “too long”. 
• Specific wording suggestions for Guideline Recommendation #6 follow.  
o “Avoid prescribing more than three days supply, unless circumstances clearly warrant 
additional opioid therapy.” 
• The supporting text for Guideline Recommendation #6 should also include information and tools 
about safe medication storage and disposal. 
GUIDELINE RECOMMENDATION #7: Providers should evaluate benefits and harms with patients within 1 to 4 
weeks of starting opioid therapy for chronic pain or of dose escalation. Providers should evaluate benefits and 
harms of continued therapy with patients every 3 months or more frequently. If benefits do not outweigh 
harms of continued opioid therapy, providers should work with patients to reduce opioid dosage and to 
discontinue opioids. (Recommendation category: A: Evidence type: 4) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #7. 
• Guideline Recommendation #7 should apply to all patients. Several Workgroup members 
expressed concern that the wording suggested that Guideline Recommendation #7 applied only 
to opioid naïve patients. 
• Individual workgroup members also suggested specific edits to Guideline Recommendation #7, 
particularly the final sentence. There was concern that it implied that all patients should be at a 
dose of zero opioids (…and discontinue) and failed to suggest what else providers should do 
besides eliminating opioid dose.  
The majority of members would prefer that the last clause be either:  
1. “…providers should work with patients to reduce opioid dosage OR discontinue opioids AND 
IMPLEMENT OTHER THERAPIES.” 
2. “…providers should work with patients to reduce opioid dosage and discontinue opioids IF 
INDICATED, AND IMPLEMENT OTHER THERAPIES.” 
Alternately, a completely revised last sentence in Guideline Recommendation #7 could read: 
• “If harms outweigh the benefits of opioid therapy, clinicians must work with patients to 
seek alternative or adjunctive therapies for pain as part of a careful reduction or 
discontinuation of opioid dosage.” 
• ‘….If harms outweigh the benefits of opioid therapy, providers should work with 
patients to seek alternative or adjunctive therapies for pain as a careful reduction of 
opioid dosage or discontinuation (if necessary) of opioid therapy.’ 
GUIDELINE RECOMMENDATION #8: Before starting and periodically during continuation of opioid therapy, 
providers should evaluate risk factors for opioid-related harms. Providers should incorporate into the 
management plan strategies to mitigate risk, including considering offering naloxone when factors that 
increase risk for opioid overdose, such as history of overdose, history of substance use disorder, or higher 
opioid dosages (≥50 MME), are present. (Recommendation category: A; Evidence type: 4) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #8. 
• Two members suggest that Guideline Recommendation #8 would be stronger with the inclusion 
of concomitant use of central nervous system (CNS) depressants or sedatives among the listed 
risk factors. 
GUIDELINE RECOMMENDATION #9: Providers should review the patient’s history of controlled substance 
prescriptions using state prescription drug monitoring program (PDMP) data to determine whether the patient 
is receiving high opioid dosages or dangerous combinations that put him or her at high risk for overdose. 
Providers should review PDMP data when starting opioid therapy for chronic pain and periodically during 
opioid therapy for chronic pain, ranging from every prescription to every 3 months. (Recommendation 
category: A; Evidence type: 4) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #9. 
• The first bullet of the supporting text for Guideline Recommendation #9 implies that 
pharmacists are solely responsible for inaccurate data entry, to correct that, the phrase “if a 
pharmacist” should be deleted. 
• The bulleted information in the supporting text for Guideline Recommendation #9 should also 
apply to patients on high dosages and dangerous combinations, not just patients receiving 
medications from multiple providers. 
• Workgroup members observe that PDMP access and utility varies among states. Issues of data 
sharing can limit PDMP utility in border areas. CDC and its federal partners are encouraged to 
support PDMP development and operation across the country and help work towards efficient 
data access and interfaces for all providers of controlled substances. 
GUIDELINE RECOMMENDATION #10: When prescribing opioids for chronic pain, providers should use urine 
drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for 
prescribed medications as well as other controlled prescription drugs and illicit drugs. (Recommendation 
category: B; Evidence type: 4) 
All members of the Workgroup agreed with the evidence type for Guideline Recommendation #10. 
The majority of Workgroup members felt that Guideline Recommendation #10 should be a Category A 
recommendation rather than Category B. The universal recommendation is perceived to be both more 
focused on patient safety and less likely to result in urine drug testing being applied selectively among 
already stigmatized or stereotyped patients. 
• Supporting text for Guideline Recommendation #10 should encourage providers to use the 
simplest urine drug testing appropriate for each patient to reduce the cost and improve the 
feasibility of this recommendation. 
• Supporting text for Guideline Recommendation #10 should emphasize the need for providers to 
be educated about interpretation of the results of the urine drug testing implemented in their 
practice settings. 
• Research on risks and benefits of urine drug testing is limited, and more such research is 
encouraged. 
GUIDELINE RECOMMENDATION #11: Providers should avoid prescribing opioid pain medication for patients 
receiving benzodiazepines whenever possible. (Recommendation category: A; Evidence type: 3) 
All members of the Workgroup agreed with the type and category of evidence for Guideline 
Recommendation #11. 
• Workgroup members observe and support that the intention of Guideline Recommendation #11 
is to discourage concurrent prescribing of opioids and benzodiazepine medications, however, 
several members felt that the current language presumes that the benzodiazepine prescription 
is appropriate and fails to encourage patient-centered decision making about risks and benefits 
for each medication. 
• Supporting text for Guideline Recommendation #11 could include language about the 
importance of the pharmacist in co-prescribing situations and the role for use of prescription 
drug monitoring programs (PDMP) for identifying concurrent medication use. 
• Workgroup members noted that the wording of Guideline Recommendation #11 has changed 
significantly during the comment and review process. Several workgroup members preferred 
the original wording. 
• Some Workgroup members preferred that this statement be modified to say, “Providers should 
USE CAUTION WHEN prescribing opioids…” rather than, “Providers should AVOID prescribing 
opioids.”  Several Workgroup members supported the “AVOID” wording; two members strongly 
preferred the “AVOID” wording.  
o Discussion surrounded concerns about inter-professional communication (i.e., 
psychiatrists, primary care physicians) challenges and the need for providers and 
patients to jointly discuss the patient’s needs, prioritize patient goals, and weigh risks of 
concurrent benzodiazepine and opioid exposure before deciding upon initiating, 
continuing to prescribe, or tapering either medication.   
• Risk mitigation in the presence of co-prescription was universally supported by the Workgroup. 
GUIDELINE RECOMMENDATION #12: Providers should offer or arrange evidence-based treatment (usually 
medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) 
for patients with opioid use disorder. (Recommendation category: A; Evidence type: 3) 
All members of the Workgroup agreed with the evidence type for Guideline Recommendation #12. 
There was disagreement among the Workgroup members with regards to the Category for Guideline 
Recommendation #12. One member felt strongly that this should be a Category B. The remaining 
Members were comfortable with Category A.  
• Workgroup members commend the wording of Guideline Recommendation #12, particularly the 
“Providers should offer or arrange…” clause because they felt it would help encourage primary 
care providers to be proactive about treatment for opioid use disorder and perhaps encourage 
more providers to acquire training and licensure for buprenorphine prescribing. 
• Workgroup members were in agreement that the evidence for medication assisted treatment 
for opioid-use disorder is strong and recommend that the evidence type for Guideline 
Recommendation #12 be upgraded from type 3 to type 2. 
 
Review of Supplemental Materials: Clinical Evidence Review, Contextual Evidence Review, and 
Comments from Stakeholders, Peer-Reviewers, and the Public 
• The Clinical Evidence Review was thorough and well-done for the specific clinical questions. 
• Workgroup members recommend continued support for future clinical and contextual research 
on benefits and risks of opioid therapy for chronic pain. 
• Future updates of the Contextual Evidence Review should seek out more information about 
specific non-pharmacologic therapies for chronic pain, such as exercise therapies, interventional 
therapies, integrative medicine, and behavioral therapies. 
• Evidence in the Contextual Evidence Review supports that mental health disorders frequently 
co-occur among people with chronic pain. The supporting text for Guideline Recommendations 
#2 and #5 which describe evaluating pain and function should be modified to include evaluation 
of patient mood as well. 
• Comments from constituents demonstrated the breadth and variety of positions on the issue of 
opioid therapy for chronic pain among adults managed in primary care. There seemed to be a 
general agreement, however, that guidelines are needed, even if this set of guidelines is only the 
first step. 
• Comments from patients and family members, in particular, expressed the desire that patient-
centered care is enhanced rather than reduced by these Guidelines. Members felt that the 
guidelines could be implemented in a manner consistent with patient-centered care. 
 
Gary Mendell, Shatterproof
My name is Gary Mendell.  Related to my qualifications, I am a father who has had the anguish of having 
to bury his first born son, who was addicted to opioids.  I am also the founder and CEO of Shatterproof, 
a national organization committed to preventing as many of our loved ones as possible from becoming 
addicted to prescription drugs, illicit drugs and alcohol. Our organization has brought together as 
advisors many of the preeminent experts in the field, and is focused on identifying and helping to 
implement solutions to the tragic epidemic of overdose deaths shattering families across our country. 
I and several of my advisors have read every word of the Proposed 2016 Guideline for Prescribing 
Opioids for Chronic Pain (“CDC Guideline”) and offer the following: 
I and my advisors are very sensitive to the many Americans who suffer with chronic pain.  We note that 
the CDC Guideline makes clear it is not intended for those “patients undergoing active cancer treatment, 
palliative care, or end-of-life care because of the unique therapeutic goals, ethical considerations, 
opportunities for medical supervision, and balance of risks and benefits with opioid therapy in such 
care”.  It also notes:  “It is important that patients receive appropriate pain treatment with careful 
consideration of the benefits and risks of treatment options. This guideline is intended to improve 
communication between providers and patients about the risks and benefits of opioid therapy for 
chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated 
with long-term opioid therapy, including abuse, dependence, overdose, and death.” 
To reverse this horrific epidemic of opioid drug overdose deaths and prevent opioid-related morbidity, 
the medical community is urgently in need of guidance from the CDC because aggressive opioid 
prescribing is harming pain patients and fueling an unprecedented epidemic of addiction and overdose 
deaths. 
I and many at Shatterproof have seen firsthand countless wonderful people who have become addicted 
to prescription painkillers, many of which have died, leaving their families torn apart.  And countless 
others who are living subpar lives in clutches of active addiction.   
As all of you know, the CDC Guideline is not based on public opinion, or conflicts of interest related to 
the profits of opioid sales. Rather, they are based upon an unbiased, exhaustive analysis of the best 
available research.  The CDC can wait for years for further research, but if it does, tens of thousands of 
our loved ones will die, and tens of thousands of families will be torn apart beyond imagination.  Not to 
mention the millions of Americans who will lead subpar lives, with they and their families agonizing, 
waiting for that call that no parent, sibling, or child every wants to receive. 
In this regard: 
1. I strongly urge the CDC to revise Recommendation #1 be strengthened by listing specific chronic
conditions for which opioids should be avoided.
2. I strongly urge the CDC to not revise Recommendation #5 related to levels of dosage.
3. I strongly urge the CDC to not revise Recommendation #6 related to duration of dose.
4. I strongly urge the CDC to not revise any other of the recommendations.
5. I strongly urges the CDC to release the CDC Guideline as quickly as possible.
It is time, in fact well past time, for the CDC Guideline, as recommended above, be issued and 
implemented without any further delay.  I as a father of four other children and families all across 
America are depending on this. 
Andrew Kolodny, MD 
 
Chief Medical Officer 
Phoenix House Foundation
Andrew Kolodny, Phoenix House
Draft of oral comments for CDC meeting on proposed opioid guideline 
Primary care clinicians have contributed to an epidemic of overdose deaths and addiction by 
overprescribing opioids. We didn’t do this out of malicious intent. For most of us, it was a desire to treat 
pain more compassionately that led to overprescribing. To bring this public health crisis under control, 
doctors must prescribe more cautiously. 
In response to an industry-funded campaign, sales for opioids increased exponentially. Doctors were 
taught that unrealistic fear of addiction was resulting in needless suffering and that opioids would 
provide long-term relief of chronic pain. Doctors were misinformed. 
Primary care clinicians need guidance on opioid prescribing that is free of industry bias. 
Prescribing opioids short-term for acute pain and in palliative care is not controversial. But their 
widespread use for chronic pain may actually harm more people than it helps. Many patients on long-
term opioids continue to suffer from significant pain and dysfunction. We have also come to realize that 
addiction and other serious side effects are common. 
Overprescribing of opioids isn’t just bad for patients. As opioids have become readily available in our 
medicine chests and classrooms, teenagers are experimenting with them. Unaware that these pills are 
similar to heroin, many recreational users are becoming addicted and dying from overdoses. 
The Centers for Disease Control has demonstrated a strong association between increased opioid sales 
and overdose deaths. This suggests that prescribing needs to be reduced. Opioid manufacturers, and the 
pain advocacy organizations they fund, do not agree with this approach. They argue that opioids are still 
underused for chronic pain and that prescribing needs to increase. And they work against efforts to 
promote cautious use. The most recent example has been successful effort to delay the release of the 
CDC’s guideline. 
For doctors to prescribe more cautiously, an accurate appreciation of risks and benefits is required. The 
CDC’s proposed guideline helps accomplish this. 
Untreated chronic pain is a serious problem. But opioids are rarely the answer. Chronic pain patients 
need and deserve compassionate care and evidence-based treatment. 
  
 
 
Susan Peschin, Alliance for Aging Research
My name is Sue Peschin and I serve as president and CEO of the Alliance for Aging Research, the leading non-profit 
organization dedicated to accelerating the pace of science to improve aging and health. Thank you for the opportunity to 
comment on the draft CDC Guideline for Prescribing Opioids for Chronic Pain. I am speaking today to respectfully 
request modifications to this draft guideline in order for healthcare providers to deliver appropriate care to aging pain 
suffers. 
Research shows that older adults are the highest risk age group for persistent pain, yet they are too often undertreated or 
do not receive the appropriate therapy. Psychosocial factors, like the tendency of older adults to underreport their pain and
lower adherence rates to prescribed pain medications often results in increased hospital stays, disability, interference with 
activities of daily living, sleep disturbances, depression, and suicidal thoughts and suicide.  
There has been significant controversy about the guideline development process itself. What has been lost in the mix is 
the real controversy—that there is a limited or weak evidence base for almost all of these recommendations and that we 
need significant federal investment in clinical research to fill these key knowledge gaps. Who are the chronic pain patients
for whom long-term opioid treatment would be most effective? Who is physiologically at higher risk of physical 
dependence on opioids? And, which patients will experience reduced tolerance while on long-term opioid treatment? Such
gaps should be identified in the introductory statement.  
In recommendation 1, the guideline should acknowledge the real-world concerns that accompany non-pharmacologic 
therapy and non-opioid pharmacologic therapy as first-line treatments for chronic pain. While approaches such as 
acupuncture, massage, CBT, and exercise demonstrate short-term benefits, the primary focus of this guideline was 
designed for the long-term management of chronic pain, so further evidence on them is needed before they can be 
suggested as an alternative to opioids. Most of these treatments are not reimbursed by public and private insurers, so 
providers should be directed to consider their patient’s coverage status before prescribing an unaffordable intervention. 
Additionally, we are concerned about the potential overuse of acetaminophen and NSAIDs by older adults for chronic 
pain management and that the risks associated with them may be underestimated by providers attempting to avoid the 
prescription of an opioid—particularly for older adults who have multiple chronic conditions. NSAIDS are 
contraindicated for several diseases that seniors often experience concurrently with pain. Acetaminophen also has a 
maximum daily limit that can be exceeded in the pursuit of chronic pain management without proper education.  
The dosage thresholds in recommendation 5 are in direct conflict with the FDA and its approved product labeling, which 
deliberately chose to exclude dosage thresholds based on evidence review. A June 2015 piece in the journal Pain 
Medicine found that “The lack of dosage uniformity and regulatory approaches across the United States raises the concern 
that dosage levels are not informed by high-quality evidence, are arbitrary, and may amount to experimentation with 
increased risk to patients.” Recommendation 5 is not supported by existing evidence. We urge that this recommendation 
be removed from the list entirely. 
Recommendation 6 of the draft guideline attempts to limit opioid overuse by imposing a 3-day limit for prescription of 
opioids to treat acute pain. Comments submitted to you by the AMA highlighted that the clinical evidence provided in the 
evidence review for this recommendation focused largely on the emergency setting and that there is a lack of evidence to 
support this recommendation for use in treatment of acute pain post-surgery, which will disproportionately impact older 
patients. Adults over age 65 are 2.6 times more likely to have surgery than those than those ages 45-64. We urge the 
modification of Recommendation 6 to remove a time or specific pill limit for acute pain treatment. The emphasis of this 
recommendation should be on healthcare providers prescribing the lowest dose of a short-acting opioid in a number and 
duration that the provider determines to be clinically necessary.  
Disabling pain in older adults is a significant quality of life issue that creates a huge burden for patients, family caregivers,
and society—and we would greatly appreciate more acknowledgement of this side of the discussion as this process moves 
forward. Opioids may not be the panacea, but they have helped reduce pain and improve function for millions of people. 
Future efforts and reforms should continue to focus on balance and the need to ensure access while preventing harm, 
rather than advocating for only one solution to a very complex problem. 
Jane Ballantyne, University of WashingtonBallantyne Comments on CDC Guideline January 9, 2016 I am an anesthesia pain specialist and have been since 1990.  In the 1990s through 2008, I was the chief of an academic pain program in Boston.  Throughout that span, the prescribing of opioids for chronic pain in the United States quadrupled, and it continues to rise.  Whereas opioids were rarely used for chronic pain because they were thought to be ineffective or unsafe, more recently they have been used in up to 7% of chronic pain cases1 and rising2, and chronic pain rates are steadily increasing along with improved survivals and an aging population.  There are numerous factors that produced the rise in opioid prescribing for chronic pain, but most importantly, there was new teaching that came largely from palliative care and industry.3 This teaching aimed to 1) establish the right of chronic pain patients to receive opioids and the duty of clinicians to prescribe, 2) change the belief that opioids were not effective for chronic pain, 3) change the belief that opioids were not safe and 4) encourage open ended dosing on the basis that opioid pain relief was best obtained if opioids were dosed according to the stated pain level.   The result was that both the number of people receiving opioids, and the doses they were receiving, increased exponentially.  And a whole culture changed. By the end of the 1990s, my colleagues and I began to question the basis of the teaching we had received, and our own practice.  Patients receiving high doses of opioids typically reported high pain levels despite the opioid they were receiving, and they rarely experienced the improvements in function and quality of life we had hoped for. We searched the literature and found no evidence to support our practice, and we turned to the laboratory to try and explain the paradox of increasing pain despite increasing opioid doses.4   We published our findings, we lectured, we presented to the FDA, we wrote guidelines, but nothing seemed to stem the tide of increased and unsafe prescribing.  We find ourselves now, over 20 years later, with growing epidemiological evidence that shows clearly that unfettered opioid prescribing for pain has harmed both society and pain patients, and has not relieved the nation’s burden of chronic pain.5-7 Yet there is a reluctance to act on the basis that “more research is needed” – research that will take years to complete, if it ever gets done at all.  The CDC guideline is urgently needed.  The guideline was very carefully crafted using the best available evidence, expert opinion from a group of individuals with extensive experience of writing practice guidelines, and stakeholder input from a broad and balanced group of stakeholders.  The guideline suggests precautions that very few people would argue, precautions that are identical to those in all previous chronic opioid guidelines, both national and international.  In an attempt to move practice away from what has clearly been shown to be ineffective and unsafe – continuous long term high dose opioid treatment - two new changes are suggested: lower standard doses, and shorter duration of treatment for uncomplicated acute pain.  The guideline does not suggest taking opioids away from people who have already become dependent, does not suggest taking opioids away from people who can benefit, does not suggest anything that would harm pain patients.  Yet it has produced a barrage of criticism, often based on an irrational fear of opioid restrictions.   It is that criticism that brings us to the table today.  I hope that the Board of Scientific Counselors will appreciate the urgent need for action, the reality of the limited state of the evidence, and the care with which the CDC guideline was crafted.  
Ballantyne Comments on CDC Guideline January 9, 2016 
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Judy Rummler, FED UP! Coalition
Comments for January 28th presentation (for print and oral version) 
from Judy Rummler, Chair of the FED UP! Coalition and Founder of the Steve Rummler Hope Foundation 
Thank you for the opportunity to present comments on this very important issue. 
I am Judy Rummler, Chair of the FED UP! Coalition.  The FED UP! Coalition is working to find ways to prevent our 
children, spouses, parents, and friends from becoming addicted to opioids and to eliminate opioid overdose 
deaths.  FED UP! is a grass roots coalition of individuals and organizations from across the country.  We hold 
rallies and advocate for change in public policy that will help pain patients and those suffering with the disease 
of addiction.  We are fed up with the failure of the FDA to take action that could end the overprescribing of 
opioids and save thousands of lives.  We applaud the CDC for creating this proposed guideline which would lead 
to more cautious opioid prescribing and reverse the trend of ever-increasing overdose deaths. 
Many of our members and partners have friends and family members who have died from opioid overdoses.  
The voices of these lost loved ones have been silenced, but their stories need to be told. 
My story, similar to thousands of others, is about the loss of my son Steve Rummler.  If Steve had had the 
opportunity to present to you five years ago, I am sure that he would have said that he had intractable chronic 
pain due to his back injury.  He would have said that he needed his opioids in order to any have any “quality of 
life.”  He had become addicted to the opioid painkillers that were being prescribed to him for his chronic pain, 
and he would have been terrified at the thought of losing access to his pills.  Steve died of an accidental 
overdose on July 1, 2011. Among his belongings we found a note referring to his prescription that said: "At first 
it was a lifeline - Now it is a noose around my neck." 
As the mother of a son who suffered with chronic pain and the founder of the Steve Rummler Hope Foundation, 
I have compassion for pain patients.  Their voices are being heard in this discussion and they have posted many 
comments.  But there are more than 200,000 Americans who have tragically died from the opioid epidemic, and 
these mothers, fathers, sons and daughters are unable to post comments or otherwise participate in this 
discussion.  These are people who had faith in their doctor’s knowledge of the risks associated with opioids and 
who were not expecting that something bad would happen to them.  I urge the CDC and this Workgroup to 
consider these silenced voices when evaluating the need to release this guideline.  What would they say about a 
guideline that could have saved their lives? 
This proposed guideline is long overdue as a way to prevent pain patients from getting started in a cycle of 
opioid use that can lead to more pain, the disease of addiction and overdose death.   
Thank you! 
Judy Rummler, 
Chair, FED UP! Coalition 
Founder, Steve Rummler Hope Foundation 
Gary Franklin, WA State Dept of Labor and Industries
Gary M. Franklin, MD, MPH 
WA State Dept of Labor and Industries 
PO Box 44321 
Olympia, WA 98504-4321 
Email: fral235@lni.wa.gov 
Medical Director, WA Dept of Labor and Industries, Olympia, WA and Research Professor, Depts of Environmental and 
Occupational Health Sciences, Neurology, and Health Services,  University of Washington, Seattle 
Testimony for the Washington State Agency Medical Director’s Group, representing all of the public health agencies in WA 
state (Medicaid, public employees benefits, workers compensation, Dept of Health, Corrections), in strong support of the 
draft CDC Guideline for Prescribing Opioids for Chronic Pain 
I am Gary Franklin, Medical Director of the WA Department of Labor and Industries, and Research Professor at the 
University of Washington.   I am also co-chair of the Washington Agency Medical Director’s Group (AMDG), 
representing all of the public agencies in WA that purchase or regulate health care.  The opioid epidemic represents the 
worst man-made epidemic in modern medical history: over 175,000 deaths from unintentional overdose, many more 
hundreds of thousands of emergency department  and hospital admissions from overdoses, severe adverse events such 
as neonatal  abstinence syndrome, and millions with severe dependence or addiction from taking prescribed opioids for 
chronic non-cancer pain. The recent paper by Case and Deaton (PNAS, 2015) pointed out the shocking increase in 
mortality among middle-aged lower educated whites-a large proportion of this increase in mortality in a very 
susceptible group of Americans is related to unintentional overdose of prescribed opioids.  
I reported the first deaths in the US from unintentional overdose of prescribed opioids in a peer reviewed journal (2005, 
Am J Ind Med). These unintentional overdose deaths primarily occurred among injured workers who had entered the 
workers compensation system due to a mild musculoskeletal injury. This was the saddest thing I had seen in many 
years as Medical Director.   
By 2006, the public programs in Washington already had over 10,000 citizens on doses of opioids greater than 100 
mg/day morphine equivalents, and by 2008, this translated into 508 deaths from prescribed opioids. More than half of 
these deaths were in the Medicaid program.  In response, the WA AMDG, in full collaboration with a large group of 
the state’s well respected academic and clinical pain experts, developed the nation’s first opioid dosing guideline in 
2007 to guide effective  use of opioids and reduce the risk to our citizens. The AMDG followed up with increasingly 
comprehensive revisions to the guideline in 2010 and 2015. The most recent edition (June 2015, URL: 
http://www.agencymeddirectors.wa.gov/guidelines.asp) is highly consistent with the Draft CDC Guidelines. Two 
separate published statewide surveys of primary care prescribers showed that 85% supported the dosing threshold (120 
mg/day MED) in the WA guidelines, and felt that the 120 threshold was too high or just about right.  
How in the world did all this happen? The important thing to recognize is that much of the teaching and lobbying that 
led to out of control opioid prescribing was based on no credible scientific evidence:  1. There is no ceiling on dose-
This specific teaching  led to law changes in more than 20 states that included language such as ,"No doctor shall be 
sanctioned for any amount of opioid written" (WA regulations). We now know that there is a very strong dose 
dependent relationship between average daily dose and overdose poisonings and death. 2. The way to treat tolerance is 
to keep increasing the dose. The only randomized trial done to date demonstrates that increasing the dose has no 
beneficial  impact on any primary pain or function outcome (Naliboff et al, J Pain, 2011). 3. Addiction is rare, less than 
1%. Recent studies (Degenhardt, Lancet Psychiatry, 2015) have shown that severe dependence 
and opioid use disorder occur in up to 30% of those receiving opioids chronically. In additionto the more serious 
adverse outcomes related to opioids, there is emerging evidence that even modest opioid use for acute low back pain 
can double the risk of long term disability-this was a Class I prospective study of risk factors in nearly 2000 low back 
cases (Franklin et al. Am J Ind Med, 2008). In other words, it is highly likely that opioids are contributing to the 
initiation and persistence of disability in our workers’ compensation systems, and to these workers entering the Social 
Security Disability and Supplemental Security Income systems. 
The CDC Guideline has been criticized for coming up with medium-high recommendations that in some cases are 
based on lower level evidence. This is the same methodology used by the American Pain Society/American Academy 
of Pain Medicine evidence-based guideline published in 2009 (J Pain 10:113-130). The same organizations that are 
now criticizing this aspect of the Draft CDC guideline came up with 25 recommendations, 18/25 (72%) of which were 
“Strong” recommendations based on “Low” level evidence. The evidentiary underpinning of the draft CDC guideline is 
very strongly done, with both a formal evidence assessment and a supplementary contextual evidence review.  
The federal government found insufficient evidence on long term effectiveness of opioids to reach any conclusion, but 
there was strong evidence supporting dose dependent risk for serious harm related to chronic opioid use  (Chou et al, 
Ann Int Med,2015). In the face of this evidence, and the points raised above, the public agencies in Washington State 
strongly support and applaud the CDC’s draft guideline.  
Don Flattery, Citizen advocate/Impacted parent
I am participating in this public process to implore the CDC to issue the draft opioid prescribing guidelines 
as soon as possible. The epidemic of opioid prescription drug and heroin addiction the country is facing 
is a public health crisis which continues to worsen rather than diminish despite considerable expenditure 
of vast local, state and federal resources. More importantly, the horrific loss of life continues to climb as 
public health practitioners, medical personnel, researchers and public policy analysts continue 
deliberations over strategies to address the issue. We can not wait for more research, deliberation and 
debate - the imperative to act is now.  
My name is Don Flattery and I live in Fairfax County, Virginia.  I am a recently retired federal manager, 
an appointed member of the Virginia Governor’s Task Force on Prescription Drug and Heroin Abuse, and 
I am an active participant in the development of a strategic plan for community action on opioid and heroin 
use in Fairfax County.  But I am not writing today in any of those roles.  I am addressing the Board solely 
as a grieving parent, someone who has suffered the loss of his 26 year old and only son to an opioid 
overdose sixteen months ago.  My beautiful, talented, highly educated and loving son became addicted to 
OxyContin as a working adult pursuing his career passion in the film industry. Like thousands of others, 
including members of the medical community, he did not fully comprehend the addictive power of opioid 
drugs and that misunderstanding led to his demise. 
The curve of prescribed opioids over the last two decades has gone exponential and with 259 million 
opioid prescriptions written as recently as 2012, opioid painkillers are ubiquitously available and present 
in our communities, workplaces, schools and medicine cabinets. There is a direct, immutable nexus 
between opioid prescribing and the explosion of opiate addiction and overdose deaths. Until we can “bend 
the curve” of the number of prescribed opioid pain relievers, we will continue to swim in place and all the 
federal, state and community resources we can bring to bear for education, prevention, and treatment will 
be for naught. We must ensure more cautious prescribing of opioid drugs in this country and CDC’s 
guidelines are a commonsense, first step in doing so. 
Without question, the millions of opioid prescriptions in the US contributes enormously to their 
availability for non medical purposes but the crisis before us is not just a matter of (mostly young) people 
abusing otherwise “safe as prescribed” medications. That characterization ignores the significant role and 
pathway to opioid addiction and mortality that medically prescribed opioids play in this crisis. The fastest 
rate of prescription opioid drug overdose deaths is occurring in the 55 to 64 year old age group - these are 
not people snorting crushed opioid  pain relievers after a high school social event - they are people who 
became dependent and then addicted to their prescribed narcotics. Moreover, the incidence of non medical 
OPR use has declined from 2.7 million users in 2002 to 1.8 million non medical users in 2012. Despite 
contrary assertions that will be made to the Board through this process, it is a fact that medically prescribed 
opioids are directly implicated and a primary cause of the addiction and mortality crisis before us.  
In other forum and policy discussions, the lack of physician training regarding addiction has been widely 
discussed and recognized as a “gap” in medical education. A gap sadly filled through prior information 
campaigns from opioid manufacturers.  CDC’s voluntary opioid prescribing guidelines will provide a 
commonsense tool for informing prescriber decisions regarding opioids and associated risks.  A tool that 
does not impede physician decision making but one that improves patient care and protects public 
health.  
Michael Britt Doyle
I would like to share the reasons that I support greater caution in prescribing opioids: 
 My wife, Wynne Doyle, passed away 10 months ago.  When we met 22 years earlier, Wynne was an incredibly 
beautiful, vibrant woman. We married in 1995 and had three children over the following five years. She had 
been a cheerleader, homecoming queen, marathon runner, and world traveler. Post-partum depression and the 
extended use of high doses of opiate-derived pain medication that accompanied a third C-section birth were not 
something either of us paid attention to because no one discussed the dangers openly at the time. The internet 
was not the information source it is now, so we relied on the various doctors we saw and the medication 
regimens they ordered. 
It wasn’t until Andrea Yates drowned her children in 2006 that the world began to take post-partum depression 
seriously, and it wasn’t until recently that people started taking notice of the massive problem our country has 
with opiate addiction. According to a recent Time Magazine article titled Why America Can’t Kick Its Painkiller 
Problem , 4 out of 5 new heroin addicts started with prescription opiates.  
Wynne drew the line at “street drugs.” She never would have tried heroin because, above all else, she 
considered herself a lady. I’m convinced that the pain she was in during withdrawal when she couldn’t refill a 
prescription is what drove her to alcohol more than anything else.  
An average of 46 Americans die from opioid overdoses every day. This epidemic has seemingly gained 
momentum under the radar for several years and has become almost socially acceptable by the mere fact that 
the drug comes in pill form that a doctor prescribes. I don’t even know how many times I heard Wynne say “I’m 
just following the doctor’s orders!”   
The worst part for me over the years was watching Wynne come home from several substance abuse programs 
or hospital visits with what seemed like as many prescriptions of other drugs like Klonopin, Suboxone, 
Lorazepam, Tramadol, and many others that could easily become addictions as well. I tried very hard to 
understand the logic and asked the doctors at the facilities why they needed to give her more prescriptions as 
she left, but I was never fully satisfied with the answers I got because it seems so incredibly illogical to me[ .  
I still find it incredible that the hospital that removed Wynne’s massive kidney stone in the final week of her life 
sent her home with heavy, opiate-based pain medication prescriptions even though they had 15 years of files on 
her countless visits to their emergency room where they did medical detoxification to save her life. 
I felt truly helpless for the past 15 years while Wynne's addiction ripped our family apart both emotionally and 
financially. I am working with Shatterproof as an ambassador to get the word out, and am also writing a book 
about our experiences because I can't imagine what we went through can't serve as a warning for others. 
Thank you for your consideration. 
Best, 
 Britt 
 Britt Doyle 
Founder 
Edgewood Impact 
750 Edgewood Ave. 
Mill Valley, CA 94941 
415-533-0358 
www.edgewoodimpact.net 
Facebook; Twitter; Linked In 
Kerilyn Whitehead
Educating about Addiction and Overdoses as the Numbers Rise.  
Many people are not aware of the growing epidemic of addiction. There is a stigma surrounding 
society that addiction is something one can control; one can decide whether or not he wants to be an 
addict. People are taught to look at addicts as criminals and deadbeats who deserve the life they have 
“built” for themselves. This could not be further from the truth behind addiction. Further education 
needs to be given not only to children, adolescents, and teenagers in schools, but families and medical 
professionals as well.  
Addiction is a disease just like diabetes, cancer, Alzheimer’s and Lyme’s disease.  Addiction not 
only affects the addict, but the addict’s family, friends and anyone in the addicts close circle.  These 
caregivers have to be educated how to take care of themselves as well as treating the loved one in their 
life with the disease.  
April 1, 2015 is a day I will never forget. At about 3:30 in the morning, I awoke to my parents’ 
frightened screams.  They were screaming my brother’s name from his room in hopes he would 
respond. My nineteen year old brother was lying in his bed, unresponsive. Strange noises came from his 
mouth and nose.  I got out of bed to see what was going on his room and immediately called 911.   
One of the last instructions I can remember is the dispatcher asking me to put my phone to my 
brothers mouth and as soon as I said “okay…” the dispatcher said, “Okay ma’am, I can hear the weird 
noises you were talking about.”  The dispatcher told me that she suspected the weird noises my brother 
was making was “ineffective breathing”.  I had no idea what that meant but I knew it did not sound 
good.  Next thing I knew, she was telling me I had to give my brother CPR until help arrived. I had been 
certified in CPR my whole life but have never actually had to use on anyone before.  I was hesitant and 
started screaming at the woman on the phone that I just could not do it.  She told me I had to.  I did not 
have a choice. I could hear the severity of the situation in her tone. I nervously began administering CPR 
to my brother. My baby brother – the one person in my life I share an irreplaceable bond with.  
When the EMTs arrived they immediately took over, sending me and my parents downstairs to wait 
while they administered Narcan, oxygen, and whatever else needed to get my brother breathing again. 
We later learned his respiratory rate was at a 4 (a normal respiratory rate is a 12).  He was almost dead.  
Waiting downstairs for news from the EMTs felt like an eternity. When they finally came down to let us 
know they had revived him, I felt like I could breathe again, too. They told us that they were going to 
ask him a few questions and then they put him in the ambulance to take him to the Emergency 
Room.   During that time, my brother told them he had taken Vyvanse, Adderall, and five or six 
OxyContin (20mg) pills throughout that day. My mother had found two OxyContin (20mg) pills in his 
wallet as soon as he was taken out on the stretcher and handed them over to the EMTs.  My brother was 
admitted to the Emergency Room and released after two short hours with a diagnosed "drug overdose."   
Hospitals are not given the proper tools or education they need to treat addicts and addiction or 
overdoses.  Many hospitals do not even want addicts brought into the emergency room however, they 
have no other choice.  Stamford Hospital did not treat my drug addicted brother properly however, I’m 
not sure if they actually knew how.  With more than 2 million Americans, age 12 or older, abusing or 
dependent on opioids all hospitals, doctors, and nurses should know how or what to do with this 
epidemic.  Instead, doctors, nurses, and hospitals are the ones sued and blamed for many addictions and 
overdoses.  Getting prescriptions has never been easier!  More education and awareness needs to be 
brought to this growing epidemic and it needs to happen now!  
Harold Laski, Southside Medical Center
I applaud the CDC for its efforts and intent. The problem is in the unintended consequences that are sure to occur, 
including the fear of physicians who appropriately treat those patients whose pain does not respond sufficiently to 
other pain relief modalities so that they can lead improve their quality of life. The guidelines state that they are 
voluntary but the past has shown us that State Medical Boards and others will take these as Standards of Care and 
doctors will fear for their licenses. Guideline 5 which originally read "should prescribe the lowest possible 
effective dosage" was changed to "the lowest effective dosage." leaving out the word "possible". More 
importantly the phrase "should avoid increasing dosages to 90" was changed by simply adding the word 
"generally" so that the phrase now reads "should generally avoid increasing dosage to 90 MME." The legal 
definitions of the word "generally” includes  “normally” and “usually”. Does the addition of this word really give 
physicians more leeway to prescribe medication dosing than the previous draft did? And will physicians and State 
Boards see it as such? How does the term "generally" make the difference in that sentence that the majority of 
critics of Guideline 5 requested? And not to be a stickler, but the phrase "should generally avoid increasing 
dosage to 90 MME or greater than 90 MME is redundant. Maybe I am a stickler, but that is just what physicians 
fear of the State Boards and anyone else who controls how physicians treat patients. Changes still have to be 
made so that physicians who do treat chronic pain appropriately will feel comfortable that their practice will not 
be constrained by the Guidelines. It is the CDC's obligation to create a Guideline that takes into account the 
unintended consequences of its actions. Is this hard? You bet it is. But it is their obligation to do this so that those 
patients who do rely on their doctors for pain relief can get what they deserve and that is the best medical 
treatment available at the time such that their quality of life improves sufficiently. But there are over 100 million 
Americans with some degree of Chronic Pain. If even 10% seek treatment that means that there would be a 
necessity of ten million doctors visits a month just for chronic pain. With only about 3500 pain specialists this 
would mean that each specialist would have to see over 100 patients a day. We need the generalists and family 
practitioners to treat the vast majority of chronic pain patients. Hampering them will have those intended 
consequences come to light.  And to quote an old proverb, "Don't throw the child out with the bathwater." Don't 
make those patients that will suffer due to these unintended consequences be left with a life that is incomplete and 
rife with depression, pain, and suffering. The guideline must be created so that ONLY those that merit receiving 
the controlled medications are able to get them. Mark Twain once said “There are three kinds of lies: lies, damned 
lies, and statistics.” Statistics show that controlled substances are often involved in medical cases of morbidity 
and mortality. However, this can be misleading  If we removed all those cases where the presence of the opioid 
was inappropriate such as in those persons who were not prescribed the medications at all (family members and 
friends of persons prescribed the medications, and those procuring the medication through illegal means such as 
theft or coercion), those patients who were inappropriately prescribed the medications (such as those who were 
prescribed higher doses than needed and those that were given prescriptions for the wrong medication for their 
diagnosis) then we are left with only those patients who were appropriately prescribed the correct medication and 
dose of that medication, and this group of users statistically shows a very low number of cases of morbidity and 
mortality. This all means that physicians who appropriately prescribe the medications should not feel in any way 
fearful of prescribing them to their patients who merit them. The wording of the guideline must be carefully 
changed so that physicians are not fearful. So, the guidelines must mandate a specific protocol that physicians can 
feel comfortable following and doctors must be required to take whatever educational courses would be necessary 
for them to understand the protocol.  Maybe there should be a requirement for any patient who is to receive 
controlled substances for chronic pain also be given some kind of required education on the use and abuse of the 
controlled substances.  Incentives must be given to companies that manufacture these medications so that every 
opioid available is only available in forms that cannot be abused. Not just the branded long acting opioids, but all 
opioids. Physicians and pharmacists must be able to get drug database information from anywhere in the United 
States and not just there home state. And physicians and pharmacists must have  access to drug information that at 
this point is not accessible, such as Methadone use at Methadone clinics and all opioids that are prescribed and 
distributed to patients from government institutions such as the VA. There are other unintended consequences 
such as Pharmacies that have increased the prices of the opioids 500 to 1000% or require cash payments for the 
opioids And finally there must be included in the guidelines stipulations that stop pharmacists from requiring 
from 1-6 non opioid prescriptions before they will fill the opioid prescriptions.  So the guideline must cover all of 
these factors if we are to actually control the effects that the guideline would have otherwise it becomes useless. 
Let’s do something that actually helps and does not create those unintended consequences that I started this letter 
off describing. 
Barron Joseph Clepp 
Before I retired in November of 2013, I was a Director of Human Resources  for a large organization in Houston, 
Texas.   In this position I had complete visability of terminations, drug testing, and performance evaluations for a 
working population of 1,200 people.  My thinking is that the use of “pain killers” is a large factor in people being 
terminated for cause or performance, failing drug test, and having poor evaluations.   It was common knowledge 
in our working population of 19-25 year olds the that if you got a prescription for pain killers you could feel 
better at work and not get caught.   
There were two people in my department, in their 50’s that had back problems for years.  It was clear they used 
hydrocodone /acetaminophen (Vicoden) and oxycodone/acetaminophen (Percocet).  They used the drugs to 
stop moderate pain, but also to feel better at work.  Their work performance was up and down and their 
attendance was not good.  Their addiction was clear if you just looked under their polish act of deception. 
I have also seen the same blurry-eyed acceptance of “pain killers” away from the workplace.  My son was an 
alcoholic and like so many alcoholics also took pain pills.   
He died of a heroin overdone on August 2, 2011.   He was 27 years old-Just another statistic to report. 
I have read that Opioids make a dramatic difference for moderate to severe pain and are safe as long as you use 
them safely and follow the doctor’s instructions carefully. 
This maybe true, but primary care doctors do not control them, HR departments do not control them and the 
people that get hooked on them do not control them. 
We need new prescribing guidelines with strong directions for follow-up and discontinuation of opioids. 
Lexi Reed Holtum, Steve Rummler Hope Foundation
Comments from Lexi Reed Holtum 
I am speaking to you today on behalf of the Steve Rummler Hope Foundation to express our support for the 
recent effort by the Centers for Disease Control and Prevention to introduce prescribing guidelines for opioid 
pain medicines in an effort to combat the epidemic of opioid addiction and overdose death which has caused so 
much devastation to patients and families over the last 15 years.  
Our involvement in this public health issue began like so many – with personal tragedy. My fiancé, Steve, died of 
a heroin overdose in July of 2011 at the age of 43. However, while heroin may have been the immediate cause 
of his death, what brought him to that dark place began years earlier with a back injury which became chronic - 
again, a story very familiar to many Americans. He sought the help of medical professionals who put him on 
opioid pain medicine in 2005.  Initially this brought great relief , but over time he needed to take more and more 
and it was increasingly ineffective. Ultimately, after a failed attempt at treatment and unable to find enough 
opioids through prescriptions, he turned to heroin on the night he died. We at the Foundation have been trying 
to save lives and raising awareness of this problem ever since.  One of our proudest achievements was the 
passing of Steve’s Law in 2014 which will put the opioid antidote, naloxone, into the hands of first responders 
here in Minnesota. This effort is already saving lives by reversing the effects of prescription opioids and heroin in 
acute overdose. But we realize that to truly stop the tragic loss of life on the scale we are experiencing right now 
we must begin “upstream” with the pattern of liberal opioid prescribing that has characterized American 
medicine beginning in the late 90s. It has been this change in prescribing culture that starts so many down the 
path to misery like it did with Steve. And it is a path that begins in the doctor’s office. 
The United States now consumes over 80% of the world’s opioids despite having just 5% of the world’s 
population. And with the increase in sales has come increased overdose deaths from 4,030 in 1999 to 18,893 in 
2014, an increase of over 400%. Rising alongside opioid overprescribing has been the use of heroin, which, being 
an opioid itself, is frequently turned to by users of prescriptions when access to pills becomes limited. The 
number of heroin deaths has also climbed tragically from 1,842 in 2000 to 10,574 in 2014.  Of note, the year 
2011 saw 4,397 Americans die from heroin overdose.  My fiancé was one of those. 
What is especially frustrating to those of us who have studied how this problem came about was that there was 
never any scientific evidence that these medicines were safe and effective in the long term. Further, the data 
over the last 15 years have seen no proven benefit to those taking these opioid medicines such as decreased 
rates of disability for musculoskeletal pain or reduced need for surgery such as spinal fusion. The incidence of 
both continues to increase to new heights with over 11 million recipients of SSDI in 2014 compared to 4 million 
in 1992.  In short, we have no evidence of benefit and ample evidence of harm. 
As the fiancée of someone who suffered with chronic back pain, let me be the first to say how much I 
sympathize with chronic pain patients. And to family members of those with a loved one in such a circumstance, 
let me also say I understand how desperate one can feel looking for answers to provide relief to those we love. I 
myself suffer from chronic back pain, but I have learned that these medicines are not the answer and have 
found alternative treatments that work. For too few do they safely and predictably provide lasting relief, and for 
too many they result in ruin. For that reason I applaud the efforts of the CDC and believe that they constitute 
the beginning of a reversal of this trend of overprescribing and will prevent patients from starting down a path 
that leads to despair. 
Asokumar Buvanendran, American Society of Anesthesiologists
ASA Testimony before the National Center for Injury Prevention and Control Board of Scientific 
Counselors 
January 28, 2016 
My name is Asokumar Buvanendran, and I am a pain medicine specialist at Rush University 
Medical Center and the Vice-Chair of the American Society of Anesthesiologists Committee on Pain 
Medicine.  ASA supports the federal government’s efforts to reduce opioid overdose deaths, and 
supports the majority of recommendations in the CDC Guideline.  Today, I would like to address 
ASA’s two primary concerns with the recommendations in the Guideline. 
First, ASA is concerned that the Guideline inaccurately portrays the effectiveness and risks of 
interventional procedures, which is particularly concerning since interventional pain procedures are 
a key non-opioid therapy to treat chronic pain.  When performed by a pain medicine physician, there 
are an extremely small number of complications associated with interventional therapies, such as 
epidural injections, radiofrequency denervation, and spinal cord stimulation, and the complication 
rate is far lower than the complication rate for chronic opioid therapy for chronic pain.  To make the 
available non-opioid options clear to the prescribing physician, we propose that CDC revise 
Recommendation #1 to include examples of nonpharmacological and non-opioid pharmacological 
therapies, which should including interventional pain procedures. 
Second, ASA is concerned that the Guideline would curtail perioperative physicians’, which includes 
physician anesthesiologists, surgeons, and co-managing internists or hospitalists, ability to treat 
patients’ acute pain after surgery, and any recommendations made by CDC need to balance the 
overprescribing of opioids for acute pain with perioperative physicians’ imperative to treat post-
surgical pain.  In recommendation 6, the CDC should remove the reference to “major” surgery 
because even minor surgery may require opioids for more than three days.  We recommend that the 
CDC revise the Guideline to state:  
When opioids are used for acute pain, providers should prescribe the lowest effective dose of 
short-acting opioids and should prescribe no greater quantity than needed for the expected 
duration of pain severe enough to require opioids. Three or fewer days will usually be sufficient 
for non-traumatic pain not related to surgery. 
Thank you. 
Dee DeLuca-Mattos
My name is Dee DeLuca-Mattos, I support greater caution in prescribing opioids because simply I am a mother of a 
son in recovery from opioids.  My son was the poster child for a clean, healthy, active life. Catholic school boy, 
athlete, good student, out-going, friendly, loving and more important would not take an aspirin. His addiction did not 
start from buying drugs on the streets, from a drug dealer on the wrong side of the tracks as everyone perceives. 
His started from an accident, in which he was prescribed 60 Oxycontin to go home with. 6.0, Sixty,.  
He was in his last year of college, when his addiction started and he, we, our family struggled to save him not only 
from his addiction, but we tried to save him from the medical professionals that were so recklessly prescribing them 
to him. This went I for 4 years desperately trying to understand his addiction, trying to learn as we were fighting to 
keep our son alive, costly rehabs, out patient, then the same doctors prescribing the opioids are the same doctors 
prescribing suboxone. You will never understand until you walk in the darkness of addiction, the anguish, pain and 
struggle of watching someone slowing deteriorating in front of your eyes.  I am one of the lucky ones, because 
today, my son is in recovery but he will have to fight every moment of everyday, work a program and commit 
himself to sobriety because his addiction, will never go away.  My fear! Is that he does have a car accident and the 
medical professional ignores the simple words as: Allergies: opioids, is ignored (as so commonly is ) what can 
happen. Image, that worry.  
When you have a child that is an addict your embark on a journey , one that pushes you to search for answers to 
questions you never thought in a million years you would have to know. Your alone, in the dark, and fighting a 
ticking bomb. Each night I speak with a group of women who have all been brought together not by tea, or tennis, 
but we found each other in the darkest of moments, all of our children are addicted to opioids,  most are not as 
fortunate as I and so for them and the children they have lost I pledge to help in the fight not only against drugs but 
to stand as a beacon of hope and change. I will not state the statistics from opioid overdose, or go into the lack of 
education within the medical community on how highly addictive this drug category is instead I will tell you, that 
behind ¾  of every oxycontin, Percocet or vicoden is a story of a mother struggling to save her child from death, not 
trying to save her child from Pain.  
Sarah Svoboda, National Safety Council
The National Safety Council (NSC) would like to thank the Centers for Disease Control and Prevention, the National 
Center for Injury Prevention and Control, and the Board of Scientific Counselors for their work to address our Nation’s 
opioid epidemic and to develop these draft guidelines.  
NSC is a 100-year-old Congressionally chartered nonprofit safety organization whose mission is to save lives by 
preventing injuries and deaths at work, in homes and communities, and in transportation through leadership, research, 
education, and advocacy.  
After a thorough review of the evidence assembled and the draft recommendations, NSC strongly supports these 
guidelines. There is little evidence that chronic opioid therapy (COT) offers effective relief from chronic pain.  However, 
there is abundant evidence about the harms of COT.   
These recommendations – which provide clear, evidence-based guidance for clinical decision-making – could have saved 
Bill, a 33-year old machinist, who died of an unintentional overdose of methadone in July 2006. He had been taking 
hydrocodone for severe lower back pain relief but developed a tolerance to it. On a Friday phone call, Bill’s doctor 
prescribed methadone, a long-acting opioid. The methadone dose Bill took that weekend led to his death. He left behind 
a wife and two sons. Recommendation #4 specifically cautions that “methadone should not be the first choice for an 
ER/LA opioid” as methadone’s unusual characteristics make safe prescribing for pain especially challenging.    
A number of these recommendations (numbers 7, 8, 9 and 12) cite the increased risk of opioid-use disorders in 
encouraging physicians to re-evaluate COT after three months. Michael, a 20-year old patient with Crohn’s disease, 
became addicted to the opioid painkillers prescribed for this condition. He took his own life while on a waiting list for 
substance abuse treatment. Recommendation #12 speaks directly to the life-saving role of physicians and how 
collaboration with their patients and substance abuse treatment providers can prevent senseless outcomes such as 
Michael’s.  
Betts, a chronic pain patient on COT, had concerns about the safety of her high dose and the quality of life. When she 
asked her physician if she could be addicted, the doctor dismissed her concerns. Betts looked for and found a different 
physician willing to help. Working together to set realistic treatment goals and expectations, her physician helped her 
taper off opioid pain medications, obtain counseling for her addiction, and use a variety of non-opioid therapies to 
better and more effectively manage her pain. The patient-centered principles Betts’ physician employed are echoed in 
these guidelines. 
The CDC is taking the appropriate steps by examining the existing data and making recommendations on how opioids 
should be responsibly prescribed. The principles set forth in these guidelines promote better information sharing 
between patient and provider while providing clear guidance and resources to physicians who want to effectively treat 
chronic pain. This valuable tool is greatly needed in the United States.  
Treatment of illness and injury requires a careful balancing of risks and benefits. However, we know the increased use of 
opioids has directly led to the thousands of deaths in the last 20 years. Further, epidemiological studies have suggested 
that when opioids are used for chronic pain, they worsen the quality of life. Opioids should be used with great caution 
only when all other options have failed, and continued use should be periodically re-evaluated, which is a common 
practice applied to other classes and types of drugs such as anticoagulants and isotretinoin. 
CDC has used scientific rigor and the most current available literature to develop guidelines that represent best practices 
for the use of opioids in the treatment of pain. These guidelines are not just appropriate, but necessary to save lives. 
Jonathan Fielding, UCLA School of Public Health
My name is Jonathan Fielding, M.D., MPH, MBA  I am the co-director of the UCLA Center for Healthier Children, 
Families and Communities.  I have previously served as director of Public Health and a health officer for Los 
Angeles County.  I was the founding board member and chairman of the California Wellness Foundation, the 
largest U.S. foundation devoted to disease prevention and health promotion.  I was a founding member of the 
U.S. Preventive Services Task Force and am a former president of the American College of Preventive Medicine. 
I am currently the Chair of the Community Preventive Services Task Force, an independent, nonfederal, unpaid 
panel of public health and prevention experts that provides eviden-based findings and recommendations on 
policies and programs to improve health.  I received my M.D., M.A. and M.P.H. from Harvard University and my 
MBA from the Wharton School. 
Opioids offer pain relief to many suffering patients and are an important treatment option, when medically 
indicated, for pain management; however, it is clear from prescribing data and related addiction treatment 
admission and overdose death data that the medical community has over-relied on opioids to treat pain.  
Prescription opioid sales in the US have increased by over 300% since 1999 while opioid-related overdose deaths 
nearly quadrupled1,2.  To reverse this horrific epidemic of opioid drug overdose deaths and prevent opioid-
related morbidity, the medical community is urgently in need of guidance from the CDC because aggressive 
opioid prescribing is harming pain patients and fueling an unprecedented epidemic of addiction and overdose 
deaths. 
I applaud the CDC scientific committee and the rigourous process they undertook to develop these guidelines to 
improve the dialog between primary care physicians and patients surrounding the benefits and risks associated 
with these medications for the treatment of chroinic, non-malignant and non-terminal pain.  These guidelines 
will improve the way opioids are prescribed and can ensure that patients have access to safer, more effective 
chronic pain treatments while reducing the number of people who misuse, abuse, or overdose from these 
powerful medications.   
The CDC Guideline is based upon an unbiased, exhaustive analysis of the best available research.  Critics have 
suggested that there is not definitive evidence to support the guideline related to levels of dosage and duration 
of use recommendations: however, I believe the CDC guidelines have sufficient evidence to provide clinical 
guidance to physicians and further delays will cause more American lives to be lost.  Not to mention the millions 
of Americans who will lead subpar lives. 
I have read the Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain (“CDC Guideline”) and based 
on my clinical and public health experience, I strongly urge the CDC to release the guidelines without revision as 
quickly as possible.   
Thank you for the opportunity to comment on this important draft guideline and again, I applaud the CDC’s 
leadership in developing these much needed guidelines.  I strongly encourage the immediate release of these 
guidelines without revision. 
1Paulozzi, Mack, & Hockenberry, 2014.  2CDC. Vital Signs: Overdoses of Prescription Opioid Pain Relievers – 
United States, 1999-2008.  Morbidity and Mortality Weekly Report 2011:  60(43): 1487-1492. Available at 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm?s_cid=mm60434a4_w#fig2. August 17, 
2015. 
Laurence Little
Persons giving comments must be in attendance or on the telephone at the start time of the public comment 
period listed in the Federal Register notice:   Federal Register Notice 
Written Comments: 
I can appreciate where an individual with a family member "in pain" may believe these guidelines are going to somehow 
strip their loved one from getting their pain remediated. Unfortunately their education on the subject likely comes from 
the big money drug company lobby groups who have been so successful in the past few decades ensuring the growth 
of addiction is accelerating unabated. Sadly too few understand that these guidelines could save that same person's life 
(or of a relative in their family who is addicted to these viscous drugs and has been pilfering them unbeknownst to the 
family). I would venture most folks are not aware that the fastest growing group for overdose is the age range of 45-85, 
much faster than young adults. Sadly the statistics likely underestimate the issue with seniors because when a senior 
fails to wake up in the morning nobody does the autopsy to determine they actually died of an overdose. The 
assumption is old age or due to other health issues they may have had. 
In my own experience I have been forced to accept scripts for pain killers I have flat out refused to use as they were not 
necessary. Similarly my wife was recently admonished for not filling her prescribed 30 day supply of pain killers even 
after assuring the hospital staff she did not need them post surgery. They even called her at home the next day to see if 
she had filled the prescription!  
I'm actively involved in recovery groups to try and counter the tide of direct and collateral damage. I see the ridiculously 
easy LEGAL access addicts can have 1st hand. We need to be doing more than just creating guidelines. We need to be 
closing the loopholes that allow for so many unnecessary scripts to be written and better protect people from these 
incredibly dangerous drugs.  
These drugs ruin families and lives.  I have seen this first hand in my own family. 
Laurence & Tina Little 
67 Crestview Drive 
Clinton, NJ 08809 
615 North Wolfe Street, W6035 • Baltimore, Maryland 21205 • www.jhsph.edu/cdse • cdse@jhsph.edu 
G. Caleb Alenxander, Johns Hopkins Bloomberg School of Public Health
Center for Drug Safety and Effectiveness  Center for Injury Research and Policy 
January 18, 2016 
Dear Board of Scientific Counselors:  
As you know, there is an epidemic of injuries and deaths from prescription opioids in the 
United States.  These issues are urgent.  
The CDC’s Guidelines focus on a critical area where clinicians need more guidance. Contrary 
to what some have claimed, the recommendations provide sufficient scientific support to 
justify their strength, and the derivation of “strong” recommendations is consistent with best 
practices in guideline development. A big part of the problem is that manufacturers have 
generated much of the “evidence” used to promote opioids, and almost none is relevant to 
chronic opioid use.  Despite how frequently some argue that guidelines like these may hurt 
patients’ access to effective treatments, I am not aware of any evidence to support such 
assertions.  
Much of the opposition to the Guidelines has been based on a faulty premise, namely, that 
these recommendations will somehow jeopardize the care of those living with pain.  This is a 
false dilemma that presupposes there are only two options – reducing opioid use or 
maintaining patients’ access to beneficial treatments. There are multiple options for doing 
both. High quality care for those in pain is not jeopardized by guidelines such as these; in fact, 
it requires them.  
We support transparency in the Guideline development as well as efforts to ensure the 
opportunity for stakeholders to participate. However, it is also important for those opposing 
the idea that CDC can play a constructive role in this area to disclose whether they have 
conflicts of interest, such as having received payments from manufacturers of the drugs in 
question. 
Too often those involved in conversations about opioids fall into an unproductive dichotomy. 
Those suffering from chronic pain who use opioids under medical supervision to achieve 
some relief from their debilitating conditions are pitted against those seeking to reduce the 
pain and suffering associated with prescription opioid misuse, abuse, addiction and overdose. 
The simple fact is both sides should be able to agree that opioids have a place in pain 
treatment, that the death toll from these drugs is too high, and that interventions to reduce the 
risks and maintain the benefits are urgently needed.  
I fully support the CDC’s efforts to establish meaningful Guidelines, and I believe the recently 
proposed recommendations are consistent with the evidence and do not represent any 
conflict between the laudable goals of improving the safety of clinicians’ opioid prescribing 
and improving the quality of care for those living with chronic pain. 
Thank you for your consideration. 
G. Caleb Alexander, MD, FACP 
Adrienne Breidenstine, Baltimore City Health Department
HEALTH DEPARTMENT  
Leana S. Wen, M.D., M.Sc., FAAEM 
CITY OF  BAL TIMORE  
Commissioner of Health 
1001 E. Fayette St. 
STEPHANIE RAWLINGS-BLAKE, Mayor 
Baltimore, MD 21202 
Website: health.baltimorecity.gov 
Tel: 410-396-4398 
Thank you for opportunity to provide comments on the Centers for Disease Control and 
Prevention’s (CDC) Proposed 2016 Guideline for Prescribing Opioids for Chronic Pain (CDC-
2015-0112-0001). In Baltimore City, we have declared opioid abuse a public health emergency. 
This epidemic is claiming the lives of people across our city and county.  We applaud the CDC’s 
efforts to encourage best practices for prescribing; in this case, for those suffering from chronic 
pain and also for bringing greater national attention to this public health crisis. 
With approximately 19,000 active heroin users in Baltimore City and far more who misuse and 
abuse prescription opioid medications, our city cannot be healthy without addressing opioid 
addiction and overdose.  In 2014, 303 people died from drug and alcohol overdose, which is more 
than the number of people who died from homicide. Drug addiction impacts our entire community 
and ties into nearly every issue facing our city including crime, unemployment, poverty, and poor 
health.  It claims lives every day and affects those closest to us – our neighbors, our friends, and 
our family.   
We fully support the CDC’s proposed Guideline for Prescribing Opioids for Chronic Pain. 
The guideline includes key recommendations that align with our framework to fight addiction and 
overdose in Baltimore, which is built on three pillars: 
1. Preventing deaths from overdose and save the lives of people suffering from addiction;
2. Increasing access to quality and effective on-demand treatment and provide long-term
recovery support; and
3. Increasing addiction education and awareness for the public and for providers, in order to
reduce stigma and encourage prevention and treatment.
A key part of our efforts has been to educate primary care providers on the growing opioid 
addiction and overdose epidemic and the importance of safe opioid prescribing practices as a way 
to prevent opioid addiction and overdose deaths.  
The federal government plays a critical role in advancing the campaign against addiction and 
overdose. In addition, to the proposed guideline, three specific areas must also be addressed: 
1. Expand funding and availability of on-demand addiction treatment services
2. Monitor and regulate the price and availability of naloxone.
3. Advocate for a national stigma-reduction and opioid-awareness campaign
The Baltimore City Health Department looks forward to the release of the final CDC guideline. 
We believe the guideline will be a valuable tool to continue our efforts to educate providers about 
the important role they play in addressing the opioid epidemic and improve accountability as it 
relates to safe opioid prescribing practices. Thank you again for the opportunity to provide 
comments and we look forward to working with the CDC to curb the opioid abuse epidemic in 
Baltimore City and across the country.  
1 
Joan Peters-Gilmartin, Nauset Family Practice & The Open Door of Cape Cod
January 8, 2016 
Please read my letter to CDC public comment registration supporting their proposed guidelines. 
I am not only a Primary Care Provider in Family Medicine but represent a family of loss having lost my son to 
Heroin overdose in 2014. This opioid abuse disorder began with prescription pills.  
Most of the general public have no idea about the history of Pain Management that was promulgated to health 
care providers over the last twenty years and how we got to where we are today with a widespread, full blown 
epidemic of opioid overdose deaths across all ages and demographics. Health care providers are just as poorly 
trained in assessing pain as they are in treating it and there have never been evidence-based guidelines for using 
long term opioids for chronic pain until recently. New neuro-biological  research indicates, in fact, that we have 
been doing it wrong for decades, unwittingly following the pressures of big Pharma and medical board warnings 
that pain was being under treated. In fact, we have often made chronic pain worse with long term opioid use, 
driving the patient request for increased doses by creating the condition of hyperalgesia.  
Given that the USA is the largest consumer of opioid prescriptions, it also is time to look at this issue and ask 
why that is the case. In part, prescribers were driven this way because insurance companies refused to cover 
other modalities for chronic pain that can be efficacious, and that other countries use first line, such as 
acupuncture, myotherapy/massage, chiropractic or osteopathic manipulation, biofeedback, yoga, etc.; or they 
limit access. Additionally, insurance has limited access to mental health to deal with the psychodynamic 
alterations that accompany chronic pain and are known to exacerbate it or alter the perception of pain. People 
living with chronic pain need to have a treatment plan that includes teaching them how to live with some level 
of pain and not to have it define their existence; which I see so often in clinical practice. Primary Care 
practitioners need to receive better training in the use of opioids and the management of chronic pain 
syndromes as it often takes weeks or months in regional areas to get a patient referral to a Chronic Pain 
Management specialist. Practitioners need to be mandated to use a Prescription Monitoring Program, but first 
that program needs to be uniform, nationalized and simplified for the user. The ability to renew a DEA license to 
prescribe controlled substances should be tied to demonstrated use of the PMP in the future in addition to 
proof of continuing education hours devoted to not only Pain Assessment and Management but Addiction 
Management as well. 
No one is saying “never use opioids for Chronic pain” and nowhere is it being suggested to ever not treat post- 
surgical, malignant or end of life pain and suffering. These very sensible and practical new guidelines proposed 
by the CDC for opioid use are just a recommended new paradigm for fixing the problem we have created, 
because now that we recognize the breadth and depth of the wrong that we, as a medical community have been 
part of; we have a moral and ethical responsibility to fix it. Because we have done something wrong for so long 
is no reason to continue to do so.  
As a medical provider, as a parent of loss, as an addiction recovery advocate, I support these proposed CDC 
guidelines. 
Joan Peters-Gilmartin, PA-C, MHP 
24 Mansion Street, West Harwich, MA 02671 
David Juurlink, University of Toronto and American College of Medical Toxicology
Overview of proposed comments: 
In my view, the CDC’s initiative regarding prescription opioids for chronic pain is tremendously important. If 
offered an opportunity to address the BSC meeting, I would touch briefly on i) the harms of opioids, particularly 
vis-à-vis dose (for this, I would draw upon our research on the subject), and ii) the importance of being mindful 
of physical dependence on opioids when interpreting testimonials from patients. 
Regarding dose, I believe CDC’s proposed 90 mg MME/day threshold would avert a great deal of harm if widely 
adopted. I recognize this has been a contentious issue, but the available data make very clear that the harms of 
opioids are dose-related. Our research team has documented this with regard to all-cause mortality, opioid-
specific mortality and motor vehicle collisions. In a recent paper (PLOS One 2015), we observed that among men 
receiving > 200 mg MME/day, 3.8% eventually died of opioid-related causes. The corresponding number in 
women was 2.2%. These are staggering statistics, and the notion that the benefits of such doses exceed their 
risks is highly improbable.  
Regarding physical dependence, there are few concepts more important than this when interpreting feedback 
from patients. Many patients with chronic pain who believe they need opioids hold that belief because of 
physical dependence rather than actual analgesic benefit. When a patient on chronic opioid therapy reduces his 
or her dose, or misses doses altogether, he or she often feels unwell not because their pain is inadequately 
treated, but because of the onset of opioid withdrawal. These symptoms abate when the medication is 
resumed, and patients understandably perceive this as evidence of an ongoing need for opioid therapy to 
remain well. Physical dependence is a predictable (indeed, uniform) consequence of chronic opioid therapy, and 
what it actually represents is harm, because it leads to the perpetuation of treatment that for most patients 
does not afford benefits in excess of risks. 
Emily Brunner, Hazelden Betty Ford Foundation
Written testimony of  Emily Brunner, MD 
Staff  physician, Hazelden in St. Paul, part of the Hazelden Betty Ford Foundation 
680 Stewart Avenue, St Paul, Minnesota 55102 
ebrunner@hazeldenbettyford.org 
Re: Docket No. CDC_2015-0112, Guideline for Prescribing Opioids for Chronic Pain 
I am in strong support of  the proposed draft recommendations in the CDC Guideline for Prescribing 
Opioids for Chronic Pain. 
Here at the Hazelden Betty Ford Foundation, we have seen a pronounced increase in the number of  
patients with opioid use disorders. Opioid dependence among residential treatment admissions in our youth 
program, for example, increased from 15 percent in 2001 to 42 percent in 2014. We work with countless 
families who have been devastated by opioid addiction, and far too many have lost loved ones to the disease. 
This is a crisis that demands our attention and commitment, and at the center of this problem is 
overprescribing. To be sure, we doctors didn’t start overprescribing opioids out of malicious intent, but 
rather out of a desire to relieve pain more compassionately. But years of misinformation and, frankly, a lack 
of education on addiction led us to underestimate the risks of these medications. 
It doesn’t help that the No. 1 reason people visit a physician is pain, or that physician visits are increasingly 
shorter. Pressure to make decisions and provide quick solutions add to the doctor’s dilemma.  
Reimbursement tied to patient satisfaction surveys also intensifies the pressure to prescribe opioid 
painkillers in hospital emergency departments.  Often it is easier for a physician to write a prescription to 
maintain the ‘status quo’ than to ask the difficult question, “Should I change how I am treating this patient?”  
In our view, physicians need to limit opioid medication to the treatment of moderate to severe acute pain, 
and rarely use them for chronic pain. Mistakes made with these drugs can be lethal. As a result, we have the 
responsibility to be as cautious as possible in prescribing them. 
The proposed guidelines would encourage more and better physician-patient conversations and help both 
parties by encouraging alternative interventions and treatment strategies when appropriate. 
The national crisis around opioid addiction and overdoses deserves the attention you are providing and 
requires a substantial response not only from the federal government, but from all of medicine as well.  
Every day we put off meaningful action, more people’s lives and families are endangered.  
This is not about taking needed medications away from those who need them; instead, it is about 
changing the culture around prescribing opioids so the next generation of pain patients receives the best 
and least risky treatments possible.  
Contrary to the claims of opponents, you have put forth what is actually a rather modest proposal. It’s 
not a mandate. It includes no black-and-white requirements, and it does not apply to active cancer 
treatment, palliative care for other serious illnesses or end-of-life care. The proposal is more likely to 
bring about a balanced approach than to swing the pendulum too drastically. My organization and I 
thank you for your leadership on this important topic and wholeheartedly back your efforts. 
Rebecca Cunningham, University of Michigan
Specific Comments will be less then 2 minutes and will focus on: 
1 The enormous impact of the current epidemic and the need for public health response simply can not 
be overstated  and the CDC is to be commended for taking the large action that can impact the 
nations public health. 
In my 20 years of medical practice I was first trained that opioids were dangerous medications to 
be used with great care- and then the pendulum swung to widespread opioid prescribing for 
many of our patients. With that swing I have watched first hand the river of patients brought in to 
our hospital doors who have overdosed, and the anguishing increasing calls by our 911 providers 
seeking medical guidance who are unable to revive teens and young adults often who are 
overdosing in the community and are too late for help.  There is a urgent need for public health 
action. 
2 As a clinician- educator there is great need for guidance on best practices given the current vacuum 
and wide disparity in daily and individual practice. Clinicians are currently working almost 
blindly on how to care best for their patient’s pain.  They are confused at the best action, do not 
want to see their patients in pain but without clear guidance can not make safer prescribing 
decisions. We need immediate guidance on how to best align our care with safer prescibing. 
Only then can we begin to have difficult conversations with our patients and to aid the next 
generation of doctors in safer prescribing. There is widespread lack of understanding of benefits 
and potential harms of the typical options and tremendous physician variability. Every day that 
we continue to practice medicine with this much variability and not guided by current science is 
another day that we teach our next generation of students  doctors potentially harmful practices 
and fail our patients by not providing safer options to ameliorate their pain. 
3-The state of the science around opiate use is fairly extensive and very convincing around harms and 
the need for action relative to other practice guidelines.   Although grade one evidence is the gold 
standard this is not level of evidence that drives most change in practice. Many such practice guidelines 
are typically based on observational data such as used in these guidelines --as the science of rigorous 
RCT’s is often fundamentally cost prohibitive, not ethical when studying outcomes that include death 
from overdose. Finally the time lag to obtain the highest ideal of evidence is arguably not ethical given 
the national epidemic of overdose. There are many times in medicine that doing nothing is not ethical, in 
this case waiting for the gold standard RCT longitudinal study while there is evidence that current 
practice is harmful is not ethical. 
In addition the grade of evidence provided here is well in keeping with other evidence based 
changes suggested across medical care.  Specifically the grade of evidence provided in these 
guidelines is more then sufficient to support change in practice.  
 There are several examples of national clinical guidelines for preventive care that have been released in 
the past year that moved ahead with less rigorous graded evidence then is described here.  
Faye Roscoe 
Opioids Guidelines 
It’s imperative that the CDC enforce stricter guidelines for primary care providers in prescribing opioids 
medication to patients.  While pain medications is necessary for many, opioids medication, by default is not.   
The lack of concern to best prescribe the CORRECT pain medication has fueled a drug addiction epidemic, sky-
rocketed overdoses and deaths. 
 
Several years ago my son, then 23, had knee surgery and at the time of release from the hospital the physician 
prescribed Vicodin, against the request to prescribe a non-narcotic drug due to his existing drug issues.  Had 
stricter guidelines been in place, discussing other alternatives for mediation, I believe Vicodin would not have 
been prescribed. 
 
Thank you, 
Faye Roscoe 
1160 San Miguel St. 
Gilroy, CA  95202 
Ada Guidice-Tompson
In 2002, my son Michael was treated at a hospital emergency department for renal colic and given a prescription 
for Percocet when discharged.  Neither the doctor nor pharmacist provided any information to us about 
Percocet’s potential risks.  My son died within two years of his medical exposure to Percocet.  On June 9th, 2004 
under the care of one doctor for 14 ½ months, Michael was given a prescription for a new opioid, Dilaudid, as 
well as the usual Percocet.  The next morning Michael never woke up.  He died at home in bed. The investigating 
coroner ruled the death as ‘accidental’ and the toxicology report indicated ‘hydromorphone intoxication’ as the 
cause.   
If the Draft CDC Opioid Prescribing Guideline was in effect in 2002, I am certain my son would still be alive today. 
Michael’s acute pain would be cautiously treated and he would not have been sent home with a prescription for 
a month’s supply of Percocet.  
Since my son’s death, I have encountered many individuals, friends and relatives who have been prescribed 
opioids for pain.  Many of them tell me they are doing fine, but when I speak to their family members they 
provide insight and a different perspective – they do not function like they once did and fear their loved one is 
addicted to opioids.  Many prescribers and patients truly believe opioids are helping relieve pain.  However, the 
impact on pain and its relationship to tolerance, dependence, opioid induced hyperalgesia, withdrawal and 
substance use disorder must also be carefully considered.  With long-term use of opioids, pain is often a 
surrogate for addiction.  
Opioids must be used with care and selectivity, and only when all other options, as well as the known risks of 
opioids, have been fully considered.  Patients deserve pain relief that is safe and does not cut their life short or 
reduce their quality of life.  Opioids do not have to be misused or abused to cause harm.  Every patient should 
be told that opioids are pharmaceutical grade heroin.  Looking at the increase in babies born with neonatal 
abstinence syndrome (NAS) to mothers taking opioids as directed for pain should have made us stop and take 
notice.  Prescribers cannot change the inherent properties of opioids and using opioids “as prescribed” for pain 
does not prevent harm. Pain and addiction are not mutually exclusive. Relying on REMS and other external 
measures to mitigate harm is important, however, the natural physiological reaction within a human body 
cannot be stopped or prevented when an individual ingests an opioid, even an abuse deterrent one.  
Patients who are already on opioids should not be abandoned.  I support CDC’s efforts in updating the opioid 
prescribing guideline to reflect current evidence to improve medical care for patients in pain.  For far too long 
Pharma marketing, misinformation, conflict of interest and weak regulatory controls have manipulated science, 
downplayed the inherent risks of opioids within a legally sanctioned system.  Both patients and clinicians have 
been operating under ‘impaired choices’. New prescribing guidelines are urgently needed to end the epidemic 
caused by inappropriate and overprescribing of opioids. Thank you CDC. 
Daniel Carr, American Academy of Pain Medicine
The American Academy of Pain Medicine (AAPM) is committed to ensuring the safety, efficacy, 
and cost-effectiveness of patient care through evidence-based care, patient-centered research, 
public and professional education, and science-based policy.  AAPM appreciates this 
opportunity to provide further input to the revised CDC draft guidelines on opioids for chronic 
noncancer pain. It is imperative that the guidelines be rigorous and credible, given their 
possible use to inform policy by federal and other health care systems and stakeholders such as 
insurers, legislators and law enforcement. Yet increasingly, patient and provider organizations 
are voicing concern that the guidelines fail to adhere to standards now expected of such an 
influential document and are in fact regressive in at least three fundamental respects.  
First, evidence assessment and clinical practice now routinely welcome patients in the 
development of clinical practice guidelines and their application to clinical care, e.g., through 
shared decision-making.  However, no patients or patient representatives appear to have been 
involved drafting the guidelines (and only one chronic pain expert appears to have been).  
Patients with chronic pain, particularly the large majority without substance use disorder, are 
dismayed that their exclusion, together with the guidelines’ emphasis on opioid abuse, 
perpetuate their longstanding marginalization and stigmatization. 
Second, multiple sources of the best available evidence, ranging from randomized controlled 
trials (including those conducted for new drug approval) to unpublished data from clinical trials 
and registries, are now routinely sought out and considered when preparing practice 
guidelines.  However, the evidence review of opioid efficacy and effectiveness employed by the 
CDC guideline failed to include these and omitted all literature retrieved by the same 
methodological consultant in a prior systematic review addressing the same questions. Setting 
the guidelines’ criteria for inclusion of efficacy and effectiveness studies insurmountably high 
(i.e., >1 year observation) left no clinical evidence remaining to address this important topic.  
Third, a burgeoning scientific literature aligns patients’ desire and need for individualized care 
with researchers’ ability to inform “precision medicine” amidst substantial individual variability 
in response to drug and nondrug therapies. However, in framing its recommendations the 
guideline panel ignored literature on patient variability and the need to manage it by opioid 
selection and dosing according to patient genetics, gender, age, race, ethnicity, concurrent 
medical conditions and medications, prior exposure (dose and duration) to analgesics, and 
duration, severity and etiology of pain.  
Given these and other shortcomings in the CDC guidelines, AAPM calls for revisiting the process 
by which they were prepared. If it does not appear feasible after the fact to remedy it, then a 
coalition of government agencies should be convened along with patients, pain clinicians and 
nongovernmental stakeholders to revisit the key questions and produce a product that will 
meet expectations for such an important document. 
Mark Roberts, American College of Occupational and Environmental Medicine
Comment script 
The American College of Occupational and Environmental Medicine (ACOEM) supports the CDC’s proposed recommendations for the safer and more effective use of opioids for chronic non-cancer pain (CNCP).  These practices should protect patients and the American public from the adverse effects of these prescription medications if used as guidance in clinical practice. The rationales supporting the recommendations are well reasoned and supported by the best available evidence and expert consensus.  Guidance from an unbiased, authoritative source such as the CDC is especially important in light of the continued absence of quality evidence of effectiveness of opioids for CNCP, and the rapid increase in adverse effects among patients and the public.   The proposed CDC recommendations are consistent with ACOEM’s 2014 update of its guidelines for the use of opioids based on an extensive systematic review meeting Institute of Medicine (IOM) and Cochrane Collaboration criteria.  A trained multi-disciplinary expert panel developed recommendations as specified by the IOM and the Guidelines International Network.  Key conclusions include:  
• An absence of quality evidence of effectiveness of opioids for CNCP.
• Large observational studies show harms are dose related, with sharp increases in overdoses, deathsand other adverse effects starting at 20 to 50 mg per day.
• Additional adverse effects including changes in the CNS affecting judgment and social function,reduced REM sleep, hyperalgesia leading to dose escalation, osteoporosis, suppression of adrenalhormones, feminization, birth defects, and effects on balance.
• Functional improvement as the most important outcome of any treatment for CNCP.  Studiesdemonstrate worse functional outcomes with early or chronic opioid use.
• Additional higher risk groups including motor vehicle drivers, all women due to differingmetabolism than men, younger patients, and patients with prior suicide attempts by whatevermeans, patients using sleep medication and those using H1 antihistamines concurrently withopioids.
• Need for a careful review of systems to identify adverse effects at every visit  and informed consentand opioid agreements  for all patients taking opioids chronically.
The rising rate of prescription drug overdoses, other adverse effects, injuries and deaths is a classic public health problem – increasing levels of potential hazards in a community are associated with increases in adverse effects among both patients for whom opioids are prescribed, and those using others’ opioids and suffering “collateral damage.”  The “opioid epidemic” is the result of the unprecedented widespread use of medications without evidence of effectiveness or careful consideration of hazards, leading to a public health disaster. At the least it is an uncontrolled experiment on the American public and, with wide variation in practice, poor quality care.  Clinical judgment must be guided by the best available evidence to achieve such improvements.  Clearly, better, unbiased guidance is needed to support physician and patient decision making.  More than 40 surveys of US, UK and Canadian physicians’ about opioids and CNCP, show that respondents received minimal education in pain management and felt uncomfortable prescribing opioids for CNCP because there generally are no objective findings or tests for this diagnosis and felt many patients’ perceptions of pain were confounded by untreated or inadequately treated psychiatric disorders or emotional distress.   We appreciate the CDC’s leadership in this area to protect patients and the public. 
David Laws, Georgia Overdose Prevention
Opioid Specific Addiction -Yes-Daughter- Heroin, Oxy, Roxy Morphine 
Personal Story- Our daughter Laura Hope Laws was prescribed Opioid based medication after a broken jaw 
during a soccer game at age 14. That started a journey that ended with the accidental death from overdose on 
Nov 27, 2013 at age 17. 
Specific Discussion Topics- Over Prescription Prevention/Overdose Prevention-/Education, Resources and 
Implementation of Current Laws and Practices 
On behalf of Advocates for the Reform of Prescription Opioids, Inc. (ARPO), I am submitting these comments in strong support of the CDC Opioid Prescribing Guidelines.  ARPO represents many people in the United States and Canada who have been harmed by opioid medications, a majority of whom are, or were, pain patients who became involved with opioids through a legitimate prescription for pain, only to become addicted after prolonged use.  My daughter’s storyline was a bit different: she was a cancer patient who succumbed to a teenage curiosity and died from consuming one OxyContin pill from her uncle’s prescription.  She was only eighteen, three days from her first day in college.   Her tragedy underscores how terribly potent these opioid medications are.  How can somebody die from consuming one pill? With the recent news from CDC that deaths from opioid overdoses were up significantly in 2014, when opioids were involved in 28,647 deaths, the proposed guidelines on opioid prescribing could not come at a more critical time.  And yet, there are forces within the opioid industry and their paid lobbyists and pain organizations pushing back mightily, for a variety of reasons which collectively threaten to undermine the public health benefits of these reasonable, long overdue guidelines.  We urge the CDC to not allow the profit-driven pressure from the opioid industry to delay further the adoption of these important guidelines. The opioid industry is clearly very well-organized, and they appear to be very aggressively instilling fear among pain patients who have become convinced that the federal government (and even ARPO) is trying to take their medications away from them.  No one is trying to take their meds away from them!  We are ALL pain patients at one time or another.  No one, especially pain patients, is well-served by the overly aggressive prescribing practices as has been well-documented by the CDC.  The CDC guidelines will save many lives and will also result in better health care for people who suffer from pain.   We need doctors to prescribe fewer opioids, with more moderate doses and smaller prescriptions.  Where I live in Illinois, the standard practice is a month’s supply for any pain, no matter how minor: whether for a sprained wrist (such as the one I have now), or two stitches in the palm of my hand, or the two stitches in my mouth.  In all of these cases, a few days’ worth of medication would have been more than enough (if needed at all). The bottom line is this: everyone benefits from sound, evidence-based prescribing guidelines, including pain patients.  Please adopt these guidelines as soon as possible so more people can live and enjoy better health care.  Thank you for protecting American lives! 
Pete William Jackson, Advocates for Reform of Prescription Opioids
Tanja Michelle Cupples Meece
18 January 2016 
Tanja Michelle Cupples Meece  
tanjamichellemeece@gmail.com 
1963 Saint Street 19 
Richland, WA 99354 
702-403-8299 
Re: Proposed Guidelines for Prescribing Opiates for Chronic Pain 
There are far too many opioid-related overdoses and deaths in the United States. I believe that many of these 
could have been avoided if there were tighter guidelines for the prescribing and dispensing of opioids, and a 
better monitoring system, that would track opioid prescriptions, from physician to pharmacy to client/recipient. 
The manufacture of opioids and all aspects of the supply chain, pre-dispensary, needs to be more closely 
monitored and policed, as well. 
I have personally experienced the overly-cautious physician’s approach, which was to suggest back surgery, 
rather than write another opioid prescription.  
I opted to pass on the surgery at that time and get a second opinion. I have sciatica, compressed and fractured 
and herniated discs in my upper and lower back, osteoarthritis, osteoporosis, scoliosis and other joint-related 
health issues, that have caused intermittent episodes of pain, lasting for days or weeks, for the past forty years. 
Over the past six years ,that pain has become chronic and, at times, so extreme as to leave me unable to do 
much more than lay in bed. My current physician treats these pain issues with a steroid shot, in the hip-area, 
about every six months and prescribes lidoderm patches on a regular monthly basis. 
I know there are other non-opioid medications and other treatments for chronic pain. Primary care physicians 
need to be made more aware, as should their clients, of the many less-addictive alternatives to opioids currently 
and these options should be offered to clients first, not last, as they were in my particular case. 
I would also like to offer another personal experience, related to my former physician’s refusal to write another 
opioid script, as a further reason for tightening the monitoring of opioids. When my son realized that I was in 
pain, he decided to get pain pills for me, by purchasing them by other less than legal methods. He came back in 
less than an hour, about $30.00 poorer, and he had 45 opioid tablets he'd purchased from someone who had a 
legitimate prescription, from a licensed physician for relief of chronic pain symptoms, but who used marijuana 
instead of the prescribed medication. Opioids are available and easily obtainable through black markets and 
other illegitimate and illegal means. In fact, based solely on this experience, I'd say they are far easier to obtain 
without a prescription than with, and not that much more expensive.  
Tanja Michelle Cupples Meece 
Carolyn Noel, PAINS (Pain Action Alliance to Implement a National Strategy)
PAINS is a program of the Center for Practical Bioethics in Kansas City Missouri, a 501(c)3 incorporated 
in 1984. Two of the Center’s staff served on the IOM committee that published Relieving Pain in 
America. PAINS was organized for the purpose of advancing the sixteen recommendations in the report, 
and is focused on improving chronic pain care and reducing the burden on those 100 million Americans 
who struggle with this disease. In particular, PAINS: (1) advocates for a comprehensive national 
population pain strategy, (2) promotes biopsychosocial or integrative care for chronic pain, (3) educates 
policy makers and the public about pain as a chronic disease, and (4) destigmatizes those who live with 
chronic pain and those who care for them. 
PAINS is also concerned about the abuse of prescription drugs and those who also struggle to live with 
substance abuse disorders. Although no causal connection has been established between opioids 
prescribed for those with chronic pain and opioid abuse, we are concerned about prescribing practices 
broadly and believe that clinical guidelines can be helpful to all those in the healing professions.   
PAINS has commented on the proposed CDC Opioid Prescribing Guidelines both times there were 
opportunities to do so, and an ad hoc group of our Steering Committee had the privilege of meeting with 
Dr. Houry and her team in mid-December to offer our assistance in revising the guidelines and to express 
our concerns about the guidelines. We appreciate the things that have happened since our meeting, 
including the announcement of a second public commentary period and this meeting. The inclusion of a 
chronic pain patient advocate, primary care physician and pain specialists gives us much more confidence 
in the process.   
The concerns we expressed in both of our responses, however, in a large part remain. Broadly, we resist 
the notion of “strong recommendations” and “low to very low evidence” or evidence rated as 3 or 4 in the 
newest version of the guidelines. It has been repeatedly said that this should not be of a great concern 
because the guidelines are not regulatory they are “only” recommendations. It is our view that since CDC 
has a strong “brand” and has historically been a reliable authority, guidelines will become de facto 
standard of care that physicians will be held accountable to by state medical boards, health systems, 
insurance providers, and attorneys. We, therefore, believe that serious consideration should be given to 
revising the proposed guidelines to include only those recommendations for which a strong consensus 
emerged via the public commentary periods. 
Rather than reiterating specific objections and concerns as we expressed in our submission to CDC, we 
asked for time to speak today to articulate seven principles that we offer as threshold criteria to make final 
judgments about the proposed opioid prescribing guidelines. 
1) All those in the healing professions have ethical duties and obligations to treat pain to the fullest
extent of their capacity.
2) Complex chronic diseases, including chronic pain, require comprehensive, individualized bio-
psychosocial approaches.
3) Treatments that are “meaningful and appropriate” can only be discerned via shared decision making
that includes patient’s goals and values along with clinical knowledge and judgment.
4) A risk and benefit analysis must occur for all treatments included in plan of care.
5) In most instances, treatment with the least potential for harm should precede those with greater risks;
however, there are exceptions to this rule.
6) The inherent ambiguity of human medicine calls for the exercise of caution and ongoing monitoring.
7) Although never intended, when iatrogenic harm/injuries do occur, patients are owed an explanation,
apology, assistance in remedying or ameliorating the problem and a new plan of care developed.
Ambiguity is inherent to the practice of medicine and does not necessarily imply negligence or
maleficence.
It is our view that any recommendation that does not affirm these principles should not be included in 
prescribing guidelines.   Thank you. 
Carol Thornton, Safe States Alliance
Written Comments from the Safe States Alliance regarding the Centers for Disease Control and 
Prevention's Draft Guidelines for Prescribing Opioids for Chronic Pain 
The Safe States Alliance wishes to offer its support to the Centers for Disease Control and 
Prevention (CDC) for its leadership in the development of Guidelines for Prescribing Opioids for 
Chronic Pain.  Every day, 44 people die in the United States from opioid prescription drug 
overdoses, costing the country $55.7 billion in healthcare, criminal justice, and work loss 
expenses. The amount of opioids prescribed and sold in the United States has quadrupled since 
1999, and by 2013 nearly two million Americans aged 12 or older either abused or were 
dependent on opioid painkillers. With no data to indicate an overall change in pain reported by 
Americans that would justify this significant increase or explain the considerable differences in 
opioid prescription practices between states, there is a clear need for strong guidance for the 
medical community to ensure that these potentially dangerous medications are prescribed 
responsibly. 
 The Safe States Alliance is a national non-profit 501(c)(3) organization and professional 
association whose mission is to strengthen the practice of injury and violence prevention. The 
Safe States Alliance represents a diverse membership, a large part of which is comprised of state 
health department injury and violence prevention programs. These programs are vital partners 
in the Centers for Disease Control and Prevention's Prescription Drug Overdose Boost for State 
Prevention, which provides financial resources and scientific technical assistance to support 
state prevention efforts. Specific activities include maximizing prescription drug monitoring 
programs (PDMPs), improving public insurance mechanisms to protect patients, and evaluating 
policies to identify prevention that works. Many of these state programs are actively engaged  
with the medical community and other partners to develop, disseminate, and evaluate state 
level prescribing guidelines.  
Safe States Alliance is strongly supportive of providing physicians with tools that can be used, 
along with their personal clinical judgment, to assess and develop a plan to appropriately 
address acute and chronic pain for patients in the most appropriate - and safe - way possible. 
The scientific review conducted by the expert panel provides the best available evidence on 
which to base responsible guidelines to serve as one of these necessary tools. The Guidelines for 
Prescribing Opioids for Chronic Pain will be a very useful resource for states in the development, 
review and updating of state-specific guidelines tailored to each state's unique needs. 
We thank CDC for its leadership in providing strong scientific analyses and guides to support 
states and communities in addressing this public health crisis. 
